[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 718
1. Khoo JJ, Alwi RI, Abd-Rahman I: Myoid hamartoma of breast with chondroid metaplasia: a case report. Malays J Pathol; 2009 Jun;31(1):77-80
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myoid hamartoma of breast with chondroid metaplasia: a case report.
  • Breast hamartoma is an uncommon poorly recognised benign breast neoplasm.
  • Hamartoma displaying marked smooth muscle components known as myoid hamartoma of the breast is a much rarer entity.
  • We present a case of myoid hamartoma of breast with chondroid differentiation in a 46-year-old woman.
  • The painless breast lump was circumscribed and mammography showed a well-encapsulated large, dense mass with no calcification.
  • The various immuno-histochemical staining as well as the cyto-histological changes encountered in myoid hamartomas are discussed with clinical, radiological and pathological correlation to differentiate it from other benign and malignant breast lesions.
  • [MeSH-major] Breast Diseases / pathology. Hamartoma / pathology. Muscle, Smooth / pathology
  • [MeSH-minor] Biomarkers / metabolism. Breast Neoplasms / diagnosis. Cartilage / pathology. Cell Differentiation. Diagnosis, Differential. Female. Fibroadenoma / diagnosis. Humans. Immunohistochemistry. Metaplasia / pathology. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694319.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


2. Huang YL, Chen DR, Jiang YR, Kuo SJ, Wu HK, Moon WK: Computer-aided diagnosis using morphological features for classifying breast lesions on ultrasound. Ultrasound Obstet Gynecol; 2008 Sep;32(4):565-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer-aided diagnosis using morphological features for classifying breast lesions on ultrasound.
  • OBJECTIVES: To develop and evaluate a computer-aided diagnosis (CAD) system with automatic contouring and morphological analysis to aid in the classification of breast tumors using ultrasound.
  • METHODS: We evaluated 118 breast lesions (34 malignant and 84 benign tumors).
  • Each tumor contour was automatically extracted from the digitized ultrasound image.
  • A support vector machine (SVM) classifier utilized the selected principal vectors to identify the breast tumor as benign or malignant.
  • The classification ability for breast tumors using morphological information was good.
  • CONCLUSIONS: This system differentiates benign from malignant breast tumors well and therefore provides a clinically useful second opinion.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Diagnosis, Computer-Assisted / methods. Ultrasonography, Mammary / methods
  • [MeSH-minor] Adult. Aged. Algorithms. Diagnosis, Differential. Female. Humans. Image Interpretation, Computer-Assisted / methods. Middle Aged. Principal Component Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18383556.001).
  • [ISSN] 1469-0705
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


3. Huang YL, Kuo SJ, Chang CS, Liu YK, Moon WK, Chen DR: Image retrieval with principal component analysis for breast cancer diagnosis on various ultrasonic systems. Ultrasound Obstet Gynecol; 2005 Oct;26(5):558-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image retrieval with principal component analysis for breast cancer diagnosis on various ultrasonic systems.
  • OBJECTIVES: We present a computer-aided diagnostic (CAD) system with textural features and image retrieval strategies for classifying benign and malignant breast tumors on various ultrasonic systems.
  • This study evaluated a series of pathologically proven breast tumors using various ultrasonic systems.
  • METHODS: Altogether, 600 ultrasound images of solid breast nodules comprising 230 malignant and 370 benign tumors were investigated.
  • The suspicious tumor area in the ultrasound image was manually chosen as the region-of-interest (ROI) subimage.
  • Textural features extracted from the ROI subimage are supported in classifying the breast tumor as benign or malignant.
  • In practice, high-dimensional vectors are unsatisfactory at differentiating breast tumors.
  • The image retrieval techniques were employed to differentiate breast tumors, according to the similarities of the principal vectors.
  • The query ROI subimages were identified as malignant or benign tumors according to characteristics of retrieved images from the ultrasound image database.
  • CONCLUSION: The CAD system identified solid breast nodules with comparatively high accuracy in the different ultrasound systems investigated.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Image Interpretation, Computer-Assisted / methods
  • [MeSH-minor] Area Under Curve. Breast Diseases / classification. Breast Diseases / ultrasonography. Databases, Factual. Female. Humans. Principal Component Analysis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 ISUOG.
  • (PMID = 16086435.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Devi PM, Singh LR, Gatphoh ED: Fibroadenoma with squamous metaplasia. Singapore Med J; 2007 Jul;48(7):682-3
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibroadenoma is the most common benign breast tumour in adolescent and young women.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Fibroadenoma / pathology
  • [MeSH-minor] Adult. Female. Fibrocystic Breast Disease / complications. Fibrocystic Breast Disease / pathology. Humans. Metaplasia / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17609833.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


5. Ravindra S, Suguna BV: Cytomorphology of tubular adenoma breast--a case report. Indian J Pathol Microbiol; 2006 Apr;49(2):267-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphology of tubular adenoma breast--a case report.
  • Tubular adenoma a 'pure adenoma' is a benign neoplasm of breast presenting clinically like fibroadenoma.
  • [MeSH-major] Adenoma / pathology. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Fibroadenoma / pathology. Fibrocystic Breast Disease / pathology. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933735.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 7
  •  go-up   go-down


6. Sandoval-Hermosillo F, Vázquez-Lara GA, Farias-Evangelista LD, Madrid-Venegas DC, Jiménez-Covarrubias MG, Ramírez-Villaseñor M, Delgado-Enciso I, Rodríguez-Hernández A, Montoya F, Montaño-Plasencia V, Vásquez C: [Comparing two diagnostic methods used for breast neoplasm in a cancer centre in Colima, Mexico]. Rev Salud Publica (Bogota); 2010 Jun;12(3):446-53
MedlinePlus Health Information. consumer health - Mammography.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparing two diagnostic methods used for breast neoplasm in a cancer centre in Colima, Mexico].
  • [Transliterated title] Comparación de dos métodos diagnósticos en tumores mamarios en un Centro de Cancerología de Colima, México.
  • OBJECTIVE: Determining the relationship between mammography neoplasm reports and histopathological diagnosis of neoplasms.
  • Patients were included who were attending the state cancerology centre (Centro Estatal de Cancerología) in Colima, Mexico.
  • Inclusion parameters were: females having mammography and BIRADS score of 1 or over; females having biopsy and histopathology diagnosis; females of all ages, all clinic stages having a complete clinic record.
  • RESULTS: No relationship between a BIRADS score classified as being benign (BIRADS I-II-III) or malign (BIRADS IV-V) was found with histopathological results (benign or malign) (p=0.0666).
  • CONCLUSIONS: I, III and V BIRADS scores had a relationship with histopathological diagnosis, while category II and IV BIRADS scores had no relationship.
  • [MeSH-major] Biopsy / statistics & numerical data. Breast Neoplasms / diagnosis. Cancer Care Facilities. Mammography / statistics & numerical data

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21311832.001).
  • [ISSN] 0124-0064
  • [Journal-full-title] Revista de salud pública (Bogotá, Colombia)
  • [ISO-abbreviation] Rev Salud Publica (Bogota)
  • [Language] spa
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Colombia
  •  go-up   go-down


7. Nalini R, Wilma Delphine Silvia CR, Uthappa S: Utility of blood DNA levels in diagnosis of breast cancer. J Cancer Res Ther; 2008 Apr-Jun;4(2):57-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of blood DNA levels in diagnosis of breast cancer.
  • BACKGROUND: Prognostic factors, including both histopathological and biochemical variables, influence the choice of modality and the course of therapy in breast cancer.
  • AIM: To find out if any correlation exists between blood DNA level and tumor stage, size and grade.
  • The cases comprised 25 patients with histopathologically confirmed malignant breast cancer, while 27 patients with benign breast tumors served as the control group.
  • Pearson's test was performed to find out the correlation between blood DNA levels and the TNM stage, tumor size and grade.
  • RESULTS: It was observed that blood DNA levels showed statistically significant correlation with the TNM stage, tumor size and grade.
  • CONCLUSION: The blood DNA level can be utilized as a noninvasive marker to assess tumor aggressiveness.
  • Thus, it can be useful as a prognostic marker and as a marker of tumor burden.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. DNA, Neoplasm / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Case-Control Studies. Female. Humans. Middle Aged. Neoplasm Staging. Neoplasms / diagnosis. Neoplasms / surgery. Tumor Burden

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688119.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


8. Navas Cañete A, Olcoz Monreal FJ, García Laborda E, Pérez Aznar JM: [Pseudoangiomatous stromal hyperplasia: magnetic resonance findings in two cases]. Radiologia; 2007 Jul-Aug;49(4):275-8
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Hiperplasia pseudoangiomatosa estromal: hallazgos en resonancia magnética de dos casos.
  • Pseudoangiomatous stromal hyperplasia (PASH) is a benign breast tumor of uncertain etiology, although marked hormonal influence clearly plays a role in this disease.
  • The differential diagnosis is important because this is an uncommon lesion that can simulate malignant lesions both at clinical and radiological examination, and even the histological results can be confusing.
  • [MeSH-major] Breast / pathology. Breast Diseases / diagnosis. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Pseudoangiomatous stromal hyperplasia.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17594891.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


9. Yang GZ, Li J, Ding HY: [Nipple adenoma: report of 18 cases with review of literatures]. Zhonghua Bing Li Xue Za Zhi; 2009 Sep;38(9):614-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinicopathological and immunohistochemical features, diagnosis and differential diagnosis of nipple adenoma of the breast.
  • RESULTS: The neoplasms were localized at nipples or under the areola of breast, adherent to the epidermis, mainly composed of dilated ducts in a tubular appearance associated with fibrotic matrix.
  • The tumor cells were crowding, lack of an uniform morphology and polarity with intact myoepithelial cells around the ducts.
  • CONCLUSIONS: Nipple adenoma is an infrequent type of benign breast neoplasm, presenting as sclerosing papilloma, papillomatosis or florid sclerosing adenosis.
  • A correct diagnosis is based on the peculiar location and morphology of the tumor, and immunohistochemistry is helpful in some cases.
  • [MeSH-major] Adenoma / pathology. Breast Neoplasms / pathology. Nipples / pathology
  • [MeSH-minor] Adult. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Humans. Keratin-5 / metabolism. Keratins / metabolism. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079190.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CK-34 beta E12; 0 / Keratin-5; 68238-35-7 / Keratins
  •  go-up   go-down


10. Ying MG, Chen Q, Ye YB, Chen HJ, Chen X, Zheng HY, Wu F: [Application of serum proteomic mass spectrum analysis in breast cancer]. Zhonghua Zhong Liu Za Zhi; 2010 Sep;32(9):698-702
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of serum proteomic mass spectrum analysis in breast cancer].
  • OBJECTIVE: To analyze the characteristics of serum proteins mass spectra in healthy controls, benign breast tumors, and CA15-3 negative or CA15-3 positive breast cancer patients by surface enhanced laser desorption ionization time of flight mass spectrometry (SELDI-TOF-MS).
  • METHODS: Tissue samples of 113 cases of breast cancer (93 case of CA15-3 negative, 20 case of CA15-3 positive), 103 cases of benign breast tumor and 92 cases of healthy controls were examined and analyzed by SELDI and protein chip (CM10) techniques.
  • RESULTS: Twelve significantly different protein peaks were found in serum samples between breast cancer patients and healthy controls.
  • Eleven significantly different peaks were found between benign breast tumor patients and healthy controls.
  • By combined analysis of those three different protein mass spectra, the peak 15 952 was found to be significantly different between breast cancer group and healthy controls, and the peak 7985 was significantly different among breast cancer group, benign breast tumor group and health controls.
  • The blind test with the differential proteins for the serum samples of 93 cases of CA15-3 negative breast cancer and 36 cases of benign breast tumors showed that the sensitivity was 80.6% and specificity was 91.7%.
  • The blind test in 20 cases of CA15-3 positive breast cancer and 36 cases of benign breast tumors showed that the sensitivity was 75.0% and specificity was 91.7%.
  • Four significantly different protein peaks were found between the benign breast tumor patients and CA15-3 negative breast cancer patients.
  • CONCLUSION: Significantly different protein peaks can be screened out in breast cancer, benign breast tumor patients and healthy controls by SELDI-TOF-MS analysis.
  • [MeSH-major] Blood Proteins / metabolism. Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Fibroadenoma / diagnosis. Proteomics / methods
  • [MeSH-minor] Adenoma / blood. Adenoma / diagnosis. Adenoma / metabolism. Adult. Aged. Biomarkers, Tumor / blood. Case-Control Studies. Female. Humans. Middle Aged. Mucin-1 / metabolism. Protein Array Analysis. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122387.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / Mucin-1
  •  go-up   go-down


11. Liebhardt S, Ditsch N, Nieuwland R, Rank A, Jeschke U, Von Koch F, Friese K, Toth B: CEA-, Her2/neu-, BCRP- and Hsp27-positive microparticles in breast cancer patients. Anticancer Res; 2010 May;30(5):1707-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CEA-, Her2/neu-, BCRP- and Hsp27-positive microparticles in breast cancer patients.
  • BACKGROUND: This is the first prospective case-control study that evaluates the expression of tumour-specific antigens on circulating microparticles (MP) in breast cancer patients and in women with benign breast tumour.
  • MATERIALS AND METHODS: MP were determined by flow cytometry in patients with breast cancer (n=34; T1 (n=19) and T2 (n=15)) and women with benign breast tumour (n=19).
  • RESULTS: Patients with lymph node metastases (N1, n=9) showed significantly higher numbers of annexin V(+) MP (p=0.042), CD66(+) MP (p=0.045), BCRP1(+) MP (breast cancer resistance protein) (p=0.025) and Hsp27(+) MP (p=0.034) than controls.
  • CONCLUSION: Significant differences are present between breast cancer patients with lymph node metastases and controls concerning annexin V-, CD66-, BCRP1- and Hsp27-positive MP.
  • To specify the role of these MP subpopulations in breast cancer progression, further studies enrolling larger patient groups are part of ongoing research.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Breast Neoplasms / metabolism. Carcinoembryonic Antigen / metabolism. Cell-Derived Microparticles. HSP27 Heat-Shock Proteins / metabolism. Neoplasm Proteins / metabolism. Receptor, ErbB-2 / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592365.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / Annexin A5; 0 / Carcinoembryonic Antigen; 0 / HSP27 Heat-Shock Proteins; 0 / HSPB1 protein, human; 0 / Neoplasm Proteins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


12. Ditsch N, Liebhardt S, Von Koch F, Lenhard M, Vogeser M, Spitzweg C, Gallwas J, Toth B: Thyroid function in breast cancer patients. Anticancer Res; 2010 May;30(5):1713-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid function in breast cancer patients.
  • BACKGROUND: Recent studies indicate a possible relationship between hypothyroidism and breast cancer in vivo.
  • In addition, oestrogen-like effects of thyroid hormones on breast cancer cell growth are seen in vitro.
  • Therefore, this study evaluated thyroid function in breast cancer patients, women with benign breast tumour and healthy controls.
  • PATIENTS AND METHODS: Breast cancer patients (n=65), women with carcinoma in situ (n=13) or benign breast tumour (n=27), and healthy controls (n=38) were included in the study.
  • RESULTS: fT3 and fT4 levels were highest in breast cancer patients, and differed significantly from controls (fT3 and fT4: p<0.001) as well as from patients with benign breast tumour (fT3: p=0.021; fT4: p=0.017).
  • With regard to TRAK antibodies, breast cancer patients showed the highest levels differing significantly from women with benign breast tumours (p=0.048).
  • CONCLUSION: Significant differences in fT3/fT4 as well as TRAK levels were observed among breast cancer patients, women with benign breast tumours and healthy controls.
  • [MeSH-major] Breast Neoplasms / physiopathology. Thyroid Gland / physiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592366.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Estrogens; 0 / Thyroid Hormones
  •  go-up   go-down


13. Harmer V: Breast cancer. Part 1: Awareness and common benign diseases. Br J Nurs; 2008 Aug 14-Sep 10;17(15):950-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer. Part 1: Awareness and common benign diseases.
  • Breast cancer is the most common cancer for women in the United Kingdom and topic on which there is much information.
  • This article discusses the principles behind breast awareness and breast health, detailing common benign breast diseases that cause disproportionate anxiety.
  • The NHS Breast Screening Programme is celebrating 20 years of screening this year, and in all randomized controlled trials of women aged 50 and over, mortality from breast cancer is reduced in those offered screening compared with unscreened controls (although the reduction is not statistically significant in all trials).
  • Once a breast cancer is diagnosed, the different characteristics and stage of the disease can be identified through histopathology and scans.
  • [MeSH-major] Breast Neoplasms / diagnosis
  • [MeSH-minor] Awareness. Diagnosis, Differential. England. Female. Humans. Mass Screening. Neoplasm Invasiveness. Referral and Consultation. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983015.001).
  • [ISSN] 0966-0461
  • [Journal-full-title] British journal of nursing (Mark Allen Publishing)
  • [ISO-abbreviation] Br J Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 33
  •  go-up   go-down


14. Gallicchio L, McSorley MA, Newschaffer CJ, Huang HY, Thuita LW, Hoffman SC, Helzlsouer KJ: Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease. Cancer Detect Prev; 2007;31(2):95-101
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease.
  • BACKGROUND: A cohort study was conducted among post-menopausal women to determine whether genetic polymorphisms in selected obesity-related genes (PPARG, LPL, LEPR, PON1, PON2, TNF-alpha) were associated with the progression of benign breast disease (BBD) to breast cancer and whether the selected polymorphisms modified the association between body mass and breast cancer among women with BBD.
  • METHODS: Among participants in an ongoing cohort study, 994 Caucasian post-menopausal women had a breast biopsy for BBD.
  • Of these women, 61 subsequently developed breast cancer.
  • RESULTS: In this cohort, body mass index (BMI) was positively associated with the risk of developing breast cancer.
  • In contrast, polymorphisms in PON1 (Gln192Arg) and LEPR (IVS2+6920) were associated with a decreased risk of developing invasive breast cancer.
  • No statistically significant associations were observed for polymorphisms in PPARG, PON2, LPL, or TNF and breast cancer risk or for interactions between the polymorphisms and BMI and breast cancer risk.
  • CONCLUSIONS: The findings suggest that specific polymorphisms in the PON1 and LEPR genes may play a role in progression of BBD to breast cancer among post-menopausal Caucasian women.
  • [MeSH-major] Biomarkers, Tumor / genetics. Body Weight. Breast Diseases / genetics. Breast Neoplasms / genetics. Neoplasm Proteins / genetics. Obesity / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Aryldialkylphosphatase / genetics. Cohort Studies. Female. Genetic Predisposition to Disease. Genotype. Humans. Middle Aged. PPAR gamma / genetics. Postmenopause. Receptors, Cell Surface / genetics. Receptors, Leptin. Risk Factors. Tumor Necrosis Factor-alpha / genetics

  • Genetic Alliance. consumer health - Obesity.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Body Weight.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17428620.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / PPAR gamma; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin; 0 / Tumor Necrosis Factor-alpha; EC 3.1.8.1 / Aryldialkylphosphatase; EC 3.1.8.1 / PON1 protein, human; EC 3.1.8.1 / PON2 protein, human
  •  go-up   go-down


15. Vasaturo F, Sallusti E, Gradilone A, Malacrino C, Nardo T, Avagnano G, Aglianò AM, Granato T, De Vincenzi B, Coppotelli G, Marzullo A, Soda G, Simonelli L, Modesti M, Scarpa S: Comparison of extracellular matrix and apoptotic markers between benign lesions and carcinomas in human breast. Int J Oncol; 2005 Oct;27(4):1005-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of extracellular matrix and apoptotic markers between benign lesions and carcinomas in human breast.
  • The expression of the extracellular matrix-related genes, such as fibronectin, laminin and tenascin C, and apoptosis-related genes, such as bax, bcl2 and survivin, was evaluated by reverse transcription-polymerase chain reaction (RT-PCR) and by immunohistochemistry in normal breast tissue and benign and malignant breast tumors and then correlated to several clinical parameters: estrogen and progesterone receptors, Ki67, ErbB2, tumor size, lymph node status and grading.
  • Seventy-three breast tissue samples were examined.
  • In addition, we found a statistically significant increase in survivin transcription in malign tumors compared to fibroadenomas (P=0.024).
  • The negative correlation between laminin transcription and Ki67 could suggest that laminin impacts negatively on tumor proliferation, and the positive correlation between fibronectin and lymph node status may lead to consider fibronectin as predictive of long distance metastasis.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor. Breast Diseases / metabolism. Breast Neoplasms / metabolism. Carcinoma / metabolism. Extracellular Matrix / metabolism. Gene Expression Regulation. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Cell Differentiation. Cell Line, Tumor. Cell Proliferation. Cytoplasm / metabolism. Female. Fibronectins / metabolism. Humans. Immunohistochemistry. Inhibitor of Apoptosis Proteins. Ki-67 Antigen / biosynthesis. Laminin / metabolism. Lymphatic Metastasis. Microtubule-Associated Proteins / metabolism. Neoplasm Metastasis. Neoplasm Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. RNA / metabolism. Receptor, ErbB-2 / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Tenascin / metabolism. bcl-2-Associated X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142317.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Fibronectins; 0 / Inhibitor of Apoptosis Proteins; 0 / Ki-67 Antigen; 0 / Laminin; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tenascin; 0 / bcl-2-Associated X Protein; 63231-63-0 / RNA; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


16. Buch A, Rout P, Makhija P: Adenomyoepithelioma with phyllodes tumor--a rare combination in a solitary breast lump. Indian J Pathol Microbiol; 2006 Apr;49(2):259-61
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomyoepithelioma with phyllodes tumor--a rare combination in a solitary breast lump.
  • An unusual combination of two benign breast neoplasms adenomyoepithelioma and phyllodes tumor presenting as a solitary breast lump have been described.
  • Both these tumors have tendencies to recur and have malignant potential.
  • This patient also presented with a recurrent breast neoplasm.
  • [MeSH-major] Adenomyoma / pathology. Breast Neoplasms / pathology. Myoepithelioma / pathology. Neoplasms, Multiple Primary / pathology. Phyllodes Tumor / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Indian J Pathol Microbiol. 2006 Jul;49(3):476
  • (PMID = 16933731.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


17. Ławicki S, Czygier M, Bedkowska E, Wojtukiewicz M, Szmitkowski M: Comparative evaluation of plasma levels and diagnostic values of macrophage-colony stimulating factor in patients with breast cancer and benign tumors. Pol Arch Med Wewn; 2008 Sep;118(9):464-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative evaluation of plasma levels and diagnostic values of macrophage-colony stimulating factor in patients with breast cancer and benign tumors.
  • The direct production of this cytokine has been reported in tumor cell lines in vitro and in solid tumors in vivo.
  • OBJECTIVES: In the present study, the levels of M-CSF in patients with breast cancer and in those with a benign breast tumor were evaluated.
  • PATIENTS AND METHODS: The study group was made up of 70 patients with breast cancer and 20 patients with benign tumors and the control group of 30 healthy women.
  • RESULTS: Statistically higher levels of M-CSF and CA 15-3 were found in breast cancer patients as compared to the benign tumor and control groups.
  • CONCLUSIONS: The above data suggests that M-CSF might be useful in both diagnostics and differential diagnosis of benign tumors and breast cancer (except for the lowest degree of the clinical progression).
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Macrophage Colony-Stimulating Factor / blood
  • [MeSH-minor] Adult. Aged. CA-125 Antigen / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. Poland. Predictive Value of Tests. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18846980.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


18. Román-Díaz J, Alayón-Laguer D, Fernández Nelson M, Luis B, Caceres-Perkins W, Conde-Sterling D: Rare benign breast tumor. Bol Asoc Med P R; 2010 Apr-Jun;102(2):50-2
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare benign breast tumor.
  • We report the case of a female patient with an incidental finding at routine mammography evaluation which consisted of a benign spindle cell tumor, namely Breast Myofibroblastoma.
  • It is important to recognize the benign nature of this neoplasm to prevent extensive mutilating surgical procedures.
  • [MeSH-major] Breast Neoplasms / pathology. Neoplasms, Muscle Tissue / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20939206.001).
  • [ISSN] 0004-4849
  • [Journal-full-title] Boletín de la Asociación Médica de Puerto Rico
  • [ISO-abbreviation] Bol Asoc Med P R
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Puerto Rico
  •  go-up   go-down


19. Wishart GC, Campisi M, Boswell M, Chapman D, Shackleton V, Iddles S, Hallett A, Britton PD: The accuracy of digital infrared imaging for breast cancer detection in women undergoing breast biopsy. Eur J Surg Oncol; 2010 Jun;36(6):535-40
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The accuracy of digital infrared imaging for breast cancer detection in women undergoing breast biopsy.
  • BACKGROUND: Mammography has a lower sensitivity for breast cancer detection in younger women and those with dense breasts.
  • Recent improvements in digital infrared breast imaging suggest there may be a role for this technology and we have studied its performance in 100 women prior to breast needle core biopsy (CB).
  • METHODS: All patients were imaged using a digital infrared breast (DIB) scan (Sentinel BreastScan) prior to breast biopsy.
  • RESULTS: Of 106 biopsies performed in 100 women, 65 were malignant and 41 were benign.
  • CONCLUSION: DIB using NoTouch is an effective adjunctive test for breast cancer detection in women under 70 and appears to be particularly effective in women under 50 where maximal sensitivity (78%) and specificity (75%) were observed.
  • [MeSH-major] Breast Neoplasms / pathology. Thermography / methods
  • [MeSH-minor] Aged. Biopsy, Needle. Female. Humans. Infrared Rays. Middle Aged. Neoplasm Staging. Neural Networks (Computer). Predictive Value of Tests. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Rev Clin Oncol. 2010 Sep;7(9):483 [20824903.001]
  • (PMID = 20452740.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


20. Fon LJ, Lioe TF, Mulligan KA, Johnston PG, McCormick D, Spence RA: Prognostic significance of glycoprotein pMQ1 in breast cancer. Br J Surg; 2006 Mar;93(3):309-14
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of glycoprotein pMQ1 in breast cancer.
  • Cerebral metastases from breast cancer have also been found to contain pMQ1-positive cells.
  • This study aimed to determine the role of pMQ1 in primary breast cancer.
  • METHODS: Breast cancer specimens were analysed for pMQ1 by immunohistochemistry.
  • Kaplan-Meier analyses were performed to compare clinical outcome between pMQ1-positive and pMQ1-negative tumours.
  • RESULTS: pMQ1 was expressed in most of the breast cancer specimens.
  • The surrounding normal tissue margins and benign breast tissues always lacked pMQ1 expression.
  • CONCLUSION: pMQ1 appears to be a tumour-associated protein.
  • [MeSH-major] Breast Neoplasms / chemistry. Glycoproteins / analysis. Neoplasm Proteins / analysis
  • [MeSH-minor] Adult. Aged. Breast / chemistry. Female. Follow-Up Studies. Humans. Ki-67 Antigen / analysis. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis. Receptors, Estrogen / analysis. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 16392102.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen; 0 / Tumor Suppressor Protein p53; 0 / pMQ1 glycoprotein, human
  •  go-up   go-down


21. Schwartz RA, Rothenberg J: Metastatic adenocarcinoma of breast within a benign melanocytic nevus in the context of cutaneous breast metastatic disease. J Cutan Pathol; 2010 Dec;37(12):1251-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of breast within a benign melanocytic nevus in the context of cutaneous breast metastatic disease.
  • Metastatic breast cancer of skin may be seen in a number of forms.
  • It is rare to find it in association with a benign melanocytic nevus.
  • We describe a patient with metastatic adenocarcinoma of breast within a benign melanocytic nevus and delineate this occurrence within the context of reviewing cutaneous breast metastatic disease.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Nevus, Pigmented / pathology. Skin Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Aged. Female. Humans. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 John Wiley & Sons A/S.
  • (PMID = 20002237.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


22. Bereznaya NM, Kirnasovskaya EA, Vinnichuk YD, Belova OB, Lukyanova NY: Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors. Exp Oncol; 2008 Dec;30(4):295-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors.
  • AIM: To study the expression of CD40 by cells of benign and malignant tumors of mammary gland, and to compare the efficacy of lymphocytes antitumor activity against drug resistant and sensitive breast tumors in relevance to CD40 expression.
  • METHODS: Breast tumor explants were cultured with autologous lymphocytes in double diffusion chambers.
  • Expression level of molecules on tumor cells was analyzed using immunohistochemical method (paraffin embedded slides), and on lymphocytes - by the method of indirect immunofluorescence.
  • RESULTS: The highest level of CD40 expression was detected on cells of chemoresistant malignant breast tumors, and the lowest one - on cells of benign breast tumors.
  • The decreased CD40 expression on lymphocytes from patients with drug resistant breast cancer was compared with that on lymphocytes of the patients with drug sensitive breast cancer.
  • The study of antitumor activity of autologous lymphokine activated killer cells (LAK) has shown their pronounced antitumor activity against drug resistant malignant breast tumors.
  • CONCLUSION: Marked antitumor activity of LAK from the patients with drug resistant breast cancer is associated with high expression level of CD40 on tumor cells and with its decreased expression on lymphocytes.
  • [MeSH-major] Antigens, CD40 / biosynthesis. Breast Neoplasms / immunology. Drug Resistance, Neoplasm / immunology. Killer Cells, Lymphokine-Activated / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112427.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antigens, CD40; 126547-89-5 / Intercellular Adhesion Molecule-1
  •  go-up   go-down


23. El-Attar HA, Ragab MS, Sheta MI, Ahmed AS: Hepatocyte growth factor in Egyptian females with breast benign lumps and cancers. Asian Pac J Cancer Prev; 2010;11(4):893-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocyte growth factor in Egyptian females with breast benign lumps and cancers.
  • OBJECTIVE: Estimation of the plasma level of HGF in females with benign breast lumps or breast carcinomas and correlating levels with important prognostic parameters.
  • SUBJECTS: Sixty eight adult premenopausal females were divided into control group of fifteen healthy volunteers and fifty-three patients subdivided into fifteen with benign breast lumps and thirty-eight with breast carcinomas.
  • METHODS: A thorough clinical examination, plain chest x-rays, ultrasonography of the abdomen and pelvis, pre- operative fine needle aspiration cytology, estimation of fasting serum glucose, urea, creatinine and uric acid levels, alanine aminotransferase activities, C-reactive protein, HGF level and histopathological examination of the breast masses were performed.
  • RESULTS: Significant increase in HGF levels was found in patients with benign breast lumps and in breast cancer patients when each was compared to controls and when cancer patients were compared to the benign breast lumps group.
  • CONCLUSION: The serum level of HGF is an independent prognostic indicator for breast cancer.
  • [MeSH-major] Breast Neoplasms / blood. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / blood. Carcinoma, Ductal, Breast / pathology. Fibroadenoma / blood. Hepatocyte Growth Factor / blood
  • [MeSH-minor] Age Factors. Egypt. Female. Fibrocystic Breast Disease / blood. Humans. Inflammation / blood. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Tumor Burden

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21133597.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


24. Lee JH, Kim SH, Kang BJ, Lee AW, Song BJ: Ultrasonographic features of benign adenomyoepithelioma of the breast. Korean J Radiol; 2010 Sep-Oct;11(5):522-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasonographic features of benign adenomyoepithelioma of the breast.
  • OBJECTIVE: The purpose of this study was to evaluate the ultrasonographic features of benign adenomyoepithelioma of the breast.
  • MATERIALS AND METHODS: Between 2005 and 2009, five patients had histologically confirmed adenomyoepithelioma of the breast.
  • We retrospectively evaluated the ultrasonographic findings of the tumors in correlation with the pathology, and reviewed medical records.
  • The ultrasonographic assessments were classified as Breast Imaging Reporting and Data System (BI-RADS) category 4A, with low suspicion of malignancy in two cases, and as category 4B, with intermediate suspicion of malignancy in three cases.
  • The pathology revealed benign adenomyoepithelioma in all patients.
  • CONCLUSION: Benign adenomyoepitheliomas appear as solid or complex echoic masses with suspicious malignant ultrasonographic features, which may be associated with adjacent ductectasia.
  • Although adenomyoepithelioma is a rare breast tumor, awareness of its sonographic features will be helpful for the differential diagnosis from other tumors.
  • [MeSH-major] Adenomyoepithelioma / ultrasonography. Breast Neoplasms / ultrasonography. Ultrasonography, Mammary
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Mammography. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):632-6 [10747327.001]
  • [Cites] Acta Cytol. 2000 May-Jun;44(3):488-90 [10834021.001]
  • [Cites] J Ultrasound Med. 2001 Sep;20(9):1021-4 [11549151.001]
  • [Cites] Breast J. 2002 Nov-Dec;8(6):383-4 [12390363.001]
  • [Cites] AJR Am J Roentgenol. 2003 Mar;180(3):799-803 [12591699.001]
  • [Cites] Breast. 2004 Aug;13(4):356-8 [15325675.001]
  • [Cites] Breast Cancer. 2007;14(4):429-33 [17986811.001]
  • [Cites] Hum Pathol. 1987 Dec;18(12):1232-7 [2824328.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):554-68 [1709559.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):868-76 [1384377.001]
  • [Cites] Breast J. 2006 Jul-Aug;12(4):386 [16848857.001]
  • [Cites] Breast J. 2007 Mar-Apr;13(2):203-4 [17319866.001]
  • [Cites] Acta Radiol. 2007 Feb;48(1):27-9 [17325921.001]
  • [Cites] Curr Top Pathol. 1970;53:161-220 [4323195.001]
  • (PMID = 20808695.001).
  • [ISSN] 2005-8330
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2930160
  • [Keywords] NOTNLM ; Adenomyoepithelioma / Breast / Ultrasonography
  •  go-up   go-down


25. Corzo C, Corominas JM, Tusquets I, Salido M, Bellet M, Fabregat X, Serrano S, Solé F: The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma. Cancer Genet Cytogenet; 2006 Mar;165(2):151-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma.
  • One hypothesis for breast cancer development suggests that breast carcinogenesis involves a progression of events leading from benign epithelium to hyperplasia (with or without atypia) to carcinoma in situ and then invasive carcinoma.
  • Benign lesions and normal adjacent cells were classified as normal.
  • The presence of MYC amplification only in invasive cells suggests that the finding of MYC amplification could reflect an advanced tumor progression.
  • [MeSH-major] Breast Neoplasms / genetics. Genes, myc
  • [MeSH-minor] Chromosomes, Human, Pair 8. Disease Progression. Female. Humans. In Situ Hybridization, Fluorescence. Neoplasm Invasiveness. Paraffin Embedding

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527609.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. Xu Y, Bismar TA, Su J, Xu B, Kristiansen G, Varga Z, Teng L, Ingber DE, Mammoto A, Kumar R, Alaoui-Jamali MA: Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion. J Exp Med; 2010 Oct 25;207(11):2421-37
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion.
  • In this study, we report that FLNa suppresses invasion of breast cancer cells and regulates focal adhesion (FA) turnover.
  • Two large progression tissue microarrays from breast cancer patients revealed a significant decrease of FLNa levels in tissues from invasive breast cancer compared with benign disease and in lymph node-positive compared with lymph node-negative breast cancer.
  • In breast cancer cells and orthotopic mouse breast cancer models, down-regulation of FLNa stimulated cancer cell migration, invasion, and metastasis formation.
  • These results document a regulation of FA dynamics by FLNa in breast cancer cells.


27. Wauters CA, Sanders-Eras MC, de Kievit-van der Heijden IM, Wesseling P, Venderink DJ, van Dijk Azn R, van den Wildenberg F, Kooistra BW, Strobbe LJ: Modified core wash cytology (CWC), an asset in the diagnostic work-up of breast lesions. Eur J Surg Oncol; 2010 Oct;36(10):957-62
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modified core wash cytology (CWC), an asset in the diagnostic work-up of breast lesions.
  • AIM: A quick and reliable preliminary diagnosis is essential in the management of a same-day breast clinic.
  • METHODS: From April 2008 to April 2009, biopsies were taken from lesions in the breast.
  • CWC was obtained from core needle biopsy (CNB) with a modified technique and classified into the categories: malignant, suspicious for malignancy, atypical, benign and inadequate.
  • RESULTS: CWC was obtained from 226 breast lesions.
  • In 167 of these cases subsequent resection of the lesion was performed revealing 149 carcinomas and 18 benign lesions.
  • Of the 149 malignant cases, 136 were considered as either malignant or suspicious for malignancy by CWC, 7 as atypical, 4 as benign and 2 as inadequate.
  • None of the 18 benign lesions were classified as suspicious or malignant on CWC.
  • CONCLUSIONS: In the vast majority of patients the modified CWC technique can provide a quick and reliable diagnosis of malignant breast lesions.
  • Furthermore, combining CWC with CNB histology can improve adequate, preoperative recognition of the malignant character of breast lesions.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / pathology. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Ambulatory Care / methods. Breast Diseases / diagnosis. Breast Diseases / pathology. Breast Diseases / surgery. Cohort Studies. Cytodiagnosis / methods. Diagnosis, Differential. Female. Hospitals, Teaching. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Netherlands. Preoperative Care / methods. Reproducibility of Results. Risk Assessment. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20708371.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Zhu Q, Hegde PU, Ricci A Jr, Kane M, Cronin EB, Ardeshirpour Y, Xu C, Aguirre A, Kurtzman SH, Deckers PJ, Tannenbaum SH: Early-stage invasive breast cancers: potential role of optical tomography with US localization in assisting diagnosis. Radiology; 2010 Aug;256(2):367-78
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-stage invasive breast cancers: potential role of optical tomography with US localization in assisting diagnosis.
  • PURPOSE: To investigate the potential role of optical tomography in the near-infrared (NIR) spectrum with ultrasonographic (US) localization as a means of differentiating early-stage cancers from benign lesions of the breast.
  • From this measurement, tumor angiogenesis was assessed on the basis of calculated total hemoglobin concentration (tHb) and was correlated with core biopsy results.
  • RESULTS: There were two in situ carcinomas (Tis), 35 T1 carcinomas, 24 T2-T4 carcinomas, and 114 benign lesions.
  • The mean maximum and mean average tHb of the benign group were 55.1 micromol/L +/- 22.7 and 39.1 micromol/L +/- 14.9, respectively.
  • Both mean maximum and mean average tHb levels were significantly higher in the malignant groups than they were in the benign group (P < .001).
  • The corresponding values for T2-T4 tumors were 75%, 93%, 69%, and 95%.
  • CONCLUSION: The angiogenesis (tHb) contrast imaged by using the NIR technique with US holds promise as an adjunct to mammography and US for distinguishing early-stage invasive breast cancers from benign lesions.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2004 Jan;230(1):42-8 [14695385.001]
  • [Cites] J Pathol. 2004 Oct;204(2):140-6 [15376259.001]
  • [Cites] Nature. 1989 May 4;339(6219):58-61 [2469964.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6449-65 [2684393.001]
  • [Cites] Radiology. 1995 Jul;196(1):123-34 [7784555.001]
  • [Cites] Arch Surg. 1996 Mar;131(3):301-8 [8611096.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1053-5 [9870852.001]
  • [Cites] Radiology. 2004 Dec;233(3):857-67 [15567802.001]
  • [Cites] J Biomed Opt. 2004 Nov-Dec;9(6):1152-60 [15568935.001]
  • [Cites] Eur J Radiol. 2005 Apr;54(1):72-9 [15797295.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):263-70 [15799826.001]
  • [Cites] Appl Opt. 2005 Apr 10;44(11):2140-53 [15835360.001]
  • [Cites] Radiology. 2005 May;235(2):396-401 [15770039.001]
  • [Cites] Med Phys. 2005 Apr;32(4):1128-39 [15895597.001]
  • [Cites] Phys Med Biol. 2005 Jun 7;50(11):2429-49 [15901947.001]
  • [Cites] Phys Med Biol. 2005 Jun 7;50(11):2489-502 [15901950.001]
  • [Cites] Invest Radiol. 2005 Jun;40(6):328-35 [15905718.001]
  • [Cites] J Biomed Opt. 2005 Mar-Apr;10(2):024033 [15910106.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):229-37 [16034008.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):934-47 [16023382.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):925-33 [16023383.001]
  • [Cites] Radiology. 2005 Oct;237(1):57-66 [16183924.001]
  • [Cites] Breast Cancer Res. 2005;7(6):279-85 [16457705.001]
  • [Cites] Radiol Med. 2006 Apr;111(3):440-8 [16683089.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8828-33 [16731633.001]
  • [Cites] Technol Cancer Res Treat. 2006 Aug;5(4):365-80 [16866567.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):180-7 [17154175.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4014-9 [17360469.001]
  • [Cites] Radiology. 2007 May;243(2):350-9 [17400760.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5474-9 [17875777.001]
  • [Cites] Breast Cancer Res Treat. 2008 Mar;108(1):9-22 [17468951.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(4):539-44 [18267357.001]
  • [Cites] Acad Radiol. 2008 Jul;15(7):859-66 [18572121.001]
  • [Cites] Neoplasia. 2008 Oct;10(10):1028-40 [18813360.001]
  • [Cites] J Biomed Opt. 2008 Jul-Aug;13(4):044002 [19021330.001]
  • [Cites] Cancer. 2009 Apr 1;115(7):1363-80 [19197974.001]
  • [Cites] Radiology. 2009 Sep;252(3):665-72 [19567644.001]
  • [Cites] J Biomed Opt. 2009 Jul-Aug;14(4):044005 [19725717.001]
  • [Cites] Clin Radiol. 2000 Jan;55(1):40-4 [10650109.001]
  • [Cites] Radiology. 2000 Dec;217(3):841-8 [11110952.001]
  • [Cites] Ultrasound Med Biol. 2002 Jan;28(1):19-26 [11879948.001]
  • [Cites] Neoplasia. 2002 Jul-Aug;4(4):347-54 [12082551.001]
  • [Cites] Opt Lett. 2003 Mar 1;28(5):337-9 [12659436.001]
  • [Cites] Neoplasia. 2003 Sep-Oct;5(5):379-88 [14670175.001]
  • (PMID = 20571122.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB002136
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2909434
  •  go-up   go-down


29. Farkash EA, Ferry JA, Harris NL, Hochberg EP, Takvorian RW, Zuckerman DS, Sohani AR: Rare lymphoid malignancies of the breast: a report of two cases illustrating potential diagnostic pitfalls. J Hematop; 2009;2(4):237-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare lymphoid malignancies of the breast: a report of two cases illustrating potential diagnostic pitfalls.
  • Breast involvement by lymphoma is uncommon and poses challenges in diagnosis.
  • Lymphomas may clinically, radiologically, and morphologically mimic both benign and neoplastic conditions.
  • We describe two cases of lymphoid malignancies predominantly involving the breast, both presenting diagnostic dilemmas.
  • The first case, ALK-negative anaplastic large-cell lymphoma involving a seroma associated with a breast implant, is an emerging clinicopathologic entity.
  • Anaplastic large-cell lymphoma has been identified in association with breast implants and seroma formation relatively recently.
  • The second case, hairy cell leukemia involving the breast and ipsilateral axillary sentinel lymph node, is, to our knowledge, the first reported case of hairy cell leukemia involving the breast at the time of diagnosis.
  • While a localized bone lesion was present at time of diagnosis, bone marrow involvement was relatively mild in comparison to that seen in the breast and lymph node.
  • In the first case, lymphoma occurred in a clinical setting where malignancy was unsuspected, highlighting the importance of careful morphologic evaluation of paucicellular samples, as well as awareness of rare clinicopathologic entities, in avoiding a misdiagnosis of a benign inflammatory infiltrate.
  • In the second case, the lymphoid neoplasm exhibited classic morphologic and immunophenotypic features, but presented at an unusual site of involvement.
  • Knowledge of the patient's concurrent diagnosis of hairy cell leukemia involving the bone marrow and bone helped avoid a misdiagnosis of carcinoma rather than lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Medica (Hradec Kralove). 2003;46(4):175-7 [14965169.001]
  • [Cites] Ann Hematol. 2003 Jul;82(7):397-404 [12764549.001]
  • [Cites] Hematol Oncol Clin North Am. 2006 Oct;20(5):1065-73 [16990107.001]
  • [Cites] Ann Plast Surg. 2007 Jul;59(1):56-7 [17589261.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):455-63 [18223553.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1265-8 [18594466.001]
  • [Cites] Am J Surg Pathol. 2008 Sep;32(9):1299-309 [18636016.001]
  • [Cites] Cancer. 2008 Oct 1;113(7):1511-20 [18704988.001]
  • [Cites] JAMA. 2008 Nov 5;300(17):2030-5 [18984890.001]
  • [Cites] Cancer. 1979 Apr;43(4):1339-49 [445334.001]
  • [Cites] Br J Cancer. 1989 Oct;60(4):605-9 [2803932.001]
  • [Cites] J Clin Oncol. 1988 Aug;6(8):1280-4 [3411340.001]
  • [Cites] Cancer. 1972 Jun;29(6):1705-12 [4555557.001]
  • [Cites] Ann Intern Med. 1973 Jan;78(1):113-8 [4565899.001]
  • [Cites] Cancer. 1974 May;33(5):1399-410 [4823484.001]
  • [Cites] Semin Oncol. 1984 Dec;11(4):370-80 [6505704.001]
  • [Cites] Plast Reconstr Surg. 1994 Oct;94(5):628-33; discussion 634-6 [7938285.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):505-7 [8604821.001]
  • [Cites] Plast Reconstr Surg. 1997 Aug;100(2):554-5 [9252643.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):357-64 [10375092.001]
  • [Cites] J Clin Pathol. 2000 Jun;53(6):445-50 [10911802.001]
  • [Cites] Cancer Causes Control. 2000 Oct;11(9):819-27 [11075871.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):115-9 [11908714.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):e115-8 [12653596.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Leuk Lymphoma. 2003 Jul;44(7):1173-8 [12916870.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):561-4 [16983530.001]
  • (PMID = 20309431.001).
  • [ISSN] 1865-5785
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2798933
  • [Keywords] NOTNLM ; Anaplastic large cell lymphoma / Anaplastic lymphoma kinase / Breast / Breast implant / Hairy cell leukemia / Primary breast lymphoma / Seroma / T-cell neoplasm
  •  go-up   go-down


30. Rinaldi P, Giuliani M, Belli P, Costantini M, Romani M, Distefano D, Bufi E, Mulè A, Magno S, Masetti R, Bonomo L: DWI in breast MRI: role of ADC value to determine diagnosis between recurrent tumor and surgical scar in operated patients. Eur J Radiol; 2010 Aug;75(2):e114-23
MedlinePlus Health Information. consumer health - Scars.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DWI in breast MRI: role of ADC value to determine diagnosis between recurrent tumor and surgical scar in operated patients.
  • INTRODUCTION: Purpose of our study is to evaluate the role of the apparent diffusion coefficient (ADC) in the diagnosis of recurrent tumor on the scar in patients operated for breast cancer.
  • Assess, therefore, the weight of diagnostic diffusion echo-planar sequence, in association with the morphological and dynamic sequences in the diagnosis of tumor recurrence versus surgical scar.
  • MATERIALS AND METHODS: From September 2007 to March 2009, 72 patients operated for breast cancer with suspected recurrence on the scar were consecutively subjected to magnetic resonance imaging (MRI), including use of a diffusion sequence.
  • RESULTS: 26 cases were positive/doubtful at MRI and then subjected to histological typing: of these recurrences were 20 and benign were 6.
  • CONCLUSIONS: ADC value can be a specific parameter in differential diagnosis between recurrence and scar.
  • The diffusion sequence, in association with the morphological and dynamic sequences, can be considered a promising tool for the surgical indication in suspected recurrence of breast cancer.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Cicatrix / diagnosis. Diffusion Magnetic Resonance Imaging. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20172677.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


31. Maxwell AJ: Ultrasound-guided vacuum-assisted excision of breast papillomas: review of 6-years experience. Clin Radiol; 2009 Aug;64(8):801-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasound-guided vacuum-assisted excision of breast papillomas: review of 6-years experience.
  • AIM: To review the outcome of vacuum-assisted removal of breast papillomas performed in the Bolton Breast Unit.
  • MATERIALS AND METHODS: Twenty-six benign breast papillomas were excised using an ultrasound-guided, vacuum-assisted technique under local anaesthetic over a 6-year period.
  • Subsequent breast imaging (mostly routine screening mammography) was reviewed and evidence of recurrence recorded.
  • All three recurrent lesions were surgically excised and confirmed to be benign papillomas.
  • [MeSH-major] Breast Neoplasms / surgery. Papilloma, Intraductal / surgery. Ultrasonography, Interventional
  • [MeSH-minor] Aged. Biopsy / methods. Breast / pathology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / surgery. Neoplasm Recurrence, Local / ultrasonography. Treatment Outcome. Ultrasonography, Mammary. Vacuum

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19589419.001).
  • [ISSN] 1365-229X
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Li HZ, Gao Y, Zhao XL, Liu YX, Sun BC, Yang J, Yao Z: Effects of raf kinase inhibitor protein expression on metastasis and progression of human breast cancer. Mol Cancer Res; 2009 Jun;7(6):832-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of raf kinase inhibitor protein expression on metastasis and progression of human breast cancer.
  • Raf kinase inhibitor protein (RKIP) has been shown to be a metastasis suppressor in many kinds of malignant tumors.
  • But its function in breast cancer was not yet clarified completely.
  • We detected RKIP expression in clinical samples of primary breast cancer, breast cancer metastases, and in different breast cancer cells.
  • Compared with the normal breast epithelia, benign breast epithelia, or in situ ductal carcinoma, the expression level of RKIP is decreased in invasive carcinoma and significantly reduced or lost in the metastasis lymph node matched to the invasive carcinoma.
  • To explore the potential role of RKIP in breast cancer metastasis, we studied the effect of RKIP on the malignant phenotypes of the breast cancer cells with ectopically overexpression or knockdown of RKIP.
  • Consistent with these results, in the orthotopic murine models, we observed that overexpression of RKIP in breast cancer cells impaired invasiveness and metastasis, whereas down-regulation of RKIP expression promoted invasiveness and metastasis.
  • These results indicate that RKIP is a metastasis suppressor gene of human breast cancer.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Phosphatidylethanolamine Binding Protein / biosynthesis
  • [MeSH-minor] Analysis of Variance. Animals. Cell Adhesion / physiology. Cell Growth Processes / physiology. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Mice. Mice, Inbred BALB C. Neoplasm Invasiveness. Neoplasm Metastasis. Neovascularization, Pathologic / metabolism. Statistics, Nonparametric. Tissue Distribution


33. Wang L, Wang Y, Liu Y, Cheng M, Wu X, Wei H: Flow cytometric analysis of CK19 expression in the peripheral blood of breast carcinoma patients: relevance for circulating tumor cell detection. J Exp Clin Cancer Res; 2009;28:57
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow cytometric analysis of CK19 expression in the peripheral blood of breast carcinoma patients: relevance for circulating tumor cell detection.
  • BACKGROUND: Immunocytochemistry and RT-PCR have been widely used for the detection of circulating tumor cells in patients with breast cancer but their specificity is limited.
  • Our purpose is to utilize a convenient and specific technology to detect circulating tumor cells in breast cancer patients.
  • A total of 73 blood specimens including 25 healthy volunteers and 48 patients with breast carcinoma and benign tumor were tested by flow cytometry to quantify the expression of CK19.
  • CK19 was detected in 27% of breast cancer patients but none control gives positive result.
  • CONCLUSION: Our research convinces that the detection of CK19 in peripheral blood by flow cytometry is also a specific and feasible method to monitor circulating tumor cells in breast cancer.
  • [MeSH-major] Breast Neoplasms / metabolism. Flow Cytometry / methods. Keratin-19 / metabolism. Neoplastic Cells, Circulating / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Cell Line, Tumor. Humans. Indicator Dilution Techniques. Middle Aged. Neoplasm Staging. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2001 Jan 10;162(1):65-73 [11121864.001]
  • [Cites] J Cancer Res Ther. 2005 Oct-Dec;1(4):221-6 [17998657.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):824-42 [11390532.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):17-20 [11438448.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3404-12 [12177100.001]
  • [Cites] Int J Oncol. 2002 Nov;21(5):1111-7 [12370762.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4338-43 [12409333.001]
  • [Cites] Ann Oncol. 2003 Jun;14(6):849-55 [12796021.001]
  • [Cites] Jpn J Clin Oncol. 2003 Apr;33(4):167-72 [12810830.001]
  • [Cites] Breast. 2004 Feb;13(1):35-41 [14759714.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1392-400 [14977842.001]
  • [Cites] J Clin Pathol. 2004 Sep;57(9):903-11 [15333648.001]
  • [Cites] Acta Biochim Pol. 2004;51(3):747-55 [15448736.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2632-40 [9704713.001]
  • [Cites] Br J Cancer. 1998 Nov;78(9):1194-8 [9820179.001]
  • [Cites] Breast Cancer Res Treat. 2004 Oct;87(3):215-24 [15528964.001]
  • [Cites] Br J Cancer. 2004 Nov 15;91(10):1813-20 [15505629.001]
  • [Cites] Int J Oncol. 2005 Mar;26(3):721-30 [15703829.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1420-30 [15735118.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):251-6 [15937912.001]
  • [Cites] Gynecol Oncol. 2006 Feb;100(2):355-60 [16203027.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):2013-9 [16287086.001]
  • [Cites] Biomed Pharmacother. 2005 Oct;59 Suppl 2:S384-6 [16507415.001]
  • [Cites] Arch Oral Biol. 2006 Dec;51(12):1112-9 [16806049.001]
  • [Cites] Breast Cancer Res. 2006;8(4):R36 [16846533.001]
  • [Cites] Anticancer Res. 2007 May-Jun;27(3A):1337-41 [17593628.001]
  • [Cites] Ann Oncol. 2007 Oct;18(10):1623-31 [17515404.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):39-46 [11249047.001]
  • (PMID = 19397830.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Keratin-19
  • [Other-IDs] NLM/ PMC2685124
  •  go-up   go-down


34. Celis JE, Moreira JM, Gromova I, Cabezón T, Gromov P, Shen T, Timmermans V, Rank F: Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia. Mol Oncol; 2007 Jun;1(1):97-119
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.
  • The identification as well as the molecular characterization of breast precancerous lesions in terms of increased risk of progression and/or recurrence is becoming a critical issue today as improved non-surgical procedures are detecting cancer at an earlier stage.
  • The strategy we have been pursuing to identify early apocrine breast lesions is based on the postulate that invasive apocrine carcinomas evolve from epithelial cells in terminal duct lobular units (TDLUs) in a stepwise manner that involves apocrine metaplasia of normal breast epithelia, hyperplasia, atypia, and apocrine carcinoma in situ.
  • First, we identify specific protein biomarkers for benign apocrine metaplasia and thereafter we search for biomarkers that are highly overexpressed by pure invasive apocrine carcinomas.
  • Here we present studies in which we have used antibodies against components of a benign apocrine signature that includes 15-prostaglandin dehydrogenase (15-PGDH), a protein that is expressed by all benign apocrine lesions, and markers that are highly overexpressed by pure invasive apocrine carcinomas such as MRP14 (S100A9), psoriasin (S100A7), and p53 to identify precancerous lesions in sclerosing adenosis (SA) with apocrine metaplasia.
  • The latter is a benign proliferative lesion of the breast that exhibits an increase in the size of the TDLUs and characterized by retained two-cell lining, and myoepithelial (ME) and stromal hyperplasia.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Breast Neoplasms / metabolism. Fibrocystic Breast Disease / metabolism. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / biosynthesis. Precancerous Conditions / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2002 Jan 1;115(Pt 1):39-50 [11801722.001]
  • [Cites] Mod Pathol. 1994 Oct;7(8):813-8 [7838835.001]
  • [Cites] Ann Surg. 2002 Dec;236(6):785-93; discussion 793 [12454517.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jul;104(1):75-85 [17009105.001]
  • [Cites] J Cell Biol. 1997 Dec 29;139(7):1873-84 [9412479.001]
  • [Cites] Adv Anat Pathol. 2004 Jan;11(1):1-9 [14676636.001]
  • [Cites] Eur J Radiol. 2005 Apr;54(1):6-14 [15797289.001]
  • [Cites] Am J Pathol. 1983 Feb;110(2):105-12 [6130702.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):146-9 [7819031.001]
  • [Cites] Radiographics. 1999 Oct;19 Spec No:S80-3 [10517446.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):459-72 [17157787.001]
  • [Cites] Am J Surg. 1990 May;159(5):473-8 [2334010.001]
  • [Cites] J Pathol. 2004 Mar;202(3):274-85 [14991892.001]
  • [Cites] Virchows Arch. 1998 Mar;432(3):255-60 [9532005.001]
  • [Cites] Am J Surg. 1993 Sep;166(3):237-43 [8368433.001]
  • [Cites] J Cutan Pathol. 1999 Mar;26(3):113-8 [10235375.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):708-13 [10227293.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1316-23 [16835330.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):555-69 [15644556.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):26-41 [19383285.001]
  • [Cites] Anticancer Res. 1988 Nov-Dec;8(6):1217-22 [3064712.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):693-7 [10505026.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):13-8 [10658905.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):872-9 [11978511.001]
  • [Cites] Biochem Pharmacol. 2006 Nov 30;72(11):1622-31 [16846592.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Lab Invest. 2002 Jun;82(6):737-46 [12065684.001]
  • [Cites] Am J Pathol. 2000 Jul;157(1):323-9 [10880402.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):355-61 [10197443.001]
  • [Cites] Ir J Med Sci. 1989 Jun;158(6):137-40 [2570047.001]
  • [Cites] Recent Results Cancer Res. 1998;152:11-21 [9928543.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Trends Cell Biol. 1996 Sep;6(9):341-7 [15157431.001]
  • [Cites] J Cell Biol. 2007 Apr 9;177(1):87-101 [17420292.001]
  • [Cites] Breast Cancer Res. 2003;5(5):R151-6 [12927046.001]
  • [Cites] BMJ. 1997 Mar 29;314(7085):925-8 [9099114.001]
  • [Cites] J Dermatol Sci. 2007 Feb;45(2):147-50 [17071058.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] J Natl Cancer Inst. 1975 Aug;55(2):231-73 [169369.001]
  • [Cites] Virchows Arch. 2006 May;448(5):525-31 [16570182.001]
  • [Cites] Anticancer Res. 1994 Nov-Dec;14(6B):2805-9 [7872722.001]
  • [Cites] Int J Cancer. 2003 Aug 10;106(1):8-16 [12794751.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):261-72 [16807805.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1340-2 [11684218.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):470-9 [9469330.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7818-23 [16885386.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Med Princ Pract. 2007;16(1):1-14 [17159357.001]
  • [Cites] Subcell Biochem. 1998;31:205-62 [9932494.001]
  • [Cites] J Invest Dermatol. 1991 Oct;97(4):701-12 [1940442.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4782-90 [8840999.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13(4):1033-67 [17158753.001]
  • [Cites] FEBS Lett. 2006 May 22;580(12):2935-44 [16631754.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2529-37 [8640702.001]
  • [Cites] Int J Oncol. 2005 Dec;27(6):1473-81 [16273201.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):313-9 [8546221.001]
  • [Cites] FEBS J. 2005 Jan;272(1):2-15 [15634327.001]
  • [Cites] Ann N Y Acad Sci. 1990;586:49-52 [2141459.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2006 Oct;81(1-2):14-30 [16997128.001]
  • [Cites] Mol Cell Proteomics. 2006 Mar;5(3):462-83 [16316978.001]
  • [Cites] Adv Anat Pathol. 2002 May;9(3):185-97 [11981114.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):344-9 [16400324.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):349-54 [10197442.001]
  • [Cites] J Clin Pathol. 1995 Aug;48(8):737-42 [7560201.001]
  • [Cites] Int J Cancer. 1994 Nov 1;59(3):369-72 [7927943.001]
  • [Cites] Pathol Res Pract. 1997;193(11-12):753-8 [9521507.001]
  • [Cites] Eur J Gynaecol Oncol. 1992;13(4):309-15 [1325346.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):734-46 [15897740.001]
  • [Cites] Adv Anat Pathol. 2003 May;10(3):113-24 [12717115.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):207-14 [11141494.001]
  • [Cites] JAMA. 1995 Jan 11;273(2):149-54 [7799496.001]
  • [Cites] Breast Cancer Res. 2005;7(5):190-7 [16168137.001]
  • [Cites] Mol Cell Proteomics. 2003 Jun;2(6):369-77 [12832461.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1307-12 [17182657.001]
  • [Cites] Methods. 2003 Jul;30(3):247-55 [12798139.001]
  • [Cites] Am J Clin Pathol. 2000 May;113(5 Suppl 1):S3-18 [11993707.001]
  • [Cites] Nat Chem Biol. 2006 Dec;2(12):689-700 [17108987.001]
  • [Cites] J Clin Pathol. 2004 Jul;57(7):675-81 [15220356.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):231-47 [16807803.001]
  • [Cites] Dev Biol. 1999 Feb 1;206(1):88-99 [9918697.001]
  • [Cites] Histopathology. 2001 Mar;38(3):221-4 [11260302.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):97-119 [19383289.001]
  • [Cites] Breast Cancer Res Treat. 2001 May;67(2):93-109 [11519870.001]
  • [Cites] Breast. 2002 Dec;11(6):466-72 [14965711.001]
  • [Cites] J Pathol. 2002 Mar;196(3):287-91 [11857491.001]
  • [Cites] J Mol Biol. 1993 Jun 20;231(4):982-98 [8515476.001]
  • [Cites] Semin Oncol. 2006 Dec;33(6):642-6 [17145342.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1054-60 [11474290.001]
  • [Cites] Int J Cancer. 2000 Jun 15;86(6):835-41 [10842198.001]
  • [Cites] Med Mol Morphol. 2006 Mar;39(1):8-13 [16575508.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):638-42 [17136094.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1051-61 [15254552.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):749-51 [10797302.001]
  • [Cites] Hum Pathol. 1987 Apr;18(4):381-6 [3557440.001]
  • [Cites] J Biol Chem. 1975 May 25;250(10):4007-21 [236308.001]
  • [Cites] Virchows Arch. 2002 Nov;441(5):449-55 [12447674.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):1076-91 [15252316.001]
  • [Cites] Differentiation. 1998 Aug;63(4):201-13 [9745711.001]
  • [Cites] Endocr Relat Cancer. 2001 Mar;8(1):47-61 [11350726.001]
  • [Cites] Mod Pathol. 1991 Jan;4(1):1-5 [2020652.001]
  • [Cites] Cancer Detect Prev. 2006;30(5):387-94 [17079091.001]
  • [Cites] Histopathology. 2001 Oct;39(4):433-4 [11683946.001]
  • [Cites] Oncogene. 2006 Apr 13;25(16):2328-38 [16314837.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11326-34 [16357139.001]
  • [Cites] Eur J Cancer. 2004 May;40(8):1179-87 [15110881.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jan;10(1):61-74 [15886887.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):492-522 [15695426.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):43-7 [11782356.001]
  • [Cites] Am J Surg Pathol. 1991 Jul;15(7):687-94 [2058763.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):327-44 [14754989.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):3003-9 [10383167.001]
  • [Cites] Pathology. 2006 Feb;38(1):16-20 [16484002.001]
  • [Cites] Hum Pathol. 1994 Apr;25(4):337-42 [8163266.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):633-7 [17136093.001]
  • [Cites] J Endocrinol. 1992 Mar;132(3):R5-8 [1564416.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):84-96 [18516279.001]
  • [Cites] Cancer Detect Prev. 2001;25(3):262-7 [11425268.001]
  • (PMID = 19383289.001).
  • [ISSN] 1878-0261
  • [Journal-full-title] Molecular oncology
  • [ISO-abbreviation] Mol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


35. De Vivo I, Prescott J, Wong JY, Kraft P, Hankinson SE, Hunter DJ: A prospective study of relative telomere length and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev; 2009 Apr;18(4):1152-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of relative telomere length and postmenopausal breast cancer risk.
  • During breast cancer progression, a substantial increase in chromosomal aberrations is observed in the transition from ductal hyperplasia to carcinoma in situ.
  • Consequently, telomere dysfunction, which leads to genomic instability, is hypothesized to play a causal role in the progression of breast cancer.
  • However, the few epidemiologic studies that have assessed the relationship between telomere length and breast cancer risk have been inconsistent.
  • We used quantitative real-time PCR to measure relative telomere length in genomic DNA extracted from peripheral blood leukocytes and examined its association with postmenopausal breast cancer risk in 1,122 invasive breast cancer cases and 1,147 matched controls free of diagnosed cancer nested within the prospective Nurses' Health Study.
  • Our data show that relative telomere length was not associated with a significant elevation in postmenopausal breast cancer risk [below versus above median; odds ratio, 1.23; 95% confidence interval, 0.94-1.60; P(trend) = 0.20].
  • Other established breast cancer risk factors such as family history of breast cancer and history of benign breast disease were not associated with relative telomere length in separate linear regression models each adjusted for age and disease status (P > or = 0.07).
  • Our results provide little support for an important role of telomere length, as measured in peripheral blood leukocytes, as a biomarker of breast cancer risk.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. ESTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2008 May 15;68(10):3618-23 [18483243.001]
  • [Cites] Br J Cancer. 2007 Dec 17;97(12):1696-700 [18000505.001]
  • [Cites] Mech Ageing Dev. 2000 Nov 15;119(3):89-99 [11080530.001]
  • [Cites] Nucleic Acids Res. 2002 May 15;30(10):e47 [12000852.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 20;95(16):1211-8 [12928346.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):984-8 [15300252.001]
  • [Cites] Cancer Res. 1985 Jun;45(6):2900-6 [3986816.001]
  • [Cites] Am J Epidemiol. 1987 Aug;126(2):319-25 [3605058.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10114-8 [1438199.001]
  • [Cites] Curr Opin Oncol. 1996 Jan;8(1):66-71 [8868103.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1292-9 [9731736.001]
  • [Cites] J Exp Med. 1999 Jul 19;190(2):157-67 [10432279.001]
  • [Cites] Carcinogenesis. 2005 Jul;26(7):1263-71 [15746160.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1823-30 [16567770.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:531-57 [16824017.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):815-9 [17416776.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5538-44 [17545637.001]
  • [Cites] Aging Cell. 2007 Dec;6(6):769-74 [17925004.001]
  • [Cites] Cancer Res. 1999 Dec 1;59(23):5917-21 [10606235.001]
  • (PMID = 19293310.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA082838; United States / NCI NIH HHS / CA / CA065725; United States / NCI NIH HHS / CA / R01 CA049449-19; United States / NCI NIH HHS / CA / R01 CA065725-05; United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CA / T32 CA009001-33; United States / NCI NIH HHS / CA / CA87969; United States / NCI NIH HHS / CA / CA132190-02; United States / NCI NIH HHS / CA / CA49449; United States / NCI NIH HHS / CA / CA009001-33; United States / NCI NIH HHS / CA / R01 CA065725; United States / NCI NIH HHS / CA / R01 CA082838; United States / NCI NIH HHS / CA / R03 CA132190-02; United States / NCI NIH HHS / CA / T32 CA09001; United States / NCI NIH HHS / CA / P01 CA087969-09; United States / NCI NIH HHS / CA / CA132190; United States / NCI NIH HHS / CA / R03 CA132190; United States / NCI NIH HHS / CA / T32 CA009001; United States / NCI NIH HHS / CA / CA065725-05; United States / NCI NIH HHS / CA / R01 CA049449; United States / NCI NIH HHS / CA / U01 CA049449; United States / NCI NIH HHS / CA / R01 CA082838-09
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 2DI9HA706A / Estrone; 4TI98Z838E / Estradiol
  • [Other-IDs] NLM/ NIHMS102391; NLM/ PMC2732000
  •  go-up   go-down


36. Chen C, Zhou Z, Sheehan CE, Slodkowska E, Sheehan CB, Boguniewicz A, Ross JS: Overexpression of WWP1 is associated with the estrogen receptor and insulin-like growth factor receptor 1 in breast carcinoma. Int J Cancer; 2009 Jun 15;124(12):2829-36
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of WWP1 is associated with the estrogen receptor and insulin-like growth factor receptor 1 in breast carcinoma.
  • WWP1, a HECT type E3 ubiquitin ligase frequently amplified and overexpressed in breast cancer, has the potential to become a useful clinical biomarker and therapeutic target in breast cancer.
  • The normal breast epithelium and adjacent benign epithelium are essentially negative for WWP1.
  • Cytoplasmic WWP1 immunoreactivity was observed in 76/187 (40.6%) tumors and showed a positive correlation with ERalpha (p = 0.05) and IGF-1R proteins (p = 0.001) in this cohort.
  • The positive correlations between WWP1 and ER/IGF-1R were also observed in a panel of 12 breast cancer cell lines by Western blot.
  • Interestingly, the ER levels are decreased when WWP1 is silenced in ER positive MCF7 and T47D breast cancer cell lines.
  • These findings suggest that WWP1 may play an important role in ER positive breast cancer.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Lobular / metabolism. Estrogen Receptor alpha / metabolism. Receptor, IGF Type 1 / metabolism. Ubiquitin-Protein Ligases / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / pharmacology. Biomarkers, Tumor / metabolism. Blotting, Western. Cell Proliferation / drug effects. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. RNA, Small Interfering / pharmacology. Tamoxifen / pharmacology. Tumor Cells, Cultured. Up-Regulation

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 UICC.
  • (PMID = 19267401.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Estrogen Receptor alpha; 0 / RNA, Small Interfering; 0 / estrogen receptor alpha, human; 094ZI81Y45 / Tamoxifen; EC 2.7.10.1 / Receptor, IGF Type 1; EC 6.3.2.19 / Ubiquitin-Protein Ligases; EC 6.3.2.19 / WWP1 protein, human
  •  go-up   go-down


37. Al-Khawari H, Kovacs A, Athyal R, Al-Manfouhi H, Fayaz MS, Madda JP: Breast magnetic resonance imaging: initial experience in Kuwait. Med Princ Pract; 2009;18(2):143-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast magnetic resonance imaging: initial experience in Kuwait.
  • OBJECTIVE: To report our initial experience of breast magnetic resonance imaging (MRI) in Kuwait in order to identify and characterize breast lesions.
  • SUBJECTS AND METHODS: In 58 patients ranging in age from 25 to 64 years, breast MRI was performed as a problem-solving tool (29); for suspicious local relapse of the treated breast (6); to search for a primary breast cancer in patients with metastatic axillary lymph nodes (5); for local staging of breast cancer (5); breast implants (6); screening in high-risk patients (3), and differentiation between inflammation and inflammatory carcinoma (4).
  • RESULTS: Seventy breast lesions (25 malignant, 38 benign and 7 lesions detected by MRI only) were identified in the 58 patients.
  • The sensitivity, specificity, and positive and negative predictive values of MRI in diagnosing malignant breast lesions were 96, 67, 71 and 95%, respectively, while the accuracy was 80%.
  • [MeSH-major] Breast. Breast Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Kuwait. Magnetic Resonance Imaging. Mass Screening / methods. Middle Aged. Neoplasm Staging / methods. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19204434.001).
  • [ISSN] 1423-0151
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


38. Goicoechea SM, Bednarski B, García-Mata R, Prentice-Dunn H, Kim HJ, Otey CA: Palladin contributes to invasive motility in human breast cancer cells. Oncogene; 2009 Jan 29;28(4):587-98
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palladin contributes to invasive motility in human breast cancer cells.
  • In this study, we found that the protein palladin, a molecular scaffold with an important function in actin organization, is expressed at higher overall levels in tumors compared with benign breast tissue, and also expressed significantly higher in four invasive breast cancer cell lines when compared with four non-invasive cell lines.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biochem Cell Biol. 2006;38(11):1875-92 [16790362.001]
  • [Cites] Exp Cell Res. 2006 Apr 15;312(7):974-82 [16430883.001]
  • [Cites] Proteomics. 2006 Aug;6(15):4402-9 [16807943.001]
  • [Cites] J Cell Physiol. 2006 Nov;209(2):568-79 [16897755.001]
  • [Cites] J Invest Dermatol. 2006 Nov;126(11):2387-96 [16794588.001]
  • [Cites] Proteomics. 2006 Dec;6(23):6300-16 [17133371.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e516 [17194196.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):296-305 [17211471.001]
  • [Cites] Breast Cancer Res Treat. 1999 Dec;58(3):193-204 [10718481.001]
  • [Cites] J Cell Biol. 2000 Aug 7;150(3):643-56 [10931874.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1833-8 [11280733.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5168-78 [11431356.001]
  • [Cites] Mol Biol Cell. 2001 Sep;12(9):2721-9 [11553711.001]
  • [Cites] Mol Biol Cell. 2001 Oct;12(10):3060-73 [11598191.001]
  • [Cites] Exp Cell Res. 2002 Oct 15;280(1):64-74 [12372340.001]
  • [Cites] Mol Biol Cell. 2003 Jun;14(6):2482-91 [12808045.001]
  • [Cites] Trends Cell Biol. 2003 Jul;13(7):376-85 [12837608.001]
  • [Cites] Trends Cell Biol. 2007 Mar;17(3):107-17 [17275303.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2657-65 [17363586.001]
  • [Cites] J Cell Biochem. 2007 Apr 1;100(5):1288-300 [17115415.001]
  • [Cites] Circ Res. 2007 Mar 30;100(6):817-25 [17322171.001]
  • [Cites] Biochim Biophys Acta. 2007 May;1773(5):642-52 [16926057.001]
  • [Cites] Immunity. 2007 Jun;26(6):784-97 [17570692.001]
  • [Cites] Exp Cell Res. 2007 Jul 15;313(12):2575-85 [17537434.001]
  • [Cites] Cancer Lett. 2007 Oct 8;255(2):205-18 [17537571.001]
  • [Cites] J Clin Invest. 2007 Oct;117(10):2962-73 [17885682.001]
  • [Cites] BMC Cancer. 2007;7:198 [17956604.001]
  • [Cites] J Biol Chem. 2008 Mar 7;283(10):6222-31 [18180288.001]
  • [Cites] Mol Cell Neurosci. 2003 Aug;23(4):661-8 [12932445.001]
  • [Cites] Cell Motil Cytoskeleton. 2004 Feb;57(2):84-95 [14691948.001]
  • [Cites] Cell Motil Cytoskeleton. 2004 May;58(1):17-29 [14983521.001]
  • [Cites] Mol Biol Cell. 2004 Apr;15(4):1600-8 [14767055.001]
  • [Cites] J Cell Biol. 2004 May 10;165(3):421-32 [15138294.001]
  • [Cites] FEBS Lett. 2004 May 21;566(1-3):30-4 [15147863.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Aug;5(8):647-57 [15366708.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5702-10 [7923219.001]
  • [Cites] J Cell Biol. 1998 Mar 23;140(6):1383-93 [9508771.001]
  • [Cites] Clin Exp Metastasis. 1998 Aug;16(6):501-12 [9872598.001]
  • [Cites] Oncogene. 1999 Aug 5;18(31):4440-9 [10442635.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8585-94 [15574765.001]
  • [Cites] Cancer Cell. 2005 Feb;7(2):155-65 [15710328.001]
  • [Cites] Trends Cell Biol. 2005 Mar;15(3):138-45 [15752977.001]
  • [Cites] J Cell Mol Med. 2005 Jan-Mar;9(1):208-21 [15784178.001]
  • [Cites] Mol Cell Neurosci. 2005 Aug;29(4):507-15 [15950489.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6130-8 [16024614.001]
  • [Cites] Int Rev Cytol. 2005;246:31-58 [16164966.001]
  • [Cites] Exp Cell Res. 2005 Oct 15;310(1):88-98 [16125169.001]
  • [Cites] FEBS J. 2006 Jan;273(1):26-33 [16367745.001]
  • [Cites] J Cell Sci. 2006 Mar 15;119(Pt 6):995-1004 [16492705.001]
  • [Cites] Eur J Cell Biol. 2006 Apr;85(3-4):151-7 [16546557.001]
  • [Cites] Eur J Cell Biol. 2006 Apr;85(3-4):213-8 [16546563.001]
  • [Cites] J Cell Sci. 2006 Aug 15;119(Pt 16):3316-24 [16868024.001]
  • (PMID = 18978809.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009688; United States / NIGMS NIH HHS / GM / GM61743; United States / NIGMS NIH HHS / GM / R01 GM061743; United States / NIGMS NIH HHS / GM / GM061743-04; United States / NIGMS NIH HHS / GM / R01 GM061743-04; United States / NCI NIH HHS / CA / CA098240; United States / NCI NIH HHS / CA / CA09688; United States / NCI NIH HHS / CA / K08 CA098240
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Cytoskeletal Proteins; 0 / Phosphoproteins; 0 / palladin protein, human; 0 / palladin protein, mouse
  • [Other-IDs] NLM/ NIHMS72118; NLM/ PMC2633435
  •  go-up   go-down


39. Al-Harris ES, Al-Janabi AA, Al-Toriahi KM, Yasseen AA: Over expression of vascular endothelial growth factor in correlation to Ki-67, grade, and stage of breast cancer. Saudi Med J; 2008 Aug;29(8):1099-104
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Over expression of vascular endothelial growth factor in correlation to Ki-67, grade, and stage of breast cancer.
  • OBJECTIVE: To assess the significance of vascular endothelial growth factor (VEGF) protein over expression in human breast cancer, and its possible correlation with cell proliferation marker (Ki-67), grade and stage of breast cancer.
  • A retrospective study was employed on paraffin-embedded blocks from 52 female patients with breast cancer.
  • A group of 21 patients with benign breast lesions was included for comparison and 14 cases of normal breast tissue as a control group.
  • Vascular endothelial growth factor immunoexpression was considered as positive in 61.5% of malignant and in 19% of benign breast lesions.
  • No over expression sign has been noticed in normal breast tissue (p<0.005).
  • No significant difference in VEGF over expression among different histological types of breast cancer (p>0.05).
  • Vascular endothelial growth factor immunostaining was positively correlated with Ki-67, grade, stage, lymph node metastasis, and recurrence of breast cancer (p<0.05).
  • CONCLUSION: Vascular endothelial growth factor Vascular endothelial growth factor plays an important role in pathogenesis of breast cancer evolution, and supports the evidence of its role in angiogenesis and cell survival.
  • [MeSH-major] Breast Neoplasms / pathology. Ki-67 Antigen / analysis. Neoplasm Staging. Vascular Endothelial Growth Factor A / analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18690299.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


40. Martínez-Galán J, Torres B, Del Moral R, Muñoz-Gámez JA, Martín-Oliva D, Villalobos M, Núñez MI, Luna Jde D, Oliver FJ, Ruiz de Almodóvar JM: Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy. Cancer Biol Ther; 2008 Jun;7(6):958-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy.
  • The aim of the present study was to investigate the association between gene hypermethylation and main clinicopathological features of breast cancer, including diagnosis and treatment response.
  • A sensitive SYBR green methylation-specific PCR technique was used to analyze the utility of circulating DNA with CpG island hypermethylation of ESR1, APC, RARB, 14-3-3-sigma and E-cad gene promoter regions as breast cancer biomarkers.
  • Analyses were conducted of preoperative sera from 106 women with breast cancer, 34 with benign breast disease and 74 with no evidence of breast disease and of post-treatment sera from 60 of the breast cancer patients.
  • Mean serum values of methylated ESR1 and 14-3-3-sigma gene promoters significantly differed between breast cancer patients and healthy controls (p = 0.0112 for ESR1 and p = 0.0047 for 14-3-3-sigma).
  • When their results were combined, it was found that hypermethylation of these two genes differentiated between breast cancer patients and healthy controls (p < 0.0001) with a sensitivity of 81% (95% confidence interval: 72-88%) and specificity of 88% (95% CI: 78-94%).
  • Presence of methylated ESR1 in serum of breast cancer patients was associated with the ER negative phenotype (p = 0.0179).
  • Serum hypermethylation at ESR1 and 14-3-3-sigma loci was observed in cancer patients, in situ carcinoma and benign breast disease.
  • Preliminary clinical applications of this approach have revealed several shortcomings, including a frequent presence of methylated 14-3-3-sigma in sera from women with breast benign disease.
  • These findings cast some doubts on the utility for early cancer diagnosis of highly sensitive techniques to identify hypermethylation of specific gene promoters in DNA extracted from serum.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Estrogen Receptor alpha / metabolism. Exonucleases / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] 14-3-3 Proteins. Case-Control Studies. DNA Methylation. DNA, Neoplasm / metabolism. Disease Progression. Exoribonucleases. Female. Humans. Phenotype. Polymerase Chain Reaction. Promoter Regions, Genetic. Sensitivity and Specificity. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379196.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Estrogen Receptor alpha; 0 / Neoplasm Proteins; EC 3.1.- / Exonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.- / SFN protein, human
  •  go-up   go-down


41. Wang H, Arun BK, Wang H, Fuller GN, Zhang W, Middleton LP, Sahin AA: IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J; 2008 May-Jun;14(3):261-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas.
  • Overexpression of IGFBP2 and IGFBP5 contributes to the invasiveness and progression of several human cancers, but their roles in the metastasis of breast cancer have not been investigated in detail.
  • To determine their roles, we examined IGFBP2 and IGFBP5 expression levels in 164 T1 breast carcinomas using tissue microarrays and immunohistochemistry.
  • No or very low expression of IGFBP2 and IGFBP5 was detected in normal breast epithelium or benign breast tissue with fibrocystic change.
  • Moderate to strong cytoplasmic staining for IGFBP2 and IGFBP5 was detected in 49.1% and 50.3% of T1 invasive breast carcinomas, respectively.
  • IGFBP2 and IGFBP5 expression correlated with the expression status of progesterone receptor and HER-2/neu in the overall T1 carcinoma group, but no association was found with tumor size or the expression status of estrogen receptor.
  • Our data suggest that IGFBP2 and IGFBP5 play a role in the development of metastasis and may serve as useful markers to predict lymph node metastasis in patients with small (T1) invasive breast carcinomas.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Insulin-Like Growth Factor Binding Protein 2 / biosynthesis. Insulin-Like Growth Factor Binding Protein 5 / biosynthesis
  • [MeSH-minor] Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18373644.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Insulin-Like Growth Factor Binding Protein 5
  •  go-up   go-down


42. Michalopoulos NV, Zagouri F, Sergentanis TN, Pararas N, Koulocheri D, Nonni A, Filippakis GM, Chatzipantelis P, Bramis J, Zografos GC: Needle tract seeding after vacuum-assisted breast biopsy. Acta Radiol; 2008 Apr;49(3):267-70
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Needle tract seeding after vacuum-assisted breast biopsy.
  • PURPOSE: To assess cell seeding along the needle tract of vacuum-assisted breast biopsy (VABB).
  • In 2/31 (6.5%) cases (95% CI 0.8-21.4%), benign epithelial cell displacement was observed, and the duration of VABB was significantly longer in these two cases (52.5+/-3.5 min vs. 42.0+/-4.4 min for cases without benign cell displacement; P = 0.018, Mann-Whitney-Wilcoxon test for independent samples).
  • Benign cell displacement was associated with longer VABB duration.
  • The phenomenon of tumor cell dissemination along the needle tract is of questionable clinical significance when the treatment guidelines are followed.
  • [MeSH-major] Biopsy, Needle / adverse effects. Breast / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Neoplasm Seeding

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365811.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


43. Cyran CC, Fu Y, Raatschen HJ, Rogut V, Chaopathomkul B, Shames DM, Wendland MF, Yeh BM, Brasch RC: New macromolecular polymeric MRI contrast agents for application in the differentiation of cancer from benign soft tissues. J Magn Reson Imaging; 2008 Mar;27(3):581-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New macromolecular polymeric MRI contrast agents for application in the differentiation of cancer from benign soft tissues.
  • MATERIALS AND METHODS: Thirty-two athymic rats with human breast cancer xenografts (MDA-MB-435) were imaged by dynamic MRI following enhancement with one of three new (Gd-DOTA)-conjugated PEG-core dendrimer contrast agents (effective molecular weights 161 to 323 kDa).
  • 100 cm(3)) and tumor fractional plasma volumes (%) based on a two-compartment kinetic model were performed for skeletal muscle and tumors.
  • RESULTS: The largest PEG-core contrast agent, PEG(20,000)-Gen4-(Gd-DOTA), leaked in breast tumors (K(PS) = 50 +/- 23 microL/min .
  • PEG(12,000)-Gen4-(Gd-DOTA) leaked in tumors and in normal muscle (K(PS) = 51 +/- 26 and K(PS) = 21 +/- 18 microL/min .
  • CONCLUSION: MRI assays of vascular endothelial leakiness using new PEG-core, (Gd-DOTA)-conjugated macromolecular contrast agents proved applicable for the differentiation of human breast cancer from normal soft tissue.
  • [MeSH-major] Contrast Media. Gadolinium. Heterocyclic Compounds. Magnetic Resonance Imaging. Neoplasms, Experimental / diagnosis. Organometallic Compounds
  • [MeSH-minor] Animals. Breast Neoplasms / diagnosis. Endothelium, Vascular. Female. Humans. Neoplasm Transplantation. Rats. Rats, Nude. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219614.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 082923; United States / NCI NIH HHS / CA / R01 CA 103850
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Heterocyclic Compounds; 0 / Organometallic Compounds; 92923-44-9 / gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


44. Li EX, Wu YY, Shi F, Wu Y, Guo JJ, Dong DF: [Relationship between serum VEGF level and VEGF, COX-2 and MVD expression in breast cancer tissues]. Zhonghua Zhong Liu Za Zhi; 2007 Jul;29(7):522-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between serum VEGF level and VEGF, COX-2 and MVD expression in breast cancer tissues].
  • OBJECTIVE: To investigate the relationship between serum VEGF (sVEGF) level and VEGF, COX-2 and MVD expression in breast cancer, and to discuss their role in angiogensis of breast cancer.
  • METHODS: sVEGF level was detected by ELISA in 68 preoperative breast cancer, 35 benign breast disease and 20 healthy women.
  • The expression of VEGF, COX-2 and MVD was detected by immunohistochemical method in tissues of breast cancer and breast benign diseases, and to analyze the relationship of sVEGF, VEGF, COX-2 and MVD. RESULTS:.
  • (1) sVEGF level in preoperative breast cancers was 306.51 pg/ml (interquartile range from 190.44 to 442.04 pg/ml), in benign diseases was 150.82 pg/ml (interquartile range from 82.36 to 212.34 pg/ml), and in healthy control was 105.93 pg/ml (interquartile range from 78.54 to 157.77 pg/ml).
  • The sVEGF level of preoperative breast cancer group was significantly higher than that of breast benign disease group and healthy women (P = 0.001). (2) The VEGF expression positive rate in breast cancer (67.65%) was significantly higher than that in breast benign disease (44.12%) (P = 0.015).
  • The COX-2 expression positive rate in breast cancer (42.86%) was significantly higher than that in breast benign disease (11.43%) (P = 0.002). (3) the COX-2 expression positive rate in sVEGF high level patients (56.00%) was significantly higher than that in sVEGF normal level patients (11.11%) (P = 0.024), and MVD in sVEGF high level patients (27.32 +/- 3.40) was also higher than that in sVEGF normal level patients (15.31 +/- 6.16) (P = 0.011). (4) The sVEGF level (322.09 +/- 79.31) of 68 breast cancer patients whose VEGF was positive in breast cancer tissues was significantly higher than that in VEGF negative group (222.47 +/- 73.53) (P = 0.017). (5) The COX-2 expression positive rate in VEGF positive expression group (65.21%) was significantly higher than that in VEGF negative expression group (18.18%) (P = 0.017).
  • CONCLUSION: sVEGF level in breast cancer is significantly higher than that in breast benign disease and healthy women, and is correlated with the expression of COX-2 and MVD in breast cancer tissues.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Cyclooxygenase 2 / metabolism. Microvessels / pathology. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / metabolism. Female. Fibroadenoma / blood. Fibroadenoma / blood supply. Fibroadenoma / metabolism. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18069633.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Vascular Endothelial Growth Factor A; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


45. Thriveni K, Deshmane V, Bapsy PP, Krishnamoorthy L, Ramaswamy G: Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients. Indian J Med Res; 2007 Feb;125(2):137-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients.
  • BACKGROUND & OBJECTIVE: In breast cancer, the HER-2/neu gene is amplified in 20-30 per cent of cases.
  • Elevated serum HER-2/neu levels have been shown to be associated with a poor clinical prognosis and decreased survival in early stage breast cancer patients, and thus might help in management of the disease.
  • The present study was therefore to estimate the serum HER-2/neu levels in breast cancer patients and associate with other prognostic factors.
  • METHODS: Serum HER-2/neu levels were studied in 207 patients with cancer breast, 15 benign breast diseases (BBD) and 175 age-matched healthy controls.
  • INTERPRETATION & CONCLUSION: HER-2/neu serum test could be done more frequently in women with breast cancer irrespective of the hormone receptor status, to suggest modifications in systemic adjuvant therapy, including possibly the use of Herceptin.
  • [MeSH-major] Breast Neoplasms / diagnosis. Receptor, ErbB-2 / blood
  • [MeSH-minor] Age Factors. Female. Gene Expression Regulation, Neoplastic. Humans. India. Logistic Models. Neoplasm Staging / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431282.001).
  • [ISSN] 0971-5916
  • [Journal-full-title] The Indian journal of medical research
  • [ISO-abbreviation] Indian J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


46. Istvanic S, Fischer AH, Banner BF, Eaton DM, Larkin AC, Khan A: Cell blocks of breast FNAs frequently allow diagnosis of invasion or histological classification of proliferative changes. Diagn Cytopathol; 2007 May;35(5):263-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell blocks of breast FNAs frequently allow diagnosis of invasion or histological classification of proliferative changes.
  • Two major limitations of breast fine needle aspiration (FNA) compared with core needle biopsies (CNB) are the inability to determine whether a cancer is invasive and to classify proliferative lesions.
  • We studied 40 consecutive "rapid cell blocks" from breast FNAs with surgical pathology follow-up to test whether cell blocks can overcome these limitations.
  • Cell blocks from 12 of 14 benign breast FNAs showed sufficient cells to assign a histologic diagnosis of no hyperplasia (1 case, confirmed on follow-up) and usual hyperplasia (11 cases; confirmed in eight of 11 on follow-up).
  • Specific histologic diagnoses included intraductal papilloma (2 cases), and in situ lobular neoplasia (2 cases).
  • Cell blocks complement smears and monolayers and appear to overcome major limitations of breast FNA.
  • [MeSH-major] Biopsy, Fine-Needle. Breast / pathology. Breast Neoplasms / pathology. Neoplasms, Ductal, Lobular, and Medullary / pathology. Paraffin Embedding / methods
  • [MeSH-minor] Adenocarcinoma / classification. Adenocarcinoma / pathology. Carcinoma in Situ / classification. Carcinoma in Situ / pathology. Carcinoma, Lobular / classification. Carcinoma, Lobular / pathology. Cell Proliferation. Female. Humans. Hyperplasia. Neoplasm Invasiveness. Papilloma, Intraductal / classification. Papilloma, Intraductal / pathology. Phyllodes Tumor / classification. Phyllodes Tumor / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17427225.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Jing F, Zhang J, Tao J, Zhou Y, Jun L, Tang X, Wang Y, Hai H: Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic breast cancer patients. Onkologie; 2007 Feb;30(1-2):14-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic breast cancer patients.
  • BACKGROUND: We investigated the hypermethylation status in serum of sporadic breast cancer patients.
  • MATERIAL AND METHODS: The hypermethylation status of BRCA1, p16 and 14-3-3sigma in cancerous tissues and the paired serum of 38 sporadic breast cancer patients was examined by methylation-specific PCR (MSP) assay.
  • Normal and benign tissue and serum control DNA were also examined to determine the specificity of hypermethylation.
  • RESULTS: Hypermethylation of 1 or more genes was found in 36/38 (95%) of sporadic breast cancers.
  • No methylated products of BRCA1, p16 and 14-3-3sigma were observed in serum DNA from healthy women and patients with benign tissue specimens.
  • A gene unmethylated in the tumor DNA was always found to be unmethylated in matched serum DNA.
  • CONCLUSIONS: Hypermethylation of BRCA1, p16 and 14-3-3sigma is present in all histologic types, stages and grades in sporadic breast cancer and can be detected in serum DNA.
  • It signifies that serum-based hypermethylation screening may enhance early detection of sporadic breast cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Biomarkers, Tumor / genetics. Breast Neoplasms / blood. Breast Neoplasms / genetics. DNA Methylation. Genes, Tumor Suppressor
  • [MeSH-minor] 14-3-3 Proteins. Adult. Aged. Cyclin-Dependent Kinase Inhibitor p16 / blood. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA Mutational Analysis / methods. Exonucleases / blood. Exonucleases / genetics. Exoribonucleases. Female. Humans. Middle Aged. Neoplasm Proteins / blood. Neoplasm Proteins / genetics. Reproducibility of Results. Sensitivity and Specificity. Ubiquitin-Protein Ligases / blood. Ubiquitin-Protein Ligases / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17264521.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Neoplasm Proteins; EC 3.1.- / Exonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.- / SFN protein, human; EC 6.3.2.- / BRAP protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


48. Acs G, Dumoff KL, Solin LJ, Pasha T, Xu X, Zhang PJ: Extensive retraction artifact correlates with lymphatic invasion and nodal metastasis and predicts poor outcome in early stage breast carcinoma. Am J Surg Pathol; 2007 Jan;31(1):129-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive retraction artifact correlates with lymphatic invasion and nodal metastasis and predicts poor outcome in early stage breast carcinoma.
  • Retraction artifact resulting in clear spaces around tumor cell nests is frequently seen in histologic material and may present difficulty in their differentiation from lymphovascular invasion.
  • We noticed that retraction artifact seemed to be more common around groups of breast cancer cells compared with benign acini, and when extensively present, metastasis to axillary lymph nodes was often seen.
  • Thus, we performed a study of 304 cases of stage pT1 and pT2 breast carcinomas to test our hypothesis that extensive retraction artifact in tumors correlates with lymphatic spread and outcome.
  • Tumors were evaluated to determine the presence and extent of retraction artifact around tumor cell nests and the presence of lymphatic invasion.
  • The extent of retraction artifact in tumors was correlated with clinicopathologic tumor features and patient outcome.
  • The extent of retraction artifact showed a significant correlation with tumor size, histologic type, histologic grade, presence of lymphovascular invasion, and nodal metastasis.
  • We propose that the apparent retraction of the stroma from cells of invasive breast carcinoma on routine histologic sections is not a phenomenon merely due to inadequate fixation as currently believed.
  • Rather, it likely signifies important biologic changes that alter tumor-stromal interactions and contribute to lymphatic spread and tumor progression.
  • [MeSH-major] Artifacts. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Histocytological Preparation Techniques. Lymph Nodes / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Early Diagnosis. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. ROC Curve. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Survival Rate

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197929.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


49. Uygun K, Kocak Z, Altaner S, Cicin I, Tokatli F, Uzal C: Colonic metastasis from carcinoma of the breast that mimics a primary intestinal cancer. Yonsei Med J; 2006 Aug 31;47(4):578-82
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic metastasis from carcinoma of the breast that mimics a primary intestinal cancer.
  • Although the lung, liver, or bones are the most common location for distant metastases in breast cancer patients, metastases to the intestinal tract are very rarely recognized in the clinic.
  • We will present an unusual case of colonic metastasis from a carcinoma of the breast that mimics a primary intestinal cancer, along with a through review of English language medical literature.
  • Despite the fact that isolated gastrointestinal (GI) metastases are very rare and much less common than benign disease processes or second primaries of the intestinal tract in patients with a history of breast cancer, metastatic disease should be given consideration whenever a patient experiences GI symptoms.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Colonic Neoplasms / diagnosis. Colonic Neoplasms / secondary. Intestinal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Breast / pathology. Diagnosis, Differential. Female. Humans. Neoplasm Metastasis. Neoplasms, Second Primary / diagnosis. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1998 Jan;93(1):111-4 [9448188.001]
  • [Cites] Histopathology. 1996 Sep;29(3):233-40 [8884351.001]
  • [Cites] Am J Gastroenterol. 2000 Oct;95(10):3014-6 [11051411.001]
  • [Cites] Eur J Surg Oncol. 2002 Jun;28(4):463-4 [12099661.001]
  • [Cites] Am J Dig Dis. 1972 Oct;17(10):881-6 [5073677.001]
  • [Cites] J Surg Oncol. 1979;11(3):193-205 [459515.001]
  • [Cites] Dis Colon Rectum. 1988 May;31(5):401-2 [3366041.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):181-7 [2910416.001]
  • [Cites] Int J Biol Markers. 1988 Jan-Mar;3(1):41-8 [2854832.001]
  • [Cites] Hum Pathol. 1991 Apr;22(4):368-72 [2050370.001]
  • [Cites] Gastrointest Endosc. 1992 Mar-Apr;38(2):136-41 [1568609.001]
  • [Cites] Am J Clin Oncol. 1992 Aug;15(4):365-9 [1514536.001]
  • [Cites] J Surg Oncol. 1992 Nov;51(3):211-5 [1434649.001]
  • [Cites] Med Klin (Munich). 1992 Dec 15;87(12):631-6 [1287424.001]
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):681-2 [10919011.001]
  • (PMID = 16941751.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2687742
  •  go-up   go-down


50. Mhawech-Fauceglia P, Saxena R, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, Penetrante R: Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis. J Clin Pathol; 2007 Jun;60(6):709-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis.
  • However, its expression in other tumour types is not fully explored.
  • AIMS AND METHODS: To determine Pax-5 expression in other tumour types, immunohistochemistry was performed on 3758 benign and malignant tumours using multiple tumour microarrays, as well as on whole sections.
  • In addition, Pax-5 was seen in 24/34 (70.6%) Merkel cell carcinomas, 42/53 (79.2%) small cell carcinomas, 1/164 (0.6%) breast carcinomas, 2/204 (1%) endometrial adenocarcinomas and 1/452 (0.2%) urothelial carcinoma of the bladder.
  • [MeSH-major] B-Cell-Specific Activator Protein / metabolism. Biomarkers, Tumor / metabolism. Neoplasms / metabolism
  • [MeSH-minor] Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / metabolism. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Diagnosis, Differential. Hodgkin Disease / diagnosis. Hodgkin Disease / metabolism. Humans. Immunoenzyme Techniques. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / metabolism. Neoplasm Proteins / metabolism. Protein Array Analysis / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 2001 Jun;14(6):779-90 [11420047.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):687-92 [15832095.001]
  • [Cites] Trends Genet. 2002 Jan;18(1):41-7 [11750700.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1343-50 [12360049.001]
  • [Cites] Int Urol Nephrol. 2002-2003;34(4):495-501 [14577491.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):994-1000 [14608532.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):122-8 [14745734.001]
  • [Cites] Carcinogenesis. 2004 Oct;25(10):1839-46 [15155532.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):721-7 [15491968.001]
  • [Cites] Mech Dev. 1992 Nov;39(1-2):29-39 [1283313.001]
  • [Cites] Genomics. 1993 Dec;18(3):705-8 [7508415.001]
  • [Cites] C R Acad Sci III. 1995 Jan;318(1):57-66 [7757805.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5709-13 [7777574.001]
  • [Cites] Genes Dev. 1997 Feb 15;11(4):476-91 [9042861.001]
  • [Cites] J Immunol. 1997 Apr 1;158(7):3197-204 [9120274.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 27;94(11):5703-8 [9159136.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Clin Cancer Res. 1995 Feb;1(2):207-14 [9815975.001]
  • [Cites] Gen Physiol Biophys. 1998 Sep;17(3):211-24 [9834843.001]
  • [Cites] BJU Int. 1999 Jun;83(9):1039-44 [10368252.001]
  • [Cites] Nature. 1999 Oct 7;401(6753):556-62 [10524622.001]
  • [Cites] Int J Cancer. 2001 Aug 15;93(4):459-67 [11477548.001]
  • (PMID = 16837628.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / PAX5 protein, human
  • [Other-IDs] NLM/ PMC1955074
  •  go-up   go-down


51. Radke I, Götte M, Kersting C, Mattsson B, Kiesel L, Wülfing P: Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer. Br J Cancer; 2006 Aug 7;95(3):347-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.
  • The aim of this study was to investigate the expression of the protein tyrosine phosphatases (PTP) PRL-1, PRL-2, and PRL-3 in human breast cancer and to evaluate its clinical and prognostic significance.
  • PRL-PTP mRNA expression was examined in malignant (n = 7) and nonmalignant (n = 7) cryoconserved breast tissue samples as well as in eight breast cancer cell lines by RT-PCR.
  • Furthermore, protein expression of PRL-3 was analysed semiquantitatively by immunohistochemistry in ductal breast carcinoma in situ (n = 135) and invasive breast cancer (n = 147) by use of tissue microarray technology (TMA).
  • In 24 lymph node-positive patients we selected the corresponding lymph node metastases for analysis of PRL-3 expression, and a validation set (n = 99) of invasive breast cancer samples was examined.
  • PRL-3 mRNA expression was significantly higher in malignant compared to benign breast tissue.
  • Staining of TMAs showed PRL-3 expression in 85.9% ductal carcinoma in situ and 75.5% invasive breast carcinomas.
  • Analysis of survival parameters revealed a shorter disease-free survival (DFS) in patients with PRL-3-positive carcinomas, and in particular a significantly shorter DFS in nodal-positive patients with PRL-3 overexpressing tumours as compared to PRL-3-negative breast carcinomas (66+/-7 months (95% CI, 52-80) vs 97+/-9 months (95% CI, 79-115); P = 0.032).
  • Moreover, we found a more frequent expression of PRL-3 in lymph node metastases as compared to the primary tumours (91.7 vs 66.7%; P = 0.033).
  • Our results suggest that PRL-3 might serve as a novel prognostic factor in breast cancer, which may help to predict an adverse disease outcome.
  • [MeSH-major] Breast Neoplasms / genetics. Cell Cycle Proteins / genetics. Membrane Proteins / genetics. Neoplasm Proteins / genetics. Protein Tyrosine Phosphatases / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Female. Follow-Up Studies. Gene Expression Profiling. Humans. Lymph Nodes / pathology. Lymphatic Metastasis / genetics. Middle Aged. Neoplasm Invasiveness. Prognosis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Risk Factors. Sensitivity and Specificity. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):945-51 [14737124.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Feb;49(2):91-107 [15012971.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2393-400 [15073116.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1630-7 [15117985.001]
  • [Cites] Pathobiology. 2004;71(4):176-84 [15263806.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Sep;130(9):521-6 [15133662.001]
  • [Cites] Science. 1987 Jan 23;235(4787):442-7 [2432664.001]
  • [Cites] Mol Cell Biol. 1991 Jan;11(1):381-90 [1986233.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Crit Rev Oncol Hematol. 2001 Feb;37(2):97-114 [11166583.001]
  • [Cites] Breast Cancer Res Treat. 2001 Apr;66(3):201-8 [11510691.001]
  • [Cites] Oncology. 2001;61 Suppl 2:67-72 [11694790.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):46659-68 [12235145.001]
  • [Cites] Mol Cancer Ther. 2002 Dec;1(14):1255-64 [12516958.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):110-6 [12563310.001]
  • [Cites] Dev Biol. 2003 May 1;257(1):205-19 [12710968.001]
  • [Cites] Nat Med. 2003 Jun;9(6):713-25 [12778170.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2716-22 [12782572.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Jul;129(7):375-82 [12884024.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5607-15 [14654542.001]
  • [Cites] Mol Cell Biol. 1994 Jun;14(6):3752-62 [8196618.001]
  • [Cites] Semin Diagn Pathol. 1994 Aug;11(3):167-80 [7831528.001]
  • [Cites] Hum Genet. 1995 Nov;96(5):532-8 [8529999.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] Cancer Res. 1996 May 1;56(9):2013-6 [8616842.001]
  • [Cites] Cancer Lett. 1996 Dec 20;110(1-2):49-55 [9018080.001]
  • [Cites] Int J Cancer. 1997 Aug 22;74(4):455-8 [9291439.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Mar 17;244(2):421-7 [9514946.001]
  • [Cites] Stem Cells. 1998;16(6):413-28 [9831867.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7857-66 [15520192.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7318-28 [15534108.001]
  • [Cites] Int J Oncol. 2005 Apr;26(4):951-60 [15753989.001]
  • [Cites] Cancer Biol Ther. 2004 Oct;3(10):945-51 [15326366.001]
  • [Cites] Mol Cancer Ther. 2005 Nov;4(11):1653-61 [16275986.001]
  • [Cites] Mol Cancer Ther. 2006 Feb;5(2):219-29 [16505094.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1720-8 [15841074.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1569-83 [16148022.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6835-9 [16203771.001]
  • [Cites] Fertil Steril. 2005 Oct;84 Suppl 2:1173-9 [16210009.001]
  • (PMID = 16832410.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; EC 3.1.3.48 / PTP4A1 protein, human; EC 3.1.3.48 / PTP4A2 protein, human; EC 3.1.3.48 / PTP4A3 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  • [Other-IDs] NLM/ PMC2360632
  •  go-up   go-down


52. Ciatto S, Houssami N, Ambrogetti D, Bianchi S, Bonardi R, Brancato B, Catarzi S, Risso GG: Accuracy and underestimation of malignancy of breast core needle biopsy: the Florence experience of over 4000 consecutive biopsies. Breast Cancer Res Treat; 2007 Mar;101(3):291-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy and underestimation of malignancy of breast core needle biopsy: the Florence experience of over 4000 consecutive biopsies.
  • Breast core needle biopsy (CNB) is used for sampling breast lesions in both the screening and diagnostic context.
  • We present the accuracy of breast CNB from a consecutive series of 4035 core biopsies, using methods that minimise selection and verification bias.
  • False negatives occurred in 4.4% (3.4-5.4%) of cases, and where core histology was benign but discordant with (suspicious) imaging and/or clinical findings the likelihood of malignancy was 33.1% (18.5-47.7%), emphasising the importance of correlating all test information in breast diagnosis.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology
  • [MeSH-minor] Biopsy, Fine-Needle / methods. Breast Diseases / pathology. Breast Diseases / ultrasonography. Diagnosis, Differential. Follow-Up Studies. Humans. Hyperplasia / diagnosis. Hyperplasia / pathology. Neoplasm Invasiveness. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity. Stereotaxic Techniques. Ultrasonography, Mammary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16823506.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


53. Tang HW, Luo MN, Li T, Pan L: Quantitative DNA imaging in breast tumor cells by a Hadamard transform fluorescence imaging microscope. Anal Sci; 2006 May;22(5):701-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative DNA imaging in breast tumor cells by a Hadamard transform fluorescence imaging microscope.
  • In this study, the high potential value of the microscope in biomedical analysis has been demonstrated by using it to evaluate the malignancy degree of thirty cases of human breast tumors based on the measurements of cellular DNA contents, with conclusions highly accordant with pathological diagnosis.
  • The microscope was also successfully applied to cellular morphological analysis, and it was demonstrated that a significant linear relationship exists between tumor nuclear DNA contents and the nuclear area, and malignant and benign tumors are significantly different in both DNA contents and nuclear area.
  • [MeSH-major] Breast Neoplasms / pathology. DNA, Neoplasm / analysis
  • [MeSH-minor] Female. Humans. Image Cytometry. Microscopy, Fluorescence. Ploidies. Sensitivity and Specificity. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770048.001).
  • [ISSN] 0910-6340
  • [Journal-full-title] Analytical sciences : the international journal of the Japan Society for Analytical Chemistry
  • [ISO-abbreviation] Anal Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


54. Conway K, Parrish E, Edmiston SN, Tolbert D, Tse CK, Geradts J, Livasy CA, Singh H, Newman B, Millikan RC: The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study. Breast Cancer Res; 2005;7(6):R871-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study.
  • INTRODUCTION: Evidence suggests that alterations in estrogen signaling pathways, including estrogen receptor-alpha (ER-alpha), occur during breast cancer development.
  • This mutation was initially reported in one-third of hyperplastic benign breast lesions, although several recent studies failed to detect it in benign or malignant breast tissues.
  • METHODS: We screened 653 microdissected, newly diagnosed invasive breast tumors from patients in the Carolina Breast Cancer Study, a population-based case-control study of breast cancer in African American and white women in North Carolina, for the presence of the ER-alpha A908G mutation by using single-strand conformational polymorphism (SSCP) analysis and 33P-cycle sequencing.
  • RESULTS: We detected the ER-alpha A908G mutation in 37 of 653 (5.7%) breast tumors.
  • Three tumors exhibited only the mutant G base at nucleotide 908 on sequencing, indicating that the wild-type ER-alpha allele had been lost.
  • The ER-alpha A908G mutation was found more frequently in higher-grade breast tumors (odds ratio (OR) 2.83; 95% confidence interval (CI) 1.09 to 7.34, grade II compared with grade I), and in mixed lobular/ductal tumors (OR 2.10; 95% CI 0.86 to 5.12) compared with ductal carcinomas, although the latter finding was not statistically significant.
  • CONCLUSION: This population-based study, the largest so far to screen for the ER-alpha A908G mutation in breast cancer, confirms the presence of the mutant in invasive breast tumors.
  • The mutation was associated with higher tumor grade and mixed lobular/ductal breast tumor histology.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Steroid Biochem Mol Biol. 1999 Nov;71(1-2):21-7 [10619354.001]
  • [Cites] Breast Cancer Res Treat. 1999 Nov;58(1):31-9 [10634516.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7382-7 [10377423.001]
  • [Cites] Nucleic Acids Res. 1999 Mar 1;27(5):1405-7 [9973633.001]
  • [Cites] Int J Oncol. 1998 Jun;12(6):1225-8 [9592178.001]
  • [Cites] Breast Cancer Res. 2005;7(1):R113-8 [15642159.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9199-208 [15604293.001]
  • [Cites] Endocr Rev. 2004 Dec;25(6):869-98 [15583021.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):427-33 [10688862.001]
  • [Cites] Am J Epidemiol. 2000 Apr 1;151(7):703-14 [10752798.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4026-9 [10945602.001]
  • [Cites] Int J Cancer. 2000 Dec 1;88(5):733-6 [11072241.001]
  • [Cites] Breast Cancer. 2003;10(1):70-3 [12525766.001]
  • [Cites] Breast Cancer Res Treat. 2004 Apr;84(3):289-92 [15026626.001]
  • [Cites] Genes Chromosomes Cancer. 2004 May;40(1):51-4 [15034868.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):597-605 [15193262.001]
  • [Cites] Epidemiol Rev. 1993;15(1):17-35 [8405201.001]
  • [Cites] Breast Cancer Res Treat. 1995 Jul;35(1):51-60 [7612904.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2371-4 [9215322.001]
  • [Cites] Nucleic Acids Res. 1997 Nov 15;25(22):4500-4 [9358158.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Dec;82(12):4258-65 [9398750.001]
  • [Cites] J Steroid Biochem Mol Biol. 1997 Aug;62(5-6):363-72 [9449239.001]
  • (PMID = 16280033.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA058223; United States / NCI NIH HHS / CA / 5-P50-CA58223
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Estrogen Receptor alpha
  • [Other-IDs] NLM/ PMC1410768
  •  go-up   go-down


55. Hoehne FM, Taylor E: Trends in breast cancer at a county hospital. Am Surg; 2005 Feb;71(2):159-63
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in breast cancer at a county hospital.
  • Breast cancer mortality has changed dramatically with improvements in screening techniques.
  • We report our experience in breast biopsies at a county teaching hospital with a traditionally younger patient population.
  • A total of 550 breast biopsies were conducted between 1995 and 2000.
  • Data regarding age, method of breast biopsy, and pathology was reviewed.
  • One hundred twenty of 550 patients (21.8%) had breast carcinoma detected on breast biopsies with the predominant histologic subtype being invasive ductal carcinoma.
  • The mean age of patients with carcinoma was 52.8 years, whereas that of patients with benign breast disease was 43.6 years (P < 0.05).
  • Forty-three per cent of all breast cancers occurred in women under the age of 50 years.
  • During the study period, there was neither an increase in the number of breast biopsies performed per year nor a decrease in the average age of women with breast cancer.
  • However, observing a significant percentage of breast cancer patients under 50 years old, our data suggest the importance of strict adherence to current screening recommendations including self-breast examination and yearly mammography.
  • [MeSH-major] Breast Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Biopsy / statistics & numerical data. Breast / pathology. Breast Self-Examination / statistics & numerical data. California / epidemiology. Carcinoma in Situ / epidemiology. Carcinoma, Ductal, Breast / epidemiology. Carcinoma, Lobular / epidemiology. Female. Hospitals, County / statistics & numerical data. Hospitals, Teaching / statistics & numerical data. Humans. Mammography / statistics & numerical data. Mass Screening / statistics & numerical data. Middle Aged. Neoplasm Invasiveness. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16022017.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Li BJ, Huang XP, Wei WD, Wang JY, Su XD, Zhang X, Hong WS, Tang J, Zhang LJ, Long H, Yang MT, Rong TH: [Expression and clinical significance of cytokeratin 19 in bone marrow of patients with breast cancer]. Ai Zheng; 2005 Jun;24(6):735-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of cytokeratin 19 in bone marrow of patients with breast cancer].
  • BACKGROUND & OBJECTIVE: Breast cancer may undergo metastasis in early phase.
  • Distant metastasis, especially bone metastasis, may influence prognosis of breast cancer patients.
  • This study was designed to evaluate expression and clinical significance of cytokeratin 19 (CK19) in bone marrow of patients with breast cancer.
  • METHODS: Expression of CK19 mRNA in bone marrows of 65 breast cancer patients, 15 benign breast disease patients, and 8 healthy volunteers was detected by reverse transcription-polymerase chain reaction (RT-PCR).
  • Correlation of CK19 mRNA expression to clinicopathologic features of the 65 breast cancer patients was analyzed.
  • RESULTS: Positive rate of CK19 mRNA was 33.8% in the 65 breast cancer patients, and 0 in both benign breast disease patients and healthy volunteers.
  • Expression of CK19 mRNA was positively correlated with tumor size and clinical stage (P < 0.05), but was not related to age and lymph node status (P > 0.05).
  • CONCLUSIONS: CK19 mRNA may be used as a molecular marker to detect bone marrow micrometastasis in patients with breast cancer.
  • The detection may help to select proper therapy and predict prognosis of breast cancer patients.
  • [MeSH-major] Bone Marrow / metabolism. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Keratin-19 / biosynthesis
  • [MeSH-minor] Adult. Aged. Breast Neoplasms, Male / metabolism. Breast Neoplasms, Male / pathology. Carcinoembryonic Antigen / blood. Female. Fibroadenoma / blood. Fibroadenoma / metabolism. Fibroadenoma / pathology. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946491.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / RNA, Messenger
  •  go-up   go-down


57. Sabitha, Suneetha, Mohanty S, Rao P: Serum anti - TPO levels in benign and malignant breast tumors. Indian J Clin Biochem; 2009 Jul;24(3):266-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum anti - TPO levels in benign and malignant breast tumors.
  • Breast cancer is a hormone dependent neoplasm.
  • Conflicting results regarding the clinical correlation between breast cancer and thyroid diseases have been reported.
  • The objective of this study was to determine the association of anti - TPO levels in patients having complaints of a lump in breast.
  • Serum samples and Fine needle aspiration cytology (FNAC) samples were collected from 31 female patients with a lump in breast between the age group of 20-75 years.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br Med J. 1976 Jan 31;1(6004):257-9 [1082357.001]
  • [Cites] Br J Cancer. 1984 Jan;49(1):87-92 [6691901.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Nov;79(5):1232-3 [7962313.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Mar;81(3):937-41 [8772554.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Mar;81(3):990-4 [8772562.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2711-6 [9709936.001]
  • [Cites] N Engl J Med. 2006 Jun 29;354(26):2783-93 [16807415.001]
  • [Cites] Indian J Clin Biochem. 2008 Jul;23(3):279-82 [23105770.001]
  • [Cites] Tumori. 2003 Sep-Oct;89(5):523-8 [14870777.001]
  • [Cites] Jpn J Cancer Res. 1999 Sep;90(9):922-7 [10551319.001]
  • [Cites] J Endocrinol Invest. 2000 Jan;23(1):42-3 [10698051.001]
  • [Cites] Jpn J Cancer Res. 2001 May;92(5):483-7 [11376555.001]
  • [Cites] Internist (Berl). 2003 Apr;44(4):396-402, 404-8, 410-1 [12914397.001]
  • (PMID = 23105847.001).
  • [ISSN] 0970-1915
  • [Journal-full-title] Indian journal of clinical biochemistry : IJCB
  • [ISO-abbreviation] Indian J Clin Biochem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3453311
  • [Keywords] NOTNLM ; Breast cancer / FNAC / anti — TPO
  •  go-up   go-down


58. Bogorad RL, Courtillot C, Mestayer C, Bernichtein S, Harutyunyan L, Jomain JB, Bachelot A, Kuttenn F, Kelly PA, Goffin V, Touraine P, Benign Breast Diseases Study Group: Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Proc Natl Acad Sci U S A; 2008 Sep 23;105(38):14533-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors.
  • Given the essential role of this hormonal system in breast physiology, we reasoned that genetic anomalies of Prl/PrlR genes may be related to the occurrence of breast diseases with high proliferative potential.
  • Multiple fibroadenomas (MFA) are benign breast tumors which appear most frequently in young women, including at puberty, when Prl has well-recognized proliferative actions on the breast.
  • Constitutive activity of PrlR(I146L) in the breast sample from a patient was supported by increased STAT5 signaling.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Fibroadenoma / genetics. Fibroadenoma / metabolism. Mutation, Missense. Receptors, Prolactin / genetics. Receptors, Prolactin / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • SciCrunch. Clinical Genomic Database: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 Feb 20;108(5):665-71 [14696092.001]
  • [Cites] Endocrinology. 2006 Sep;147(9):4056-66 [16809439.001]
  • [Cites] Curr Med Res Opin. 2004 Apr;20(4):533-40 [15119991.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2053-60 [15169792.001]
  • [Cites] Acta Obstet Gynecol Scand. 1987;66(6):483-8 [3321867.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):4031-5 [7537382.001]
  • [Cites] Mol Endocrinol. 1996 Jan;10(1):45-56 [8838144.001]
  • [Cites] J Biol Chem. 1996 Nov 22;271(47):29707-14 [8939904.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):667-74 [9467590.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):325-35 [16900392.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Oct;2(10):571-81 [17024156.001]
  • [Cites] Endocrinology. 2007 Mar;148(3):989-1008 [17138649.001]
  • [Cites] Br J Cancer. 2007 Mar 12;96(5):841-4 [17299388.001]
  • [Cites] BMC Med Genet. 2007;8:72 [18053149.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):41-53 [18246319.001]
  • [Cites] Oncogene. 2003 Jul 24;22(30):4664-74 [12879011.001]
  • [Cites] Front Biosci. 2000 Mar 1;5:D343-52 [10704433.001]
  • [Cites] Nat Struct Biol. 2000 Sep;7(9):808-15 [10966654.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3826-32 [11502819.001]
  • [Cites] J Endocrinol. 2001 Oct;171(1):R1-4 [11572805.001]
  • [Cites] J Clin Pathol. 2001 Dec;54(12):956-60 [11729217.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):49-66 [12160086.001]
  • [Cites] Endocrine. 2003 Feb-Mar;20(1-2):177-90 [12668884.001]
  • [Cites] Recent Prog Horm Res. 2003;58:297-323 [12795425.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):35988-99 [12824168.001]
  • [Cites] Endocr Rev. 1998 Jun;19(3):225-68 [9626554.001]
  • [Cites] J Biol Chem. 1999 Apr 9;274(15):10024-34 [10187780.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):629-34 [10203283.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):275-85 [16034013.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Feb;91(2):555-62 [16278261.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1513-9 [16434456.001]
  • [Cites] J Endocrinol. 2006 Aug;190(2):271-85 [16899561.001]
  • [Cites] Biol Reprod. 2004 Mar;70(3):718-28 [14613905.001]
  • (PMID = 18779591.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Receptors, Prolactin; 0 / STAT5 Transcription Factor; 0 / Tyrphostins; 0 / alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide
  • [Other-IDs] NLM/ PMC2567233
  • [Investigator] Bachelot A; Belaroussi B; Bensimhon J; Berdah J; Blin MJ; Boudinet A; Brethon B; Bricaire C; Caby J; Caillaud G; Carel JC; Chabbert-Buffet N; Charitanski H; Chretien C; Clough K; Courtillot C; Delattre G; Denys I; Desthieux-Ngo K; Detoeuf M; Dhainault C; Duflos C; Fiori O; Genestie C; Gibaud G; Gompel A; Gracia C; Grimard A; Hofman C; Hofman H; Kuttenn F; Laki F; Lanty C; Lefranc JP; Le Frere-Belda MA; Leger D; Martinez F; May A; Meng L; Nos C; Pelletier D; Perrin A; Plu-Bureau G; Raccah-Tebbeca B; Saiovici JC; Salmon R; Sibout M; Sigal-Zafrani B; Thalabard JC; Thibaud E; Thoury A; Touraine P; Triana-Rabi KB; Uzan S; Viriot J; Yacoub S
  •  go-up   go-down


59. Ławicki S, Szmitkowski M, Wojtukiewicz M: The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients. Clin Chim Acta; 2006 Sep;371(1-2):112-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
  • BACKGROUND: In the present study, we investigated the plasma levels of M-CSF and commonly accepted tumor marker (antigen CA 15-3) in breast cancer patients in relation to the group with benign breast tumor and to the healthy controls.
  • Additionally, we compared the plasma level of M-CSF with the tumor stage of breast cancer and defined the diagnostic criteria: sensitivity, specificity, the positive and the negative predictive values.
  • METHODS: M-CSF and CA 15-3 were measured in 80 patients with breast cancer, 17 patients with benign breast tumor and in 30 healthy subjects.
  • RESULTS: There were statistically significant differences in the levels of circulating M-CSF and CA 15-3 in the breast cancer patients comparing to the group with benign breast tumor and to the control group.
  • The levels of M-CSF and CA 15-3 were also significantly higher in patients with more advanced tumor stage.
  • Statistically significant positive correlation was observed between the M-CSF and CA 15-3 levels.
  • The M-CSF and CA 15-3 diagnostic specificities were 95%.
  • We observed a higher range of the diagnostic sensitivity of M-CSF in more advanced breast tumor stage.
  • The M-CSF area under the ROC curve was larger (0.801) than the ROC area of CA 15-3 (0.785).
  • CONCLUSIONS: These results suggest that M-CSF is the good candidate for a breast cancer tumor marker.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Macrophage Colony-Stimulating Factor / blood. Mucin-1 / blood
  • [MeSH-minor] Adult. Aged. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. ROC Curve. Reagent Kits, Diagnostic. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631152.001).
  • [ISSN] 0009-8981
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / Reagent Kits, Diagnostic; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


60. Sandhya B, Babu V, Parthasarathy G, Kate V, Ananthakrishnan N, Krishnan R: Primary leiomyosarcoma of the breast: A case report and review of literature. Indian J Surg; 2010 Jul;72(Suppl 1):286-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary leiomyosarcoma of the breast: A case report and review of literature.
  • Leiomyosarcomas of the breast are rare tumours.
  • We describe herein a case of primary leiomyosarcoma of the breast in a 54-year-old woman whose preoperative clinical and cytological findings indicated a benign breast tumour.
  • Histopathological examination of the mastectomy specimen suggested a diagnosis of leiomyosarcoma, which was subsequently confirmed by immunohistochemical analysis.
  • Primary leiomyosarcoma of the breast is very rare and is difficult to diagnose preoperatively as it needs immuno-histochemical staining.
  • It is necessary to excise the tumour with sufficient margins to prevent local recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 1997;27(11):1082-5 [9413066.001]
  • [Cites] Pathol Oncol Res. 2001;7(2):151-3 [11458280.001]
  • [Cites] Surg Today. 2002;32(8):716-9 [12181723.001]
  • [Cites] Arch Gynecol Obstet. 2003 Feb;267(4):233-5 [12592426.001]
  • [Cites] Breast J. 2003 Nov-Dec;9(6):494-6 [14616945.001]
  • [Cites] Diagn Cytopathol. 2003 Sep;29(3):172-8 [12951688.001]
  • [Cites] Acta Cytol. 2003 Sep-Oct;47(5):783-6 [14526679.001]
  • (PMID = 23133273.001).
  • [ISSN] 0972-2068
  • [Journal-full-title] The Indian journal of surgery
  • [ISO-abbreviation] Indian J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3451846
  • [Keywords] NOTNLM ; Breast / Phyllodes Sandhya / Stromal tumours
  •  go-up   go-down


61. Yang JX, Han YJ, Zheng H, Luo RC: [Expression of PAK4 in breast cancer and benign breast pathological changes]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 May;30(5):981-3
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of PAK4 in breast cancer and benign breast pathological changes].
  • OBJECTIVE: To study the role of p21-activated kinase-4 (PAK4) in the occurrence, progression and metastasis of breast cancer.
  • METHOD: PAK4 expression was detected in 35 cases of normal breast, 22 breast cystic hyperplasia, 28 breast adenofibroma, 37 breast cancer (including 7 non-invasive cancer, 9 early invasive cancer and 21 invasive cancer) and 13 metastatic breast cancer tissues using immunohistochemistry for a comparison of PAK4 expression and distribution.
  • RESULTS: PAK4 was expressed mainly in the cytoplasm of the cancer cells, occasionally in the cell nuclei, and virtually not expressed in the matrix surrounding the breast cells.
  • PAK4 positivity rates increased in the order of normal breast tissues, benign changes (including breast cystic hyperplasea and breast adenoma), breast cancer and metastatic cancer tissues; in the cancer tissues, the positivity rates increased in the order of non-invasive breast tumor, early invasive tumor and invasive tumor tissues.
  • CONCLUSION: PAK4 is closely correlated to the progression and metastasis of breast cancer and may become a new diagnostic and therapeutic target of breast cancer.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. p21-Activated Kinases / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20501374.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.1.11 / PAK4 protein, human; EC 2.7.11.1 / p21-Activated Kinases
  •  go-up   go-down


62. Harsløf SS, Andersen LM, Hoyer U, Christiansen JJ: [Breast cancer metastasis to the colon]. Ugeskr Laeger; 2010 Aug 23;172(34):2309-10
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast cancer metastasis to the colon].
  • She was diagnosed with metastases of a carcinoma to the colon; the immunohistochemical profile made lobular breast cancer the most likely primary tumour.
  • But despite thorough examination, such tumour was never found.
  • Twenty-two years earlier, the patient underwent surgery for a benign breast tumour.
  • The benign diagnosis was confirmed in new slides from the then removed tissue.
  • Metastases from breast cancer to the colon are rare, and a primary tumour is usually found.
  • In this case report, however, no primary tumour was found.
  • [MeSH-major] Breast Neoplasms / pathology
  • [MeSH-minor] Aged. Colonic Neoplasms / diagnosis. Colonic Neoplasms / pathology. Colonic Neoplasms / secondary. Female. Humans. Neoplasms, Unknown Primary / diagnosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20727298.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


63. Cashell AW: Apocrine adenoma of the breast. W V Med J; 2008 Mar-Apr;104(2):16-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine adenoma of the breast.
  • A case of apocrine adenoma, a rare benign tumor of the breast is reported.
  • A left breast nodule from a 47-year-old female was found by mammography and excised.
  • The tumor was well circumscribed and composed of tightly packed tubules lined by cells with apocrine features.
  • Apocrine adenomas have been reported arising in a variety of sites including the breast, (1-5) perianal region, (6,7) eyelid, (8) and axilla. (9) Their appearance has similarities to the apocrine metaplasia commonly seen in fibrocystic change of the breast but they are well-circumscribed tumors with closely packed tubular and papillary structures.
  • They are not distinctive by mammography or physical examination and should be managed as any other breast mass.
  • [MeSH-major] Adenoma, Sweat Gland / diagnosis. Apocrine Glands / pathology. Breast Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Needle. Diagnosis, Differential. Female. Humans. Mammography. Middle Aged. Ultrasonography, Mammary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18491794.001).
  • [ISSN] 0043-3284
  • [Journal-full-title] The West Virginia medical journal
  • [ISO-abbreviation] W V Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Liu C, Yan X, Zhang X, Yang W, Peng W, Shi D, Zhu P, Huang W, Yuan Q: Evaluation of x-ray diffraction enhanced imaging in the diagnosis of breast cancer. Phys Med Biol; 2007 Jan 21;52(2):419-27
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of x-ray diffraction enhanced imaging in the diagnosis of breast cancer.
  • The significance of the x-ray diffraction enhanced imaging (DEI) technique in the diagnosis of breast cancer and its feasibility in clinical medical imaging are evaluated.
  • Different massive specimens including normal breast tissues, benign breast tumour tissues and malignant breast tumour tissues are imaged with the DEI method.
  • The differences in DEI images and their rocking curves are evaluated for early diagnosis of breast cancers.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / radiography. Mammography / methods
  • [MeSH-minor] Absorption. Algorithms. Breast / pathology. Female. Humans. Image Enhancement / methods. Image Processing, Computer-Assisted / methods. Radiographic Image Enhancement. Radiographic Image Interpretation, Computer-Assisted. Scattering, Radiation. X-Ray Diffraction. X-Rays

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17202624.001).
  • [ISSN] 0031-9155
  • [Journal-full-title] Physics in medicine and biology
  • [ISO-abbreviation] Phys Med Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


65. Lopes N, Sousa B, Martins D, Gomes M, Vieira D, Veronese LA, Milanezi F, Paredes J, Costa JL, Schmitt F: Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer; 2010;10:483
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions.
  • BACKGROUND: Breast cancer is a heterogeneous disease associated with different patient prognosis and responses to therapy.
  • We aimed to study the expression of these three proteins by immunohistochemistry in a series of breast lesions.
  • METHODS: We have used a cohort comprising normal breast, benign mammary lesions, carcinomas in situ and invasive carcinomas and assessed the expression of the VDR, CYP27B1 and CYP24A1 by immunohistochemistry.
  • RESULTS: The results that we have obtained show that all proteins are expressed in the various breast tissues, although at different amounts.
  • The VDR was frequently expressed in benign lesions (93.5%) and its levels of expression were diminished in invasive tumours (56.2%).
  • Additionally, the VDR was strongly associated with the oestrogen receptor positivity in breast carcinomas.
  • CYP27B1 expression is slightly lower in invasive carcinomas (44.6%) than in benign lesions (55.8%).
  • In contrast, CYP24A1 expression was augmented in carcinomas (56.0% in in situ and 53.7% in invasive carcinomas) when compared with that in benign lesions (19.0%).
  • CONCLUSIONS: From this study, we conclude that there is a deregulation of the Vitamin D signalling and metabolic pathways in breast cancer, favouring tumour progression.
  • Thus, during mammary malignant transformation, tumour cells lose their ability to synthesize the active form of Vitamin D and respond to VDR-mediated Vitamin D effects, while increasing their ability to degrade this hormone.
  • [MeSH-major] 25-Hydroxyvitamin D3 1-alpha-Hydroxylase / metabolism. Breast / metabolism. Breast Neoplasms / metabolism. Receptors, Calcitriol / metabolism. Steroid Hydroxylases / metabolism. Vitamin D / metabolism
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Blotting, Western. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Cohort Studies. Disease Progression. Female. Gene Expression Profiling. Humans. Immunoenzyme Techniques. Metabolic Networks and Pathways. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Vitamin D3 24-Hydroxylase

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Metastasis. 1994 May;12(3):195-202 [8194194.001]
  • [Cites] Cancer Res. 1991 Jan 1;51(1):239-44 [1846309.001]
  • [Cites] J Histochem Cytochem. 1998 Nov;46(11):1335-7 [9774633.001]
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6 Suppl):1721S-4S [15585794.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3579-86 [15867263.001]
  • [Cites] Am J Physiol Renal Physiol. 2005 Jul;289(1):F8-28 [15951480.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2370-6 [16214919.001]
  • [Cites] Virchows Arch. 2005 Oct;447(4):688-94 [16012853.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):153-64 [16111884.001]
  • [Cites] Breast Cancer Res. 2005;7(6):R980-6 [16280049.001]
  • [Cites] Science. 2006 Apr 14;312(5771):233-6 [16614213.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Aug;100(4-5):184-92 [16828283.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Virchows Arch. 2007 Jan;450(1):73-80 [17123107.001]
  • [Cites] Nat Rev Cancer. 2007 Sep;7(9):684-700 [17721433.001]
  • [Cites] J Histochem Cytochem. 2007 Dec;55(12):1257-64 [17875655.001]
  • [Cites] Proc Nutr Soc. 2008 May;67(2):115-27 [18412986.001]
  • [Cites] J Cell Biochem. 2008 Nov 1;105(4):980-8 [18767073.001]
  • [Cites] Anticancer Res. 2009 Jan;29(1):155-7 [19331145.001]
  • [Cites] Int J Cancer. 2009 Sep 15;125(6):1328-33 [19437538.001]
  • [Cites] Mol Pharmacol. 2009 Oct;76(4):702-9 [19570947.001]
  • [Cites] J Cell Biochem. 1999 Dec 15;75(4):640-51 [10572247.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Nat Genet. 2000 Jun;25(2):144-6 [10835626.001]
  • [Cites] Circ Res. 2000 Aug 4;87(3):214-20 [10926872.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3371-9 [10955825.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Histochem J. 2002 Jan-Feb;34(1-2):35-40 [12365798.001]
  • [Cites] Mol Cell Endocrinol. 2003 Feb 28;200(1-2):67-80 [12644300.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Lancet. 1979 Dec 22-29;2(8156-8157):1335-6 [92676.001]
  • [Cites] Cancer Res. 1984 Apr;44(4):1677-81 [6322984.001]
  • [Cites] Cancer Res. 1987 Dec 15;47(24 Pt 1):6793-9 [2824042.001]
  • [Cites] Science. 1988 May 13;240(4854):889-95 [3283939.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Sep;67(3):607-13 [2842365.001]
  • [Cites] Am J Clin Pathol. 1988 Sep;90(3):233-9 [2458030.001]
  • [Cites] J Bone Miner Res. 1998 Mar;13(3):325-49 [9525333.001]
  • (PMID = 20831823.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Calcitriol; 1406-16-2 / Vitamin D; EC 1.14.- / 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; EC 1.14.- / Steroid Hydroxylases; EC 1.14.13.126 / CYP24A1 protein, human; EC 1.14.13.126 / Vitamin D3 24-Hydroxylase
  • [Other-IDs] NLM/ PMC2945944
  •  go-up   go-down


66. Foschini MP, Krausz T: Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential. Semin Diagn Pathol; 2010 Feb;27(1):77-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential.
  • Salivary gland-type neoplasms of the breast are uncommon and comprise numerous entities analogous to that more commonly seen in salivary glands.
  • The clinicopathologic spectrum ranges from benign to malignant but there are important differences as compared with those of their salivary counterpart.
  • In the breast, benign adenomyoepithelioma is recognized in addition to malignant one, whereas in the salivary gland a histologically similar tumor is designated as epithelial-myoepithelial carcinoma without a separate benign subgroup.
  • Mammary adenoid cystic carcinoma is a low-grade neoplasm compared with its salivary equivalent.
  • It is also important to appreciate that in contrast to "triple negative" conventional breast carcinomas with aggressive course, most salivary-type malignant breast neoplasms behave in a low-grade manner.
  • Most of these tumors are capable of differentiating along both epithelial and myoepithelial lines, but the amount of each lineage-component varies from case to case, contributing to diagnostic difficulties.
  • Another family of salivary gland-type mammary epithelial neoplasms is devoid of myoepithelial cells.
  • The number of cases of salivary gland-type mammary neoplasms in the published data is constantly increasing but some of the rarest subtypes like polymorphous low-grade adenocarcinoma and oncocytic carcinoma are "struggling" to become clinically relevant entities in line with those occurring more frequently in salivary glands.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Breast Neoplasms / pathology. Neoplasms, Complex and Mixed / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adenoma, Pleomorphic / metabolism. Adenoma, Pleomorphic / pathology. Adenomyoepithelioma / metabolism. Adenomyoepithelioma / pathology. Breast Neoplasms, Male / metabolism. Breast Neoplasms, Male / pathology. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Female. Humans. Male. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306833.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


67. Yang J, Hu A, Wang L, Li B, Chen Y, Zhao W, Xu W, Li T: NOEY2 mutations in primary breast cancers and breast hyperplasia. Breast; 2009 Jun;18(3):197-203
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NOEY2 mutations in primary breast cancers and breast hyperplasia.
  • PURPOSE: The NOEY2 gene mutations and protein expression in human breast cancers, adjacent breast tissues and breast benign lesions were analysed to explore the potential correlation between the mutation spectrum and breast cancer development and progression.
  • EXPERIMENTAL DESIGN: The promoter, exon and intron regions of NOEY2 gene were amplified by polymerase chain reaction (PCR) with DNA extracted from 50 human breast cancer and corresponding adjacent breast tissues as well as 50 breast benign lesions, respectively.
  • RESULTS: Twenty-one of 50 (42%) breast cancer mutations were identified in promoter (11 cases) and exon 2 (seven cases on untranslation region and three on coding region) and 17 of 50 (34%) adjacent breast tissues (all were atypical hyperplasia lesions) occurred mutations, including six promoter mutations and 11 exon 2 changes (10 cases on untranslation region and one on coding region).
  • Interestingly, the mutations were identified in both breast cancers and the corresponding adjacent breast tissues collected from the same patient in seven of them.
  • No mutation was identified in all benign breast tissues.
  • Immunohistochemical analysis showed that two of 17 mutational adjacent breast tissue samples were NOEY2 immunoreaction negative, and in all 21 mutations of breast cancers five cases were of loss of NOEY2 expression.
  • NOEY2 gene mutations were not correlated with patient ages, histological types, tumour sizes, histological grades, clinical stages, axillary lymph node metastases or with the condition of hormone receptor (ER, PR) expression and HER2 amplification.
  • CONCLUSIONS: The mutations of human NOEY2 were identified in human breast cancers and the corresponding adjacent breast tissues.
  • The presence of NOEY2 mutations in human breast cancer and early-stage lesions indicates that NOEY2 mutations may be partly associated with breast tumourigenesis.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. rho GTP-Binding Proteins / metabolism
  • [MeSH-minor] Adult. Aged. DNA Mutational Analysis / methods. Female. Gene Expression Regulation, Neoplastic. Humans. Hyperplasia / genetics. Hyperplasia / pathology. Immunohistochemistry. Middle Aged. Mutation. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / pathology. Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19482475.001).
  • [ISSN] 1532-3080
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DIRAS3 protein, human; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


68. Shaker OG, Ay El-Deen MA, Abd El-Rahim MT, Talaat RM: Gene expression of E-selectin in tissue and its protein level in serum of breast cancer patients. Tumori; 2006 Nov-Dec;92(6):524-30
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression of E-selectin in tissue and its protein level in serum of breast cancer patients.
  • AIMS AND BACKGROUND: This study aims to detect the expression of E-selectin in tissue and the serum level of its soluble form in patients with primary breast cancer and benign breast tumors and to correlate the results with the clinicopathological data of the subjects.
  • Group A comprised 30 patients with primary breast cancer, group B 9 patients with benign breast tumors, and group C 11 healthy control women undergoing reduction mammoplasty.
  • E-selectin gene expression was investigated in breast tissues by PCR techniques and soluble E-selectin was measured in sera by ELISA.
  • It was expressed in 61.5% of patients with grade 2 breast cancer and in 82.4% of patients with grade 3 breast cancer.
  • E-selectin gene expression was detected in 60%, 73.3% and 100% of patients with stage II, III and IV tumors, respectively.
  • It was detected in 81.8% of patients with node-positive primary breast cancer and in 50% of patients with node-negative cancer.
  • E-selectin was found on the membranes of peritumoral endothelial cells while it was not found on breast epithelial cells.
  • They increased significantly with increasing breast cancer stage (P < 0.001) and were significantly higher in patients with lymph node involvement than in patients without node involvement (P < 0.001).
  • CONCLUSIONS: The studied marker showed associations with established prognostic parameters such as lymph node involvement and histological tumor grade.
  • E-selectin can be regarded as a promising strategy in improving tumor therapy.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. E-Selectin / metabolism. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Adolescent. Adult. Aged. Breast Diseases / metabolism. Case-Control Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. In Situ Hybridization. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Predictive Value of Tests. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17260494.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / E-Selectin
  •  go-up   go-down


69. Hagemann T, Binder C, Binder L, Pukrop T, Trümper L, Grimshaw MJ: Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells. DNA Cell Biol; 2005 Nov;24(11):766-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells.
  • There is increased staining of endothelins (ET-1, -2, and -3) and receptors (ET-RA and -RB) in invasive breast tumors compared to nonneoplastic tissue, and ETs stimulate MCF-7 cell invasion in vitro.
  • We analyzed ETstimulation of benign and transformed mammary epithelial cells, and whether expression of ETs is sufficient to induce invasiveness.
  • In breast cancer patient serum, ET-1 was increased in those patients with lymph node metastases compared to those with no lymph node involvement; ETs, however, had no mitogenic effect on breast tumor cell lines in vitro.
  • The benign mammary epithelial cell line, hTERT-HME1, and the poorly invasive breast tumor cell line MCF-7 secreted low levels of ET-1, while the invasive cell lines SKBR3 and MDAMB231 secreted high levels.
  • In contrast to transformed cells, ET stimulation or overexpression did not induce an invasive phenotype in benign cells.
  • Benign cells do not respond to ETs, and ET expression is not sufficient to induce invasion; however, the level of ET production by tumor cells correlates with their invasiveness, and increasing expression of the ET axis promotes breast tumor cell invasion via both receptors, while MMP-14 is induced via ET-RA.
  • [MeSH-major] Breast Neoplasms / metabolism. Endothelins / biosynthesis. Epithelial Cells / metabolism. Receptor, Endothelin A / biosynthesis. Receptor, Endothelin B / biosynthesis
  • [MeSH-minor] Calcium / metabolism. Cell Line. Cell Line, Tumor. Endothelin-1 / blood. Endothelin-1 / metabolism. Enzyme Induction. Female. Humans. Lymphatic Metastasis. Mammary Glands, Human / metabolism. Mammary Glands, Human / pathology. Matrix Metalloproteinases / biosynthesis. Neoplasm Invasiveness. Phenotype. Signal Transduction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16274297.001).
  • [ISSN] 1044-5498
  • [Journal-full-title] DNA and cell biology
  • [ISO-abbreviation] DNA Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endothelin-1; 0 / Endothelins; 0 / Receptor, Endothelin A; 0 / Receptor, Endothelin B; EC 3.4.24.- / Matrix Metalloproteinases; SY7Q814VUP / Calcium
  •  go-up   go-down


70. Jabłonowska E, Kołacinska A, Kuydowicz J, Przybyłowska K, Jabłonowski Z: Interleukin-6 and the IL-6 (-174) C/G polymorphism in breast pathologies and in HIV-infected patients. Arch Med Sci; 2010 Dec;6(6):860-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-6 and the IL-6 (-174) C/G polymorphism in breast pathologies and in HIV-infected patients.
  • INTRODUCTION: Breast cancer and acquired immunodeficiency syndrome (AIDS) are key issues for modern medicine.
  • MATERIAL AND METHODS: Thirty-one women with benign breast tumours, 42 breast cancer patients and 40 HIV-infected females were enrolled in the study.
  • RESULTS: Serum IL-6 in patients with benign breast tumours was significantly lower than in females with breast cancer (p = 0.017) and HIV-infected women (p = 0.032).
  • We did not find statistically significant differences in serum IL-6 level between females with breast cancer and HIV-infected women (p = 0.749).
  • Comparing the distribution of genotypes and frequency of the IL-6 (-174) C/G polymorphism between the three study groups - breast cancer patients, patients with benign breast tumours, and HIV-infected patients - we did not find any statistically significant differences.
  • CONCLUSIONS: IL-6 can play an important role in pathogenesis of breast cancer and HIV infection and its level is higher than in the control group irrespective of distribution of genotypes and frequency of the IL-6 (-174) C/G polymorphism.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22427758.001).
  • [ISSN] 1896-9151
  • [Journal-full-title] Archives of medical science : AMS
  • [ISO-abbreviation] Arch Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC3302696
  • [Keywords] NOTNLM ; HIV / breast diseases / interleukin-6 / polymorphism
  •  go-up   go-down


71. Looi LM, Cheah PL, Ng MH, Yip CH, Mun KS, Rahman NA: Comparison of telomere length and telomerase activation between breast fibroadenoma and infiltrating ductal carcinoma in Malaysian women. Asian Pac J Cancer Prev; 2010;11(3):713-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of telomere length and telomerase activation between breast fibroadenoma and infiltrating ductal carcinoma in Malaysian women.
  • A study was initiated to explore possible differences in handling telomere attrition in the most common lignant and benign tumours of the breast in Malaysian women.
  • Infiltrating ductal carcinoma (IDC) and fibroadenoma (FA) represented the malignant and benign prototypes respectively.
  • 29 IDC, 28 FA and 22 benign non-lesional control (BNL) breast tissue samples were analysed for telomerase activation using a Telomerase PCR ELISA kit (Boehringer Mannheim).
  • The findings imply that telomere attrition and telomerase activation differ between malignant and benign tumours of the breast and may be important for targeted therapy.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Fibroadenoma / pathology. Telomerase / metabolism. Telomere / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Case-Control Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Polymerase Chain Reaction. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21039041.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


72. Queiroga FL, Pérez-Alenza D, Silvan G, Peña L, Lopes CS, Illera JC: Serum and intratumoural GH and IGF-I concentrations: prognostic factors in the outcome of canine mammary cancer. Res Vet Sci; 2010 Dec;89(3):396-403
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The biological implication of the growth hormone/insulin like growth factor-I (GH/IGF-I) axis in canine mammary tumours (CMT) has been recently demonstrated, however its clinical and prognostic implications are unknown.
  • Hormonal determinations were done by enzyme immunoassays techniques validated for canine species in serum and tumour tissue from 32 bitches with CMT and in serum and normal mammary tissue from 10 controls.
  • Serum and tissular GH and IGF-I concentrations were significantly higher in the case of malignant tumour compared with benign and controls.
  • GH and IGF-I elevated concentrations were significantly associated with tumour relapse and/or metastases during follow-up and in dogs with reduced survival times; however these parameters were not independent prognostic factors in multivariate analysis.
  • [MeSH-major] Breast Neoplasms / veterinary. Dog Diseases / diagnosis. Growth Hormone / blood. Insulin-Like Growth Factor I / analysis
  • [MeSH-minor] Animals. Breast / chemistry. Breast / pathology. Dogs. Estrogen Receptor alpha / analysis. Female. Immunoenzyme Techniques / veterinary. Neoplasm Metastasis. Prognosis. Prospective Studies. Receptors, Progesterone / analysis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20381105.001).
  • [ISSN] 1532-2661
  • [Journal-full-title] Research in veterinary science
  • [ISO-abbreviation] Res. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Receptors, Progesterone; 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone
  •  go-up   go-down


73. Malhaire C, El Khoury C, Thibault F, Athanasiou A, Petrow P, Ollivier L, Tardivon A: Vacuum-assisted biopsies under MR guidance: results of 72 procedures. Eur Radiol; 2010 Jul;20(7):1554-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinical accuracy of magnetic resonance imaging-guided breast vacuum-assisted biopsy (MR-VAB).
  • RESULTS: Twenty-three patients (median age 51 years) were at high risk (BRCA1 = 11, BRCA2 = 7, familial risk = 5), 23 had a suspected local recurrence of breast cancer.
  • According to histopathology results, 29 lesions were benign, 10 were high-risk (papillary = 2, radial scar = 1, atypical epithelial hyperplasia = 7) and 33 malignant (ductal carcinoma in situ = 8, invasive cancers = 25).
  • CONCLUSION: MRI-guided VAB represents an accurate tool for the histological diagnosis of lesions visible only at MRI.
  • [MeSH-major] Biopsy. Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Bleomycin. Breast / surgery. Dactinomycin. Female. Humans. Middle Aged. Neoplasm Staging. Radiography. Retrospective Studies. Tumor Burden. Vacuum. Vinblastine

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2004 Feb;198(2):240-1 [14759781.001]
  • [Cites] AJR Am J Roentgenol. 2003 Feb;180(2):347-51 [12540431.001]
  • [Cites] Eur Radiol. 2004 Oct;14(10):1725-31 [15248080.001]
  • [Cites] AJR Am J Roentgenol. 2008 Dec;191(6):1798-804 [19020252.001]
  • [Cites] AJR Am J Roentgenol. 2001 Mar;176(3):721-7 [11222213.001]
  • [Cites] AJR Am J Roentgenol. 2007 Aug;189(2):468-74 [17646475.001]
  • [Cites] Acta Radiol. 2006 Nov;47(9):907-13 [17077039.001]
  • [Cites] AJR Am J Roentgenol. 2009 Apr;192(4):1128-34 [19304724.001]
  • [Cites] AJR Am J Roentgenol. 2003 Nov;181(5):1283-93 [14573421.001]
  • [Cites] Radiology. 2006 Jan;238(1):54-61 [16304093.001]
  • [Cites] N Engl J Med. 2004 Jul 29;351(5):427-37 [15282350.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jul;179(1):171-8 [12076929.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jun;184(6):1782-7 [15908530.001]
  • [Cites] AJR Am J Roentgenol. 2009 Feb;192(2):341-51 [19155393.001]
  • [Cites] Eur J Radiol. 2009 Nov;72(2):289-94 [18723305.001]
  • [Cites] Am J Hum Genet. 1991 Feb;48(2):232-42 [1990835.001]
  • [Cites] Lancet. 2005 May 21-27;365(9473):1769-78 [15910949.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3248-58 [18474876.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):386-91 [18202414.001]
  • [Cites] AJR Am J Roentgenol. 2007 Oct;189(4):852-9 [17885056.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):352-3 [18202408.001]
  • [Cites] Radiology. 2007 Aug;244(2):356-78 [17641361.001]
  • [Cites] Radiology. 2007 Sep;244(3):672-91 [17709824.001]
  • [Cites] Eur Radiol. 2002 Jun;12(6):1463-70 [12042955.001]
  • [Cites] Radiology. 1999 Aug;212(2):543-9 [10429716.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):982-90 [16456807.001]
  • [Cites] Eur Radiol. 1999;9(8):1656-65 [10525886.001]
  • [Cites] Radiology. 2007 Aug;244(2):381-8 [17641362.001]
  • [Cites] AJR Am J Roentgenol. 2006 Jun;186(6):1733-6 [16714667.001]
  • [Cites] AJR Am J Roentgenol. 1999 Nov;173(5):1323-9 [10541112.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jul;185(1):183-93 [15972421.001]
  • [Cites] Lancet. 2007 Aug 11;370(9586):485-92 [17693177.001]
  • [Cites] Eur Radiol. 2008 Jan;18(1):168-76 [17609959.001]
  • (PMID = 20119729.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 1CC1JFE158 / Dactinomycin; 5V9KLZ54CY / Vinblastine; VAB protocol
  •  go-up   go-down


74. Kukreti S, Cerussi AE, Tanamai W, Hsiang D, Tromberg BJ, Gratton E: Characterization of metabolic differences between benign and malignant tumors: high-spectral-resolution diffuse optical spectroscopy. Radiology; 2010 Jan;254(1):277-84
eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of metabolic differences between benign and malignant tumors: high-spectral-resolution diffuse optical spectroscopy.
  • PURPOSE: To develop a near-infrared spectroscopic method to identify breast cancer biomarkers and to retrospectively determine if benign and malignant breast lesions could be distinguished by using this method.
  • By using self-referencing differential spectroscopy (SRDS) analysis, the existence of specific spectroscopic signatures of breast lesions on images acquired by using diffuse optical spectroscopy imaging in the wavelength range (650-1000 nm) was established.
  • There were 17 patients with benign breast tumors and 22 patients with malignant breast tumors.
  • RESULTS: Discrimination analysis helped separate malignant from benign tumors.
  • A total of 40 lesions (22 malignant and 18 benign) were analyzed.
  • CONCLUSION: The SRDS method revealed localized tumor biomarkers specific to pathologic state.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Photochem Photobiol. 2000 Sep;72(3):383-91 [10989610.001]
  • [Cites] Breast Cancer Res Treat. 2007 Sep;104(3):249-55 [17051424.001]
  • [Cites] Br J Cancer. 2001 Apr 20;84(8):1016-22 [11308247.001]
  • [Cites] Magn Reson Med. 2001 Jun;45(6):994-1000 [11378876.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jul;68(1):45-54 [11678308.001]
  • [Cites] J Biomed Opt. 2002 Jan;7(1):60-71 [11818013.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 21;94(16):1197-203 [12189222.001]
  • [Cites] Magn Reson Med. 2003 Dec;50(6):1134-43 [14648561.001]
  • [Cites] Breast. 2003 Jun;12(3):179-82 [14659324.001]
  • [Cites] J Biomed Opt. 2004 Jan-Feb;9(1):230-8 [14715078.001]
  • [Cites] J Biomed Opt. 2004 May-Jun;9(3):464-73 [15189083.001]
  • [Cites] J Biomed Opt. 2004 May-Jun;9(3):541-52 [15189092.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6468-73 [9177241.001]
  • [Cites] Radiology. 1998 Oct;209(1):269-75 [9769842.001]
  • [Cites] J Magn Reson Imaging. 1999 Aug;10(2):159-64 [10441019.001]
  • [Cites] Anticancer Res. 1999 May-Jun;19(3A):1737-46 [10470108.001]
  • [Cites] Radiology. 2004 Nov;233(2):424-31 [15516615.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):263-70 [15799826.001]
  • [Cites] Med Phys. 2005 Apr;32(4):1128-39 [15895597.001]
  • [Cites] Phys Med Biol. 2005 Jun 7;50(11):2451-68 [15901948.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):934-47 [16023382.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):925-33 [16023383.001]
  • [Cites] J Lipid Res. 2005 Sep;46(9):1983-90 [15961785.001]
  • [Cites] Radiology. 2005 Oct;237(1):57-66 [16183924.001]
  • [Cites] J Biomed Opt. 2005 Sep-Oct;10(5):051503 [16292947.001]
  • [Cites] Br J Cancer. 2006 Feb 13;94(3):427-35 [16465174.001]
  • [Cites] Biomed Pharmacother. 2005 Oct;59 Suppl 2:S302-5 [16507398.001]
  • [Cites] J Magn Reson Imaging. 2006 Aug;24(2):325-32 [16786567.001]
  • [Cites] J Biomed Opt. 2006 Jul-Aug;11(4):044005 [16965162.001]
  • [Cites] Expert Rev Med Devices. 2007 Jan;4(1):83-95 [17187474.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4014-9 [17360469.001]
  • [Cites] J Biomed Opt. 2007 Mar-Apr;12(2):020509 [17477706.001]
  • [Cites] Radiology. 2001 Jan;218(1):261-6 [11152812.001]
  • (PMID = 20032159.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA142989; United States / NCI NIH HHS / CA / U54 CA136400-01; None / None / / P41 RR001192-31; United States / NCI NIH HHS / CA / R01 CA142989-01; United States / NCRR NIH HHS / RR / P41 RR001192-31; United States / NIBIB NIH HHS / EB / R01 EB000559; United States / NCI NIH HHS / CA / U54 CA136400-02; United States / NCI NIH HHS / CA / U54 CA105480-05; United States / NCI NIH HHS / CA / U54 CA105480; United States / NCI NIH HHS / CA / U54 CA136400; United States / NCI NIH HHS / CA / R01 CA142989-02; United States / NCI NIH HHS / CA / P30-CA62203; United States / NCRR NIH HHS / RR / P41 RR003155; United States / NCRR NIH HHS / RR / P41 RR001192; United States / NCI NIH HHS / CA / P30 CA062203; United States / NCRR NIH HHS / RR / P41-RR01192
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2797652
  •  go-up   go-down


75. Galiè M, Farace P, Merigo F, Fiorini S, Tambalo S, Nicolato E, Sbarbati A, Marzola P: Washout of small molecular contrast agent in carcinoma-derived experimental tumors. Microvasc Res; 2009 Dec;78(3):370-8
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Washout of small molecular contrast agent in carcinoma-derived experimental tumors.
  • The use of contrast-enhanced magnetic resonance imaging (MRI) for the assessment of breast carcinomas reveals satisfactory sensitivity, but due to low specificity, it does not obviate the need for subsequent tissue sampling.
  • Its capability to differentiate benign from malignant lesion is under continuous investigation.
  • In particular, the study of the washout pattern is considered a promising tool to improve in vivo diagnosis and even to evaluate the response under chemotherapy.
  • To provide a comprehensive characterization of this parameter in malignant tumor models, in vivo mapping of the washout of small molecular contrast agent (Gd-DTPA, molecular weight 0.57 kDa) was carried out in three transplanted/spontaneous mammary tumors, which differed in their histopathological and microvascular features.
  • It resulted that in all models around 40% of tumor volume lacks efficient washout; washout areas are frequently, but not always, restricted to the tumor periphery and that non-washout areas are not restricted to necrotic regions.
  • Difference in the distribution of lymphatic vessels characterized spontaneous vs. transplanted tumors but did not produce a corresponding different washout pattern, confirming that Gd-DTPA drainage does not mainly depend on lymphatic architecture.
  • Finally, the efficiency of washout is correlated with parameters obtainable during the earlier phases of the enhancement curve and in malignant tumors it could be indirectly estimated from them.
  • [MeSH-major] Contrast Media / pharmacokinetics. Gadolinium DTPA / pharmacokinetics. Mammary Neoplasms, Experimental / diagnosis
  • [MeSH-minor] Animals. Female. Lymphatic Vessels / pathology. Mice. Mice, Inbred Strains. Microvessels / pathology. Neoplasm Transplantation. Neovascularization, Pathologic / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19804787.001).
  • [ISSN] 1095-9319
  • [Journal-full-title] Microvascular research
  • [ISO-abbreviation] Microvasc. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


76. Chivukula M, Domfeh A, Carter G, Tseng G, Dabbs DJ: Characterization of high-grade ductal carcinoma in situ with and without regressive changes: diagnostic and biologic implications. Appl Immunohistochem Mol Morphol; 2009 Dec;17(6):495-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The presence of RC in these neoplasms may signify some degree of host response to tumor and seems to be a sign of poor prognosis for some neoplasms.
  • RC in breast cancer is vaguely defined in the older literature.
  • We have observed periodically similar RC in a subset of high-grade ductal carcinoma in situ (HGDCIS) in breast specimens.
  • It is also critically important to recognize HGDCIS-RC for diagnostic purposes, as the differential diagnosis of RC includes, benign associations such as papilloma, fibrocystic changes and periductal mastitis.
  • Further outcome studies are necessary to determine if it has a clinical impact akin to other tumors with RC.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407654.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 13
  •  go-up   go-down


77. Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, Park BH, Chung MJ, Kang MJ, Lee DG, Moon WS: Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology; 2009;41(4):366-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic significance of SIRT1 in ovarian epithelial tumours.
  • Recently, some studies have suggested that SIRT1 could be over-expressed in breast, prostate and colon cancers and up-regulated SIRT1 inactivates p53 by deacetylation.
  • Therefore, we investigated the prevalence and the prognostic impact of SIRT1 and p53 expression in ovarian epithelial tumours.
  • METHODS: Immunohistochemical expression of SIRT1 and p53 were evaluated using tissue microarray in 40 cases of benign epithelial tumours, 36 cases of borderline tumours, and 90 cases of malignant tumours.
  • RESULTS: Expression of SIRT1 was significantly increased in malignant epithelial tumours compared to benign and borderline epithelial tumours (p < 0.001).
  • Despite the frequent expression of SIRT1 in malignant ovarian epithelial tumours, serous carcinomas of high FIGO stage showed less frequent SIRT1 expression compared to that of low stage serous carcinomas (p = 0.029).
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Sirtuins / biosynthesis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Prognosis. Sirtuin 1. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404850.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins
  •  go-up   go-down


78. Yang W, Zhang S, Chen Y, Li W, Chen Y: Shape symmetry analysis of breast tumors on ultrasound images. Comput Biol Med; 2009 Mar;39(3):231-8
MedlinePlus Health Information. consumer health - Ultrasound.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shape symmetry analysis of breast tumors on ultrasound images.
  • Shape characteristics of malignant and benign breast tumors are significantly different.
  • In this paper, the reflective symmetry of breast tumor shapes on ultrasound images was investigated.
  • A new reflective symmetry measure (RSML) derived from multiscale local area integral invariant was proposed to quantify the shape symmetry of breast tumor, which could be computed directly from the binary mask image without the shape parameterization in terms of arc length.
  • The performance of several symmetry measures for differentiating malignant and benign breast tumors at varying scales was evaluated and compared by receiver operating characteristic (ROC) analysis.
  • RSML with Gaussian kernel at scale 0.04 (related to the maximal diameter) achieved the highest area under the ROC curve (0.85) on the image data of 168 tumors (104 benign and 64 malignant).
  • The experimental results showed that the reflective symmetry of breast tumor shape was capable of providing potential diagnostic information, which could be characterized quantitatively by RSML with the appropriate scale parameter.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Image Interpretation, Computer-Assisted / methods. Ultrasonography / methods. Ultrasonography, Mammary / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178908.001).
  • [ISSN] 1879-0534
  • [Journal-full-title] Computers in biology and medicine
  • [ISO-abbreviation] Comput. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


79. Puisieux A: [Inactivation of failsafe programs by Twist oncoproteins and tumor progression]. Ann Pharm Fr; 2008 Nov-Dec;66(5-6):278-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inactivation of failsafe programs by Twist oncoproteins and tumor progression].
  • [Transliterated title] Inactivation des systèmes de sauvegarde cellulaire par les oncoprotéines Twist et progression tumorale.
  • Hence, in benign tumors, aberrant mitogenic activity is counterbalanced by the induction of these oncosuppressive pathways, leading to either apoptosis or senescence which both limit tumor outgrowth.
  • Progression towards malignant and potentially metastatic tumors requires the inhibition of these failsafe programs.
  • Based on our work on Twist oncoproteins, we propose a presentation of recent data on cellular mechanisms by which cancer cells override the surveillance machinery and escape senescence and apoptosis, and we will describe the biological impact of this process on tumor metastasis.
  • [MeSH-major] Neoplasm Metastasis / pathology. Neoplasm Proteins / physiology. Nuclear Proteins / physiology. Repressor Proteins / physiology. Twist Transcription Factor / physiology
  • [MeSH-minor] Animals. Apoptosis / physiology. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cell Aging / physiology. Disease Progression. Female. Gene Amplification / physiology. Genes, myc. Humans. Neoplasm Invasiveness. Neuroblastoma / metabolism. Neuroblastoma / pathology. Proto-Oncogene Proteins c-myc / physiology. Tumor Suppressor Protein p53 / physiology. Tumor Suppressor Proteins / antagonists & inhibitors. Tumor Suppressor Proteins / physiology. ras Proteins / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19061727.001).
  • [ISSN] 0003-4509
  • [Journal-full-title] Annales pharmaceutiques françaises
  • [ISO-abbreviation] Ann Pharm Fr
  • [Language] fre
  • [Publication-type] Addresses; English Abstract
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins c-myc; 0 / Repressor Proteins; 0 / TWIST1 protein, human; 0 / TWIST2 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / Twist Transcription Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


80. Singh SS, Velusami SD: Syringomatous adenoma of the nipple: report of a case. Indian J Pathol Microbiol; 2007 Oct;50(4):808-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Syringomatous adenoma of the nipple is a rarely encountered neoplasm of the breast with histological features similar to eccrine syringoma of the skin.
  • This tumour which is locally invasive with high potential for recurrence if incompletely excised is considered benign and a complete excision is sufficient.
  • We report a case of syringomatous adenoma of the nipple in a postmenopausal diabetic woman who was incidentally found to have a subareolar mass in her right breast.
  • A clinicopathological study and histological differential diagnosis of this unusual tumour is described.
  • [MeSH-major] Nipples / pathology. Syringoma / diagnosis. Syringoma / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Female. Humans. Mammography. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306564.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


81. Fujita T, Hayashi K, Katanoda K, Matsumura Y, Lee JS, Takagi H, Suzuki S, Mizunuma H, Aso T: Prevalence of diseases and statistical power of the Japan Nurses' Health Study. Ind Health; 2007 Oct;45(5):687-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For all diseases except ovarian cancer, the prevalence of a past diagnosis increased markedly with age, and incidence rates could be predicted based on the degree of increase in prevalence between two adjacent 5-yr age groups.
  • The predicted incidence rate for uterine myoma, hypercholesterolemia, and hypertension was > or =3.0 (per 1,000 women, per year), while the rate of thyroid disease, hepatitis, gallstone disease, and benign breast tumor was predicted to be > or =1.0.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18057812.001).
  • [ISSN] 0019-8366
  • [Journal-full-title] Industrial health
  • [ISO-abbreviation] Ind Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


82. Rimkus C, Martini M, Friederichs J, Rosenberg R, Doll D, Siewert JR, Holzmann B, Janssen KP: Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer. Br J Cancer; 2006 Nov 20;95(10):1419-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer.
  • The gene SASH1 (SAM- and SH3-domain containing 1) has originally been identified as a candidate tumour suppressor gene in breast cancer.
  • Moreover, nine benign adenomas and 10 liver metastases were analysed.
  • Overall, 48 out of 113 primary colon tumours showed SASH1 expression that was at least 10-fold lower than the levels found in normal colon tissue.
  • [MeSH-major] Colonic Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Colon / metabolism. Colon / pathology. Down-Regulation. Female. Genes, Tumor Suppressor. Humans. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Precancerous Conditions / genetics. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 2001 Jul 30;1520(1):89-93 [11470164.001]
  • [Cites] Cell Immunol. 2005 May;235(1):46-55 [16137664.001]
  • [Cites] Oncogene. 2001 Aug 30;20(38):5373-7 [11536050.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Oct 19;288(1):137-41 [11594764.001]
  • [Cites] Nat Struct Biol. 2002 Jun;9(6):453-7 [11992127.001]
  • [Cites] Oncogene. 2003 May 15;22(19):2972-83 [12771949.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Aug;37(4):369-80 [12800148.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22118-23 [15037605.001]
  • [Cites] Fam Cancer. 2004;3(2):93-100 [15340259.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):737-47 [15381729.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Nature. 1995 Feb 16;373(6515):573-80 [7531822.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27 [8996076.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(21):9646-60 [16227612.001]
  • [Cites] EMBO J. 2001 Aug 1;20(15):4173-82 [11483520.001]
  • (PMID = 17088907.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / SASH1 protein, human; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2360597
  •  go-up   go-down


83. Endo K, Oriuchi N, Higuchi T, Iida Y, Hanaoka H, Miyakubo M, Ishikita T, Koyama K: PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol; 2006 Aug;11(4):286-96

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients.
  • FDG-PET provides information that is not obtainable with other imaging modalities, and is very effective in the diagnosis and management of patients with various types of cancers.
  • PET and/or PET/CT using FDG is clinically useful in the detection of cancer, the differentiation of malignant and benign lesions, the staging of cancer before therapy, and the assessment of cancer therapy, as well as for determining the recurrence after therapy of most cancers, including lung cancer, gastrointestinal cancer, breast cancer, and malignant lymphoma.
  • PET/CT has become the new standard approach to imaging in the diagnosis and management of many cancer patients.
  • [MeSH-major] Fluorodeoxyglucose F18. Neoplasms / diagnosis. Neoplasms / diagnostic imaging. Positron-Emission Tomography / methods. Tomography, Emission-Computed / methods
  • [MeSH-minor] Breast Neoplasms / diagnosis. Breast Neoplasms / diagnostic imaging. Carcinoma / diagnosis. Carcinoma / diagnostic imaging. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / diagnostic imaging. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / diagnostic imaging. Lymphoma / diagnosis. Lymphoma / diagnostic imaging. Neoplasm Staging / methods. Whole Body Imaging / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Oct 20;23 (30):7445-53 [16157939.001]
  • [Cites] Gut. 2003 Jun;52 Suppl 4:iv23-9 [12746265.001]
  • [Cites] Ann Surg Oncol. 2005 Jul;12(7):561-9 [15889211.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):2927-33 [10898336.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2785-808 [15837727.001]
  • [Cites] J Nucl Med. 2002 Aug;43(8):1018-27 [12163626.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23 (21):4577-80 [15837974.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23 (21):4652-61 [15837965.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2500-7 [12815135.001]
  • [Cites] J Nucl Med. 1995 Oct;36(10 ):1811-7 [7562048.001]
  • [Cites] Chest. 2004 Jun;125(6):2294-9 [15189954.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1676-88 [10764428.001]
  • [Cites] Ann Surg. 1998 Mar;227(3):319-23 [9527052.001]
  • [Cites] Radiographics. 2003 Mar-Apr;23 (2):315-40; quiz 533 [12640150.001]
  • [Cites] J Nucl Med. 2005 Feb;46(2):267-73 [15695786.001]
  • [Cites] Semin Nucl Med. 2002 Jan;32(1):6-12 [11839070.001]
  • [Cites] Radiology. 1998 Mar;206(3):755-60 [9494497.001]
  • [Cites] Blood. 2003 May 15;101(10 ):3875-6 [12531812.001]
  • [Cites] Radiology. 2006 Apr;239(1):34-49 [16567482.001]
  • [Cites] Radiology. 2004 May;231(2):305-32 [15044750.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3495-502 [11032590.001]
  • [Cites] J Nucl Med. 2004 Dec;45(12 ):1989-98 [15585472.001]
  • [Cites] J Nucl Med. 2006 Jan;47(1):14-22 [16391182.001]
  • [Cites] J Nucl Med. 1994 Jan;35(1):104-12 [8271030.001]
  • [Cites] J Nucl Med. 2002 Apr;43(4):492-9 [11937593.001]
  • [Cites] JAMA. 2001 Feb 21;285(7):914-24 [11180735.001]
  • [Cites] Gut. 2006 Jan;55(1):10-2 [16344572.001]
  • [Cites] J Nucl Med. 2003 Nov;44(11):1784-8 [14602860.001]
  • [Cites] N Engl J Med. 2006 Feb 2;354(5):496-507 [16452561.001]
  • [Cites] J Nucl Med. 2001 May;42(5 Suppl):1S-93S [11483694.001]
  • [Cites] Br J Radiol. 2006 Jan;79(937):32-6 [16421402.001]
  • [Cites] J Nucl Med. 1998 Jun;39(6):1016-20 [9627336.001]
  • [Cites] J Nucl Med. 2005 Jul;46(7):1144-50 [16000283.001]
  • [Cites] Gut. 2006 Jan;55(1):68-73 [15970580.001]
  • [Cites] Chest. 2004 Nov;126(5):1656-66 [15539740.001]
  • [Cites] Blood. 1998 Jun 15;91(12 ):4464-71 [9616140.001]
  • [Cites] Cancer. 2000 Dec 15;89(12 ):2547-54 [11135214.001]
  • [Cites] J Nucl Med. 2006 Mar;47(3):426-31 [16513611.001]
  • [Cites] J Nucl Med. 2000 Jul;41(7):1177-89 [10914907.001]
  • [Cites] Eur J Cancer. 2001 May;37(7):862-9 [11313174.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23 (21):4643-51 [15837966.001]
  • [Cites] Radiology. 2006 Feb;238(2):405-22 [16436809.001]
  • [Cites] J Nucl Med. 2004 Dec;45(12 ):2058-62 [15585482.001]
  • [Cites] Eur J Nucl Med. 2001 Nov;28(11):1707-23 [11702115.001]
  • [Cites] Chest. 2004 Jun;125(6):2300-8 [15189955.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1689-95 [10764429.001]
  • [Cites] J Nucl Med. 2001 Jul;42(7):989-92 [11438616.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Apr;127(4):1087-92 [15052206.001]
  • [Cites] J Nucl Med. 2006 Mar;47(3):451-69 [16513615.001]
  • [Cites] Br J Surg. 2004 Aug;91(8):1004-9 [15286962.001]
  • [Cites] J Nucl Med. 2000 Aug;41(8):1369-79 [10945530.001]
  • (PMID = 16937302.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 51
  •  go-up   go-down


84. Ku J, Campbell C, Bennett I: Leiomyoma of the nipple. Breast J; 2006 Jul-Aug;12(4):377-80
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leiomyoma is a rare, benign neoplasm of the nipple.
  • Clinicians should be aware that this is a rare, but potential cause of chronic persistent pain and swelling in the region of the nipple-areola complex of the breast.
  • [MeSH-major] Breast Neoplasms / pathology. Leiomyoma / pathology. Nipples

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16848853.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Zhang S, Lin QD, DI W: Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):522-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BRMS1 (breast cancer metastasis suppressor) has recently been identified as a metastasis-suppressor gene for human breast cancer and melanoma.
  • We hypothesize that the role of BRMS1 in tumor progression may not be limited to breast cancer and melanoma.
  • We previously found that BRMS1 mRNA levels in primary ovarian epithelial carcinomas were significantly lower than that in normal ovarian and benign tumors (P < 0.05), and statistical analysis of BRMS1 mRNA levels revealed that BRMS1 mRNA levels were significantly higher in early tumor stages (I, II) compared with advanced tumor stages (III, IV) in which lymph node or distant metastases were present (P < 0.01).
  • BRMS1 expression did not alter the proliferation of HO-8910PM cells in vitro and primary tumor formation in vivo.
  • Also, BRMS1 transfectants form significantly less metastatic to organs of peritoneal cavity in orthotopically implanted ovarian tumor nude models.
  • These data suggested that in addition to its already described role in breast cancer and melanoma, BRMS1 functions as a metastasis-suppressor gene in ovarian carcinoma by modifying several metastatic-associated phenotypes, offering a new target for therapeutic intervention.
  • [MeSH-major] Gene Expression Regulation / physiology. Neoplasm Proteins / physiology. Ovarian Neoplasms / prevention & control
  • [MeSH-minor] Animals. Cell Movement. Cell Proliferation. Disease Models, Animal. Down-Regulation. Female. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Invasiveness. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / prevention & control. Neoplasms, Glandular and Epithelial / secondary. Peritoneal Neoplasms / prevention & control. Peritoneal Neoplasms / secondary. RNA, Messenger / metabolism. Repressor Proteins. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Tumor Cells, Cultured. Tumor Stem Cell Assay

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681721.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BRMS1 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins
  •  go-up   go-down


86. Lardinois D, Weder W, Roudas M, von Schulthess GK, Tutic M, Moch H, Stahel RA, Steinert HC: Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer. J Clin Oncol; 2005 Oct 1;23(28):6846-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A diagnosis was obtained in 69 of these patients, including 37 (54%) with solitary metastases and 32 (46%) with lesions unrelated to the lung primary.
  • Histopathologic examinations of these 32 lesions revealed a second clinically unsuspected malignancy or a recurrence of a previous diagnosed carcinoma in six patients (19%) and a benign tumor or inflammatory lesion in 26 patients (81%).
  • The six malignancies consisted of carcinoma of the breast in two patients, and carcinoma of the orbit, esophagus, prostate, and non-Hodgkin's lymphoma in one patient each.
  • Benign tumors and inflammatory lesions included eight colon adenomas, four Warthin's tumors, one granuloma of the lower jaw, one adenoma of the thyroid gland, one compensatory muscle activity due to vocal chord palsy, two occurrences of arthritis, three occurrences of reflux esophagitis, two occurrences of pancreatitis, two occurrences of diverticulitis, one hemorrhoidal inflammation, and one rib fracture.
  • CONCLUSION: Solitary extrapulmonary FDG accumulations in patients with newly diagnosed lung cancer should be analyzed critically for correct staging and optimal therapy, given that up to half of the lesions may represent unrelated malignancies or benign disease.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Lung Neoplasms / radionuclide imaging. Neoplasm Metastasis / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Inflammation. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Radiopharmaceuticals. Sensitivity and Specificity. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16192576.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


87. Ikeda S, Shibata T, Funakoshi N: Immunohistochemical detection of telomerase reverse transcriptase (TERT) protein in benign and malignant tumor cells of the breast. Rinsho Byori; 2005 Jun;53(6):487-93
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of telomerase reverse transcriptase (TERT) protein in benign and malignant tumor cells of the breast.
  • Telomerase activity is associated with immortality and is expressed in various malignant tumors.
  • In this study, the expression of TERT was investigated by immunocytochemistry to determine whether it is a useful marker for differential diagnosis in benign or malignant breast tumors.
  • We examined imprint smears prepared from 63 surgically resected breast lesions, and 27 cases of secretion or aspiration cytology smears had been routinely diagnosed.
  • In conclusion, the expression of TERT protein might be a useful marker for differential diagnosis in malignant and benign breast tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / diagnosis. DNA-Binding Proteins / analysis. Telomerase / analysis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunohistochemistry / methods. In Situ Hybridization. RNA, Messenger / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Rinsho Byori.2005 Aug;53(8):748
  • (PMID = 16026073.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


88. Preda A, Novikov V, Möglich M, Floyd E, Turetschek K, Shames DM, Roberts TP, Corot C, Carter WO, Brasch RC: Magnetic resonance characterization of tumor microvessels in experimental breast tumors using a slow clearance blood pool contrast agent (carboxymethyldextran-A2-Gd-DOTA) with histopathological correlation. Eur Radiol; 2005 Nov;15(11):2268-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance characterization of tumor microvessels in experimental breast tumors using a slow clearance blood pool contrast agent (carboxymethyldextran-A2-Gd-DOTA) with histopathological correlation.
  • Carboxymethyldextran (CMD)-A2-Gd-DOTA, a slow clearance blood pool contrast agent with a molecular weight of 52.1 kDa, designed to have intravascular residence for more than 1 h, was evaluated for its potential to characterize and differentiate the microvessels of malignant and benign breast tumors.
  • Precontrast single-slice inversion-recovery snapshot FLASH and dynamic contrast-enhanced MRI using an axial T1-weighted three-dimensional spoiled gradient recalled sequence was performed in 30 Sprague-Dawley rats with chemically induced breast tumors.
  • Endothelial transfer coefficient and fractional plasma volume of the breast tumors were estimated from MRI data acquired with CMD-A2-Gd-DOTA enhancement injected at a dose of 0.1 mmol Gd/kg body weight using a two-compartment bidirectional model of the tumor tissue.
  • The correlation between MRI microvessel characteristics and histopathological tumor grade was determined using the Scarff-Bloom-Richardson method.
  • Using CMD-A2-Gd-DOTA, no significant correlations were found between the MR-estimated endothelial transfer coefficient or plasma volumes with histological tumor grade.
  • Analysis of CMD-A2-Gd-DOTA-enhanced MR kinetic data failed to demonstrate feasibility for the differentiation of benign from malignant tumors or for image-based tumor grading.
  • [MeSH-major] Magnetic Resonance Imaging. Mammary Neoplasms, Experimental / blood supply. Mammary Neoplasms, Experimental / pathology. Organometallic Compounds

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Invest. 1998;16(4):225-30 [9589031.001]
  • [Cites] Anticancer Res. 1991 Sep-Oct;11(5):1783-92 [1837443.001]
  • [Cites] J Magn Reson Imaging. 1999 Aug;10(2):170-7 [10441021.001]
  • [Cites] Am J Obstet Gynecol. 2000 Oct;183(4):956-63 [11035346.001]
  • [Cites] Sci Am. 1994 Jul;271(1):58-65 [8066425.001]
  • [Cites] J Magn Reson Imaging. 2001 Sep;14(3):237-42 [11536400.001]
  • [Cites] J Comput Assist Tomogr. 1991 Jul-Aug;15(4):621-8 [2061479.001]
  • [Cites] Radiology. 2001 Feb;218(2):562-9 [11161179.001]
  • [Cites] Acta Radiol Suppl. 1997;412:91-9 [9240087.001]
  • [Cites] Invest Radiol. 1994 Jun;29 Suppl 2:S8-11 [7928277.001]
  • [Cites] Radiat Res. 1985 Mar;101(3):460-72 [3983362.001]
  • [Cites] Magn Reson Med. 1990 Oct;16(1):117-31 [2255233.001]
  • [Cites] Magn Reson Med. 1991 Feb;17(2):357-67 [2062210.001]
  • [Cites] Magn Reson Imaging. 1992;10(1):97-108 [1545688.001]
  • [Cites] Radiology. 1996 Mar;198(3):893-8 [8628889.001]
  • [Cites] Magn Reson Med. 1993 May;29(5):616-22 [8505897.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Mar;30(3):448-55 [12722742.001]
  • [Cites] Invest Radiol. 1996 May;31(5):288-93 [8724128.001]
  • [Cites] Invest Radiol. 2000 Apr;35(4):213-8 [10764089.001]
  • [Cites] Eur Radiol. 2003 Feb;13(2):354-65 [12599002.001]
  • [Cites] Invest Radiol. 1991 Dec;26(12 ):1035-40 [1722486.001]
  • [Cites] AJR Am J Roentgenol. 1998 Oct;171(4):941-9 [9762973.001]
  • [Cites] Radiology. 1996 Mar;198(3):813-8 [8628876.001]
  • [Cites] J Magn Reson Imaging. 1999 Feb;9(2):177-86 [10077011.001]
  • [Cites] Magn Reson Med. 2001 May;45(5):880-6 [11323815.001]
  • [Cites] Magn Reson Med. 1995 Dec;34(6):845-52 [8598811.001]
  • [Cites] Eur Radiol. 2001;11(7):1276-84 [11471624.001]
  • [Cites] J Magn Reson Imaging. 2001 Jun;13(6):882-8 [11382948.001]
  • [Cites] Radiology. 1999 Oct;213(1):265-72 [10540670.001]
  • [Cites] Magn Reson Med. 1990 Jan;13(1):77-89 [2319937.001]
  • [Cites] Anticancer Res. 1984 Jan-Apr;4(1-2):5-12 [6712176.001]
  • [Cites] J Magn Reson Imaging. 1999 Jun;9(6):777-85 [10373025.001]
  • [Cites] J Magn Reson Imaging. 1997 Jan-Feb;7(1):82-90 [9039597.001]
  • [Cites] Br J Cancer. 1957 Sep;11(3):359-77 [13499785.001]
  • [Cites] Cancer Res. 1988 Dec 15;48(24 Pt 1):7022-32 [3191477.001]
  • [Cites] Magn Reson Med. 2000 Mar;43(3):403-9 [10725883.001]
  • [Cites] Cancer Metastasis Rev. 1987;6(4):559-93 [3327633.001]
  • [Cites] Cancer. 1987 Sep 15;60(6):1299-305 [3040213.001]
  • (PMID = 16012822.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA82923
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organometallic Compounds; 0 / carboxymethyl-dextran-A2-gadolinium-DOTA
  •  go-up   go-down


89. Papantoniou V, Koutsikos J, Sotiropoulou M, Feida E, Tsiouris S: Recurrent bilateral mammary fibromatosis (desmoid tumor) imaged with technetium-99m pentavalent dimercaptosuccinic acid [99mTc-(V)DMSA] scintimammography. Gynecol Oncol; 2005 Jun;97(3):964-9
Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent bilateral mammary fibromatosis (desmoid tumor) imaged with technetium-99m pentavalent dimercaptosuccinic acid [99mTc-(V)DMSA] scintimammography.
  • BACKGROUND: Breast fibromatosis is a rare, benign, recurring, locally destructive entity.
  • Two years later, she was re-evaluated due to a three times as large mass recurrence on X-ray mammography. (99m)Tc-(V)DMSA scintimammography revealed diffuse increased radiotracer uptake occupying the entire breast.
  • A less widespread similar uptake was observed in the contralateral breast.
  • CONCLUSIONS: (99m)Tc-(V)DMSA scintimammography can provide information regarding the nature of the lesion, its extent and bilateral involvement (especially in dense breasts) and could prove useful as a predictor of its potential for recurrence.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Fibromatosis, Aggressive / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Technetium. Technetium Tc 99m Dimercaptosuccinic Acid

  • Genetic Alliance. consumer health - Desmoid Tumor.
  • Genetic Alliance. consumer health - Fibromatosis.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15896828.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 494JNQ8L28 / Technetium Tc 99m Dimercaptosuccinic Acid; 7440-26-8 / Technetium
  •  go-up   go-down


90. Bettstetter M, Woenckhaus M, Wild PJ, Rümmele P, Blaszyk H, Hartmann A, Hofstädter F, Dietmaier W: Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer. J Pathol; 2005 Apr;205(5):606-14
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer.
  • Maspin, a member of the serpin family, has been reported to suppress metastasis and angiogenesis in breast and prostate cancers.
  • Overexpression of maspin was associated with adverse prognostic features in several other tumours.
  • Significant upregulation of maspin expression was found in MSI-H tumours compared to both MSS/MSI-L tumours and matched benign colonic mucosa.
  • Intense nuclear maspin immunostaining was seen specifically in MSI-H tumours (p = 0.013), de-differentiated tumours (p = 0.006), and at the invasion front.
  • These findings provide new insights into the role of maspin in colorectal cancer progression and may be useful for diagnosis and treatment strategies.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. Microsatellite Repeats. Neoplasm Proteins / metabolism. Serpins / metabolism
  • [MeSH-minor] Blotting, Western. Cell Nucleus / metabolism. CpG Islands. Cytoplasm / metabolism. DNA Methylation. DNA, Neoplasm / genetics. Genes, Tumor Suppressor. Humans. Neoplasm Invasiveness. Neoplasm Staging. Promoter Regions, Genetic. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Transcription, Genetic

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15714592.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / RNA, Neoplasm; 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


91. Afify AM, Stern R, Michael CW: Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Diagn Cytopathol; 2005 Mar;32(3):145-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Archival paraffin-embedded cell blocks of serous fluids from 28 cases of reactive mesothelial cells, 14 cases of MM, 20 cases of metastatic ovarian carcinomas, 17 cases of metastatic breast carcinomas, 12 cases of metastatic lung ACA, and 12 cases of metastatic gastrointestinal ACA were stained with HA using a biotinylated HABP and CD44S.
  • All MMs and 93% (26/28) of the benign mesothelial cells were positive for intracytoplasmic HA vs. none of ACAs.
  • CD44S was expressed in 100% (28/28) of mesothelial hyperplesia, 86% (12/14) of MMs, 70% (14/20) of ovarian carcinomas, 29% (5/17) of breast carcinomas, 25% (3/12) of gastrointestinal ACAs, and 8% (1/12) of lung ACAs.
  • CD44 may prove useful in conjunction with other stains in the differential diagnosis of mesothelioma and ADA.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, CD44 / metabolism. Ascitic Fluid / metabolism. Hyaluronic Acid / metabolism. Mesothelioma / diagnosis. Pleural Effusion, Malignant / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Neoplasm Metastasis. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15690337.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44S antigen; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


92. Wang FM, Liu HQ, Liu SR, Tang SP, Yang L, Feng GS: SHP-2 promoting migration and metastasis of MCF-7 with loss of E-cadherin, dephosphorylation of FAK and secretion of MMP-9 induced by IL-1beta in vivo and in vitro. Breast Cancer Res Treat; 2005 Jan;89(1):5-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The loss of E-cadherin-mediated adhesion and the increase of MMP-9-induced migration had been shown to play an important role in the transition of epithelial tumors from a benign to an invasive state.
  • To determine whether SHP-2 promotes invasion and metastasis, we transfected MCF-7 breast cancer cell lines with SHP-2-GFP, SHP-2C > S-GFP and analyzed the effects of the SHP-2 on cell migration, invasion, and metastasis.
  • [MeSH-major] Breast Neoplasms / physiopathology. Cadherins / metabolism. Cell Movement. Focal Adhesions / chemistry. Matrix Metalloproteinase 9 / secretion. Neoplasm Metastasis / physiopathology. Protein Tyrosine Phosphatases / metabolism. Protein-Tyrosine Kinases / chemistry
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Focal Adhesion Kinase 1. Focal Adhesion Protein-Tyrosine Kinases. Gene Expression. In Vitro Techniques. Interleukin-1. Intracellular Signaling Peptides and Proteins. Mice. Mice, Nude. Phosphorylation. Protein Tyrosine Phosphatase, Non-Receptor Type 11

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15666191.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cadherins; 0 / Interleukin-1; 0 / Intracellular Signaling Peptides and Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Focal Adhesion Kinase 1; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases; EC 2.7.10.2 / Ptk2 protein, mouse; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.1.3.48 / Ptpn11 protein, mouse; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


93. Corben AD, Nehhozina T, Garg K, Vallejo CE, Brogi E: Endosalpingiosis in axillary lymph nodes: a possible pitfall in the staging of patients with breast carcinoma. Am J Surg Pathol; 2010 Aug;34(8):1211-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endosalpingiosis in axillary lymph nodes: a possible pitfall in the staging of patients with breast carcinoma.
  • The occurrence of benign epithelial inclusions in lymph nodes is well documented and can sometimes mimic metastatic carcinoma.
  • Benign müllerian inclusions, such as endometriosis and endosalpingiosis, are common in pelvic and para-aortic lymph nodes, but their presence in supradiaphragmatic lymph nodes is a rare event.
  • We report our experience with 3 patients found to have endosalpingiosis in axillary sentinel lymph nodes obtained for staging of breast carcinoma.
  • Endosalpingiosis had been misinterpreted as metastatic carcinoma at another hospital in 1 of the 3 patients, with subsequent dissection of 19 additional benign axillary lymph nodes.
  • Morphologic identification of ciliated cells and "peg" cells is most helpful to recognize this benign inclusion, and positive immunoreactivity for WT1 and/or PAX8 can be used to support the diagnosis.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Diagnostic Errors / prevention & control. Epithelial Cells / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cilia. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Neoplasm Staging. Paired Box Transcription Factors / analysis. Predictive Value of Tests. Sentinel Lymph Node Biopsy. Unnecessary Procedures. WT1 Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20631604.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors; 0 / WT1 Proteins
  • [Number-of-references] 32
  •  go-up   go-down


94. Roncella S, Ferro P, Franceschini MC, Bacigalupo B, Dessanti P, Sivori M, Carletti AM, Fontana V, Canessa PA, Pistillo MP, Fedeli F: Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin. Diagn Mol Pathol; 2010 Jun;19(2):92-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin.
  • As was reported that human mammaglobin (hMAM) may be expressed in malignant pleural effusions (PEs), we investigated the relevance of hMAM reverse-transcriptase polymerase chain reaction (RT-PCR) for their diagnosis and determination of primary origin.
  • Two hundred and twenty-eight malignant (132 male, 96 female) and 185 benign (132 male, 53 female) PEs were investigated.
  • Statistical analyses evaluated the diagnostic performance parameters in all PEs and in cytologically negative malignant PEs, the association between hMAM and benign or malignant status by the direct index of correlation [diagnostic odds ratio (DOR)], chi test, and P value (P).
  • In addition, the discriminative diagnostic power of hMAM expression, independently in breast cancer, lung cancer (LC), malignant mesothelioma (MM), and other cancers was evaluated.
  • In the entire patient population, hMAM was detected in 45.6% and 5.4% of malignant and benign PEs, respectively, in the male group in 41.7% and 4.5% and in the female group in 51.0% and 7.5% of malignant and benign PEs, respectively.
  • A statistically significant correlation between hMAM and malignancy was found in the entire population (DOR=14.68, P<0.001) and in the male (DOR=15.00, P<0.001) or female (DOR=12.77, P<0.001) groups. hMAM RT-PCR increased the diagnostic rate of malignant PEs as it allowed us to detect as malignant 32.1% of cytologically negative PEs.
  • In female patients the positivity of hMAM indicated with higher probability (50.8%) the origin of PEs from breast cancer but lower probability from LC (17%), MM (9.4%), or other cancers (15.1%), whereas in male patients it indicated with similar probability (about 40%) the origin from LC or MM.
  • Our results suggest that hMAM RT-PCR may provide information both in the diagnosis of PE and in the search for the primary site of neoplasia, either in male or female patients.
  • [MeSH-major] Breast Neoplasms / complications. Breast Neoplasms / diagnosis. Neoplasm Proteins / genetics. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / etiology. Reverse Transcriptase Polymerase Chain Reaction / methods. Uteroglobin / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Female. Humans. Male. Mammaglobin A. Middle Aged. United States. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20502186.001).
  • [ISSN] 1533-4066
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


95. Pérez M, Liu Y, Schootman M, Aft RL, Schechtman KB, Gillanders WE, Jeffe DB: Changes in sexual problems over time in women with and without early-stage breast cancer. Menopause; 2010 Sep-Oct;17(5):924-37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in sexual problems over time in women with and without early-stage breast cancer.
  • OBJECTIVE: We aimed to evaluate whether age-matched women with and without early-stage breast cancer differentially experience sexual problems over time and whether changes in patients' problems differ by type of surgical procedure.
  • METHODS: We conducted four interviews (4-6 wk, 6 mo, and 1 and 2 y) after tumor resection (patients) or after a negative/benign screening mammogram (controls).

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Sexual Problems in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast. 2008 Oct;17(5):436-40 [18479922.001]
  • [Cites] J Clin Epidemiol. 2009 Jul;62(7):759-65 [19013762.001]
  • [Cites] J Stud Alcohol Drugs. 2009 Jul;70(4):623-7 [19515304.001]
  • [Cites] J Environ Manage. 2009 Aug;90(11):3528-33 [19647362.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2371-80 [10561299.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2659-69 [10561339.001]
  • [Cites] Psychooncology. 1999 Nov-Dec;8(6):538-45 [10607986.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):946-54 [10679665.001]
  • [Cites] Arch Intern Med. 2000 Apr 10;160(7):953-8 [10761960.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 5;92(13):1054-64 [10880548.001]
  • [Cites] J Consult Clin Psychol. 2000 Aug;68(4):697-709 [10965644.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 6;92(17):1422-9 [10974078.001]
  • [Cites] Addiction. 2000 Nov;95 Suppl 3:S381-94 [11132364.001]
  • [Cites] Menopause. 2001 Summer;8(2):111-9 [11256871.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1885-92 [11283119.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1288-98 [11571745.001]
  • [Cites] Ann N Y Acad Sci. 2001 Dec;949:143-50 [11795346.001]
  • [Cites] Br J Cancer. 2002 May 20;86(10):1546-50 [12085202.001]
  • [Cites] Behav Res Methods Instrum Comput. 2002 May;34(2):151-7 [12109005.001]
  • [Cites] Breast Cancer Res Treat. 2002 Oct;75(3):241-8 [12353813.001]
  • [Cites] CA Cancer J Clin. 2002 Sep-Oct;52(5):256-76 [12363325.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2254-62 [11304779.001]
  • [Cites] Psychooncology. 2002 Nov-Dec;11(6):505-17 [12476432.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3659-64 [14512398.001]
  • [Cites] Semin Oncol. 2003 Dec;30(6):799-813 [14663780.001]
  • [Cites] Am J Epidemiol. 2004 Feb 15;159(4):364-72 [14769640.001]
  • [Cites] Breast J. 2004 May-Jun;10(3):223-31 [15125749.001]
  • [Cites] Psychooncology. 2004 May;13(5):295-308 [15133771.001]
  • [Cites] Health Qual Life Outcomes. 2004 May 18;2:25 [15149547.001]
  • [Cites] Nurs Res. 1982 Sep-Oct;31(5):278-83 [6922469.001]
  • [Cites] Am J Psychiatry. 1983 Jun;140(6):734-9 [6846631.001]
  • [Cites] Cancer. 1988 Sep 15;62(6):1231-7 [3044575.001]
  • [Cites] J Consult Clin Psychol. 1988 Dec;56(6):893-7 [3204199.001]
  • [Cites] CA Cancer J Clin. 1991 Mar-Apr;41(2):112-20 [1900030.001]
  • [Cites] Cancer. 1992 Apr 1;69(7):1729-38 [1551058.001]
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1292-8 [1634919.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):783-93 [8478672.001]
  • [Cites] Annu Rev Public Health. 1993;14:43-68 [8323597.001]
  • [Cites] J Natl Cancer Inst Monogr. 1994;(16):177-82 [7999462.001]
  • [Cites] Cancer. 1995 Jan 1;75(1):54-64 [7804978.001]
  • [Cites] Arch Sex Behav. 1994 Dec;23(6):627-43 [7872859.001]
  • [Cites] J Natl Cancer Inst. 1995 Sep 20;87(18):1372-82 [7658498.001]
  • [Cites] Med Care. 1996 Jan;34(1):73-84 [8551813.001]
  • [Cites] Breast Cancer Res Treat. 1996;38(2):183-99 [8861837.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):974-86 [9060536.001]
  • [Cites] CA Cancer J Clin. 1997 May-Jun;47(3):150-3 [9152172.001]
  • [Cites] Health Psychol. 1997 May;16(3):284-98 [9152708.001]
  • [Cites] Ann Surg Oncol. 1997 Oct-Nov;4(7):564-9 [9367022.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):487-94 [9469332.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):501-14 [9469334.001]
  • [Cites] Eur J Cancer. 1998 Feb;34(3):307-14 [9640214.001]
  • [Cites] Psychooncology. 1998 Nov-Dec;7(6):470-82 [9885088.001]
  • [Cites] Ann Surg Oncol. 1999 Jun;6(4):359-66 [10379856.001]
  • [Cites] J Sex Marital Ther. 1999 Jul-Sep;25(3):237-50 [10407796.001]
  • [Cites] Breast Cancer Res Treat. 1999 Mar;54(2):109-15 [10424401.001]
  • [Cites] Breast Cancer Res Treat. 1999 May;55(2):189-99 [10481946.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5526-33 [16110013.001]
  • [Cites] Breast J. 2005 Nov-Dec;11(6):440-7 [16297089.001]
  • [Cites] J Sex Med. 2005 Jul;2(4):469-77 [16422841.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2815-21 [16782919.001]
  • [Cites] Psychooncology. 2006 Jul;15(7):579-94 [16287197.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4875-81 [17050872.001]
  • [Cites] Br J Cancer. 2006 Dec 18;95(12):1626-31 [17160080.001]
  • [Cites] Eur J Cancer. 2007 Feb;43(3):549-56 [17140788.001]
  • [Cites] J Psychosoc Oncol. 2007;25(2):19-36 [17613483.001]
  • [Cites] N Engl J Med. 2007 Aug 23;357(8):762-74 [17715410.001]
  • [Cites] Ann Surg Oncol. 2007 Nov;14(11):3078-89 [17574501.001]
  • [CommentIn] Menopause. 2010 Sep-Oct;17(5):894-5 [20700064.001]
  • (PMID = 20461020.001).
  • [ISSN] 1530-0374
  • [Journal-full-title] Menopause (New York, N.Y.)
  • [ISO-abbreviation] Menopause
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA91842; United States / NCI NIH HHS / CA / R01 CA102777; United States / NCI NIH HHS / CA / R01 CA102777-05; United States / NCI NIH HHS / CA / CA102777-05; United States / NCI NIH HHS / CA / P30 CA091842; United States / NCI NIH HHS / CA / R01CA102777
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS221562; NLM/ PMC2939280
  •  go-up   go-down


96. Engohan-Aloghe C, Hottat N, Cosaert J, Boutemy R, Fayt I, Noël JC: Evaluation of accuracy of fine needle aspiration cytology in BI-RADS3 category breast lesions: cytohistological correlation in 337 cases. Cytopathology; 2010 Jun;21(3):161-3
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of accuracy of fine needle aspiration cytology in BI-RADS3 category breast lesions: cytohistological correlation in 337 cases.
  • OBJECTIVE: To evaluate the accuracy of fine needle aspiration cytology (FNAC) in BI-RADS3 breast lesions.
  • RESULTS: The histological diagnosis showed that 88% (59/67) of BI-RADS3 breast lesions were benign.
  • However, the correlation between cytology and histology showed that most of these lesions were benign and that finally FNAC remains a useful and accurate test in the management of these lesions.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Breast / pathology. Breast Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Neoplasm Staging. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19744191.001).
  • [ISSN] 1365-2303
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


97. Schiffhauer LM, Boger JN, Bonfiglio TA, Zavislan JM, Zuley M, Fox CA: Confocal microscopy of unfixed breast needle core biopsies: a comparison to fixed and stained sections. BMC Cancer; 2009;9:265
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Confocal microscopy of unfixed breast needle core biopsies: a comparison to fixed and stained sections.
  • BACKGROUND: Needle core biopsy, often in conjunction with ultrasonic or stereotactic guided techniques, is frequently used to diagnose breast carcinoma in women.
  • This paper reports the progress in developing techniques to rapidly screen needle core breast biopsy and surgical specimens at the point of care.
  • CSLM requires minimal tissue processing and has the potential to reduce the time from excision to diagnosis.
  • METHODS: Needle core breast specimens from 49 patients were imaged at the time of biopsy.
  • These lesions had been characterized under the Breast Imaging Reporting And Data System (BI-RADS) as category 3, 4 or 5.
  • Immediately following imaging, the specimens were fixed in buffered formalin and submitted for histological processing and pathological diagnosis.
  • RESULTS: The pathologic diagnoses by standard histology were 7 invasive ductal carcinomas, 2 invasive lobular carcinomas, 3 ductal carcinomas in-situ (CIS), 21 fibrocystic changes/proliferative conditions, 9 fibroadenomas, and 5 other/benign; two were excluded due to imaging difficulties.
  • Morphologic and cellular features of benign and cancerous lesions were identified in the confocal images and were comparable to standard histologic sections of the same tissue.
  • Morphologic and cellular features of benign and cancerous lesions were identified in the confocal images.
  • Additional studies are needed to 1.) establish correlation of the confocal and traditional histologic images for the various diseases of the breast; 2.) validate diagnostic use of CSLM and; 3.) further define features of borderline lesions such as well-differentiated ductal CIS vs. atypical hyperplasia.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Microscopy, Confocal / methods
  • [MeSH-minor] Biopsy. Cell Proliferation. Contrast Media / pharmacology. Female. Humans. Medical Oncology / methods. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2002 Oct;33(10):975-82 [12395369.001]
  • [Cites] Pancreatology. 2001;1(1):48-57 [12120268.001]
  • [Cites] J Invest Dermatol. 2001 Nov;117(5):1137-43 [11710924.001]
  • [Cites] Surgery. 2000 Dec;128(6):1088-1100; discussion 1100-1 [11114647.001]
  • [Cites] BMC Cancer. 2008;8:21 [18215290.001]
  • [Cites] J Biomed Opt. 2008 Sep-Oct;13(5):054001 [19021381.001]
  • [Cites] J Biomed Opt. 2005 Sep-Oct;10(5):051602 [16292950.001]
  • [Cites] J Invest Dermatol. 1999 Sep;113(3):293-303 [10469324.001]
  • [Cites] Clin Dermatol. 2003 Sep-Oct;21(5):359-69 [14678715.001]
  • [Cites] Dermatol Surg. 2003 Aug;29(8):839-46 [12859385.001]
  • [Cites] J Biomed Opt. 2007 Sep-Oct;12(5):051901 [17994884.001]
  • (PMID = 19650910.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  • [Other-IDs] NLM/ PMC3087331
  •  go-up   go-down


98. Yamamoto H, Okumura K, Toshima S, Mukaisho K, Sugihara H, Hattori T, Kato M, Asano S: FXYD3 protein involved in tumor cell proliferation is overproduced in human breast cancer tissues. Biol Pharm Bull; 2009 Jul;32(7):1148-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FXYD3 protein involved in tumor cell proliferation is overproduced in human breast cancer tissues.
  • FXYD3, also known as Mat-8 (Mammary tumor 8 kDa), is one of mRNAs highly expressed in mouse and human breast cancers.
  • Here, we newly found that FXYD3 protein was also overexpressed in human breast cancer specimens; invasive ductal carcinomas and intra-ductal carcinomas, whereas its expression was low in benign lesion specimens; mastopathy, fibroadenoma and phyllodes tumors.
  • Here, we found that FXYD3a mRNA is a major transcript product expressed in human normal tissues as well as in breast, colon, stomach and pancreas cancer cell lines.
  • Cell proliferation rate of MCF-7 breast cancer cell line was drastically decreased when FXYD3a and 3b mRNAs were suppressed by the small interfering RNA.
  • These results suggest that FXYD3a protein is highly expressed in breast cancers, and responsible for cancer cell proliferation.
  • [MeSH-major] Breast Neoplasms / metabolism. Cell Proliferation. Membrane Proteins / biosynthesis. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Amino Acid Sequence. Blotting, Western. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Middle Aged. Molecular Sequence Data. Reverse Transcriptase Polymerase Chain Reaction. Sequence Alignment. Transfection

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19571376.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / FXYD3 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


99. Akin M, Bozkirli B, Leventoglu S, Unal K, Kapucu LO, Akyurek N, Sare M: Liver schwannoma incidentally discovered in a patient with breast cancer. Bratisl Lek Listy; 2009;110(5):298-300
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver schwannoma incidentally discovered in a patient with breast cancer.
  • BACKGROUND: Benign schwannomas, also referred to as neurilemomas, neurinomas, and perineural fibroblastomas, are encapsulated nerve sheath tumors.
  • We present a case of liver schwannoma, incidentally found in a patient with breast cancer.
  • CASE: A 66-year-old female consulted her physician for a mass she palpated on her left breast.
  • An USG-guided biopsy was performed and the histo-pathological examination revealed a "peripheral nerve sheath tumor".
  • The tumor resected from the liver was 5 x 4 x 3 cm, yellowish, soft, and capsulated tumor.
  • The tumor was diagnosed as benign liver schwannoma.
  • CONCLUSION: Schwannomas are benign, encapsulated neoplasms.
  • Symptoms and signs vary depending on the anatomical site and the size of the neoplasm; however, most schwannomas present as an asymptomatic or painless mass.
  • [MeSH-major] Breast Neoplasms. Carcinoma, Ductal, Breast. Liver Neoplasms. Neoplasms, Multiple Primary. Neurilemmoma


100. Oba M, Sasaki M, Ii T, Hoso M, Ajisaka H, Matsuki N, Miwa K: A case of lymphocytic mastopathy requiring differential diagnosis from primary breast lymphoma. Breast Cancer; 2009;16(2):141-6
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of lymphocytic mastopathy requiring differential diagnosis from primary breast lymphoma.
  • Lymphocytic mastopathy is a benign breast disease characterized by dense fibrosis, lobular atrophy, and aggregates of lymphocytes in a periductal and perivascular distribution.
  • Here, we report a case of the disease clinically and radiologically mimicking primary breast neoplasms.
  • The patient was a 50-year-old woman without diabetes who presented with two firm lumps in her right breast.
  • Breast imaging findings from mammography, ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI), respectively, revealed an abnormal appearance suspicious of malignancy.
  • A core-needle biopsy specimen showed atypical accumulation of lymphoid cells, which was not easy to differentiate from primary breast lymphomas.
  • In our case, it was difficult to distinguish this entity from breast cancer or low-grade B-cell lymphoma without surgical biopsy.
  • [MeSH-major] Breast Neoplasms / diagnosis. Lymphocytes / pathology. Lymphoma / diagnosis. Mastitis / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Mammography. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Prognosis. Radiopharmaceuticals. Tomography, X-Ray Computed. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18769994.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down






Advertisement